VOLUME 37: AUTHOR INDEX – MAIN HEADINGS

KEY: (C) = Correspondence: (LA) = Leading Article

Abu Farsakh N, 849 (C)
Adams G, 674
Adams L, 702
Adler G, 434
Ahluwalia NK, 17
Akkermans L, 643
Alavaikko M, 471
Alderson D, 505
Aldoori WH, 298 (C)
Allison MC, 838
Alstead EM, 13
Amigo L, 422
Anand BS, 296 (C), 589 (C)
Anderson B, 157 (C)
Anderson DC, 374
Anderson H, 617
Anderson JT, 598
Anderson NH, 530
Andre EA, 340
Andrews P, 477
Antonsson JB, 791
Arato A, 519
Arber N, 77
Ardill JES, 35
Arendt-Nielsen L, 603
Armengol JR, 47
Armstrong CP, 576
Armstrong D, 743
Arndt H, 374
Aronson M, 77
Asai K, 544
Atkin W, 297 (C)
Atkinson M, 465
Attanoos R, 840
Axon ATR, 44, 552

Badve S, 205, 319
Bae H, 477
Bagger JP, 603
Bain AM, 81
Bak P, 603
Bakka A, 367
Balboa A, 47
Balsitis M, 191
Bamford KB, 35
Banks LM, 220
Barbul A, 530
Barclay GR, 589 (C)
Bardhan KD, 195
Bardocz S, 353
Barlow J, 17
Baron JH, 446 (C)
Bartolomé R, 47
Bartram C, 100
Bartram CI, 4 (LA), 284
Beattie AD, 734
Beaugerie L, 708
Beckly DE, 119
Bennett JR, 639
Bennett MK, 413
Bennish ML, 402
Benson MJ, 346
Bergman JJGHM, 157 (C)
Bergue A, 292
Berlin Diarrhea/Wasting Syndrome Study Group, 524
Berliner S, 77
Bertrams J, 39
Bianchi FB, 406
Bianchi Porro G, 210
Biancone L, 690
Biemond I, 199
Billings PJ, 840
Bitoun A, 811
Bjarnason I, 63, 195, 623
Blake H, 279
Blake MA, 835
Blazeby JM, 505
Blok P, 758
Blum AL, 39, 743
Boerrigter L, 758
Bohr J, 394
Boirivant M, 690
Böker K, 568
Bommelaer G, 298 (C)
Booth JCL, 449 (LA)
Borody TJ, 477
Börsch G, 39, 591 (C), 743
Boston VE, 35
Bouchier IAD, 127, 848
Boulant J, 298 (C)
Boutron M-C, 830
Boyer J, 488
Brandl S, 477
Brandtzaeg P, 225, 367, 766
Brookes C, 585
Brookes ST, 505
Brousse N, 708, 783
Brown, ASTJM, 413
Brown DS, 353
Brown JL, 449 (LA)
Bruley des Varannes S, 457
Bruun E, 256
Brzozowski T, 749
Buckels JAC, 845
Bujanover Y, 77
Burl M, 284
Burnham WR, 445 (C)
Burroughs A, 296 (C)
Bursztyn M, 247
Busuttil A, 91
Butcher GP, 144, 220
Butruk L, 13
Bydder GM, 284

Calès P, 488
Camilleri M, 264
Camilleri MJ, 499
Campbell AP, 148
Campbell BJ, 58
Candinas D, 845
Candy S, 674
Canioni D, 783
Capeau J, 712
Capron M, 132, 242
Carpani de Kaski M, 613
Carson R, 702
Carter DC, 121
Cataleta M, 406
Celle G, 445 (C)
Cerf-Bensussan N, 783
Chalmers DM, 44
Chapman RWG, 274
Charneau J, 488
Cheng JY, 87
Choudari CP, 161 (LA)
Christensen E, 113
Chrousos GP, 544
Ciclitira PJ, 52
Clapp N, 702
Clausen MR, 684
Coffin B, 649
Collazos J, 297 (C)
Colombel J-F, 242
Colombel JF, 132, 811
Cook GC, 157 (C)
Cooper BT, 288
Cortot A, 132, 242
Cosenza V, 690
Cox MA, 288
Craanen ME, 758
Cucala M, 47
Cullen DJE, 610

da Silva RCMA, 580
Dapoigny M, 298 (C)
D'Argenio G, 690
D'Armiento FP, 690
Das PK, 361
Dauver A, 488
Davies GR, 346
Davies MH, 580
Day CP, 413
Day P, 52
de Beaux AC, 121
de Ribot X, 47
Deery A, 297 (C)
Dekker W, 758
Delaporte E, 132
Della Valle N, 690
Dent J, 329, 643
deSouza NM, 284
Desreumaux P, 132, 242
Dias JA, 340
Dietze O, 108
Domschke W, 482
Donaghy A, 63
Dorman A, 297 (C)
Dorta G, 743
Dotan G, 77
Dotan I, 77
Douds AC, 574
Dröge M, 565
Dubucquoi S, 132, 242
Duguid TJ, 353
Dwarakanath AD, 58, 585

Eastwood MA, 91
Edelbroek M, 643
Eiznhamer D, 168
Eland C, 519
Elia G, 205
Eliakim R, 386
Elias E, 580
Ell C, 309
Ellis HJ, 52
Emery S, 329
Emmons LR, 260
Englyst K, 353
Epstein O, 297 (C)
Eriksson S, 394
Eriksson SBS, 617
Erkelens DW, 654
Ernst H, 749
Etienne J-C, 292
Etienne P-L, 174
Eugène C, 292
Evans DF, 465
Everitt S, 191
Ewen SWB, 353
Eyre-Brook IA, 119, 576

Fais S, 798
Faivre J, 830
Farndon JR, 505
Farthing MJG, 13, 340, 512
Faulkner G, 177, 182
Faussone Pellegrini MS, 493
Felsenheld C, 292
Fenn CG, 195
Fiaterone JR, 413
Fingerhut A, 292
Finlayson C, 446 (C), 574
Fioramonti J, 298 (C)
Fisher N, 296 (C)
Fleming KA, 274
Florent C, 811
Florin THJ, 418
Flourié B, 649
Foley RJE, 158 (C)
Ford MJ, 264, 499
Forman D, 314
Foster CS, 144
Fowler CR, 220
Fracchia G, 477
Francis N, 623
Frankel WL, 81
French A, 557
Fretland D, 702
Frier M, 216
Frobert O, 603
Fromm M, 777
Fromont G, 783
Fuhr J, 702
Funch-Jensen P, 603

Gallati H, 260
Galmiche J-P, 457
Gangaidzo IT, 727
Gardiner KR, 530, 589 (C)
Garrido J, 422
Gazzard BG, 623
Gear MWL, 576
Gendre JP, 811
Gerber M, 674
Gerdes D, 427
Gerig M, 674
Gertner DJ, 346
GETAID Group, 811
Giaffer MH, 679
Gibson P, 536
Gilat T, 77, 591 (C)
Gillessen A, 482
Gilmore IT, 296 (C)
Gluud C, 113
Godet PG, 668
González S, 422
Goodman R, 674
Gorard DA, 445 (C)
Gordeuk VR, 727
Gosselin M, 174
Gossner L, 309
Goto J, 398
Gottesleben F, 565
Goulet O, 783
Goyal RK, 305
Graham DY, 154, 296 (C), 589 (C)
Granger DN, 374
Grant G, 353
Grasmug E, 136
Gray W, 148
Greco AV, 422
Gress TM, 434
Grisham MB, 374
Gudmand-Hoyer E, 256
Günthert AR, 819
Guslandi M, 296 (C)
Gustafson-Svrd C, 380

Hadziselimovic F, 260
Haglund UH, 791
Hahn EG, 309, 749
Hall AS, 284
Hallak A, 77
Halligan S, 100
Hammer HF, 136
Hanby AM, 205
Hanson RB, 264, 499
Haraldsen G, 225, 367
Hardcasgtle JD, 465
Hardo PG, 44
Hargest R, 826
Harris AW, 446 (C)
Hart CA, 58
Harwood D, 314
Hassan F, 44
Hawkey CJ, 177, 182, 191, 610
Heading RC, 7
Healey CJ, 274
Heaton KW, 298 (C)
Hebbard G, 329
Heggie L, 17
Herold M, 108
Hobsley M, 335
Hochberger J, 309
Hoctin-Boes G, 811
Hodgson HJF, 613
Hodgson S, 297 (C)
Hoefler G, 136
Hogåsen AK, 367
Holdsworth CD, 679
Holdsworth PJ, 552
Hopwood D, 598
Horowitz M, 329, 643
Horslen SP, 590 (C)
Hosoda K, 721
Houghton LA, 270
Hourihane DO'B, 763
Hovig T, 225
Howdle PD, 660
Howey S, 639
Hudson N, 177, 182, 191, 610
Hughes LE, 840
Huldt B, 617
Hull MA, 610
Hussaini SH, 151
Hyde GM, 148

Ibba Manneschi L, 493
Idström J-P, 743
Iftikhar SY, 465
Ilyas M, 802
Imazeki F, 721
Isaacs PET, 731
Ito Y, 721

Jahn H-U, 524
James OFW, 413
Jan D, 783
Janin A, 132, 242
Järnerot G, 394
Jass JR, 297 (C), 446 (C)
Jazrawi RP, 301 (LA)
Jehle EC, 696
Jenkins D, 296 (C)
Jewell DP, 148
Jian R, 649
Johnson CP, 23
Johnston D, 552
Jolobe OMP, 296 (C), 445 (C)
Jones K, 643
Jones KL, 329
Jones SR, 580
Jorias I, 39
Joseph AEA, 557, 574
Joyner MJ, 499
Judmaier G, 108
Julienne V, 174
Junker P, 805

Kaiser A, 427
Kalbfleisch JH, 23
Kamm MA, 95
Kapur A, 731
Kapur KC, 838
Karmeli F, 247, 386
Karttunen TJ, 71, 471

Katelaris PH, 512
Kato H, 544
Kato N, 721
Kawahito Y, 544
Keane CT, 30, 591 (C)
Keating J, 623
Keighley MRB, 845
Kelly PJ, 413
Kelsey PR, 731
Keshavarzian A, 168
Khan WA, 402
Khoo DE, 187
Khoo UY, 63
Khulusi S, 205, 319, 445 (C), 446 (C)
Kimura S, 544
Kitayama Y, 398
Kjeldsen J, 805
Klein O, 242
Klemola T, 519
Kmiot WA, 284
Knisely AS, 590 (C)
Köhl H, 591 (C)
Kondo M, 544
Konikoff FM, 77, 591 (C)
Kontakou M, 52
Konturek JW, 482
Konturek PC, 749
Konturek SJ, 482, 749
Koretz K, 819
Koskimies S, 519
Koutsomanis D, 95
Kowolik MJ, 44
Krähenbühl S, 140
Krajci P, 766
Krause M, 140
Kreuzpaintner G, 361
Kubicka S, 568
Kupferschmidt H, 140
Kvale D, 225

Labenz J, 39, 591 (C), 743
Lacarriere Y, 712
Lacombe ML, 712
Lamers CBHW, 199
Langman MJS, 177, 509, 737 (LA)
Lankisch PG, 565
Lascu I, 712
Launois B, 174
Le Prisé E, 174
Le Rhun M, 457
Ledingham S, 465
Lee WH, 87
Lehtola JK, 71
Lémann M, 649
Lennard-Jones JE, 95
Lenzi M, 406
Leonard N, 763
Lerch MM, 434
Lerebours E, 811
Leverkus F, 39
Levi S, 613
Levy J, 319
Lewis MPN, 187
Lewis WG, 552
Liberman E, 77
Lilja I, 380
Lim AG, 301 (LA)
Limb GA, 52
Lin JC, 87
Logan RFA, 177, 182
Logan RPH, 314
Lundin KEA, 766
Lynch DAF, 44

Ma Y, 406
McCallion WA, 35
McCullough JB, 598
MacDonald IA, 216
MacErlean DP, 835
McMaster P, 845
McMillan L, 235
Maconi G, 210
Macpherson A, 63, 623
McWhirter JP, 740 (LA)
Makowiec F, 696
Malagelada J-R, 47
Malbert C, 329
Manelius JJ, 71
Mang G, 140
Mann SG, 325
Manneschi L, 493
Manns M, 568
Mansfield JC, 679
Mapstone NP, 44, 660
Marrero JM, 205
Marshall DG, 30
Martinelli ALC, 589 (C)
Martinez JA, 712
Mary JY, 811
Maxwell JD, 557, 574
Maxwell RJ, 589 (C)
May A, 309
May GR, 668
Mayer AD, 845
Mazzacca G, 690
Mearin F, 47
Mehta D, 576
Meier PJ, 140
Mela GS, 445 (C)
Mendall MA, 1 (LA), 205, 319, 445 (C), 446 (C)
Meneghelli UG, 589 (C)
Meng CL, 87
Menzies IS, 623
Merrer J, 292
Meunier B, 174
Meyer JN, 256
Michiels C, 830
Michitaka K, 568
Mieli-Vergani G, 406
Miettinen A, 471
Miller A, 91
Miller AS, 552
Miller HRP, 235
Milne R, 314
Mingrone G, 422
Minguzzi M, 210
Miquel JF, 422
Misiewicz JJ, 314
Mobarhan S, 168
Modigliani R, 811
Möller P, 819
Montet JC, 157 (C)
Morris AI, 593 (LA)
Mortensen PB, 684
Moshkowitz M, 77, 591 (C)
Moundji A, 292
Mourad FH, 340
Moustafa MS, 105
Muecke T, 643
Mühldorfer S, 309
Mukai S, 544
Muller WA, 225
Munier A, 712
Muratori L, 406
Murray FE, 598
Murray-Lyon IM, 296 (C)
Murty VLN, 589 (C)

Naeem A, 512
Nakamura S, 398
Nervi F, 422
Newlands GFJ, 235
Newton M, 445 (C)
Nguyen TMA, 712
Niemelä SE, 71
Nilsen EM, 766
Ninkovic M, 144
Nölchen B, 108
Nordlinger B, 712
Northfield TC, 1 (LA), 205, 301 (LA), 319, 445 (C), 446 (C)
Northover J, 297 (C)
Nowak TV, 23
Núñez L, 422

O'Brien SG, 144
O'Callaghan A, 144
Odeh M, 441
O'Donnell LJD, 340
O'Donoghue DP, 835
Offerhaus GJA, 758
Ogutu E, 340
Ohto M, 721
Okon E, 247, 386
Olaison G, 380
O'Leary DP, 849 (C)
Olyaee M, 168
Omata M, 721
O'Morain CA, 30, 591 (C)
Oriishi T, 589 (C)
O'Riordan D, 297 (C)
Örmälä T, 519
Owens A, 835

Palitzsch K-D, 374
Pallone F, 690, 798
Palmer KR, 121, 161 (LA)
Panos MZ, 325
Parente F, 210
Partanen J, 519
Patchett SE, 13
Patel AG, 849 (C)
Patel P, 205, 319, 445 (C), 446 (C)
Patey N, 708, 783
Pechlaner Ch, 108
Peitz U, 591 (C)
Penagini R, 329
Pennington AM, 235
Pennington CR, 740 (LA)
Pereira SP, 151
Perkins AC, 216
Petit R, 488
Pfaff D, 434
Picon L, 649
Piette F, 132
Pimentel F, 422
Piotrowski J, 589 (C)
Pistorius LR, 639
Playford RJ, 595 (LA)
Plevris JN, 127
Portincasa P, 674
Potts SR, 35
Poulsom R, 205
Prevot S, 712
Price AB, 195, 623
Pryce D, 585
Pryde A, 7
Przemioslo RT, 52
Przytulski K, 13
Puglielli L, 422
Puni R, 284
Purdie DW, 639
Pusztai A, 353

Quandalle P, 242
Quine A, 445 (C)
Quipourt V, 830
Quirke P, 44, 660

Rachmilewitz D, 247, 386
Raddatz A, 422
Rambaud C, 783
Rambaud JC, 649
Rampton DS, 346
Rao KJM, 279
Raouf AA, 105
Raoul J-L, 174
Ratan J, 77
Read LC, 630
Reber PU, 849 (C)
Reilly KJ, 81
Reilly TG, 325
Reisinger EC, 136
Renooij W, 654
Rentsch R, 613
Révillon Y, 783
Reynolds N, 740 (LA)
Rhodes JM, 58, 585
Ricour C, 783
Riecken E-O, 524, 777
Rigotti A, 422
Roberts A, 216
Roberts IAG, 144
Rodenhuis S, 758
Roelofs J, 643
Rombeau JL, 81
Rosella O, 536
Rosenberg SJ, 305
Roskell DE, 148
Ross PE, 598
Rowbotham DS, 660
Rowlands BJ, 530, 589 (C)
Rowley S, 845
Roy AJ, 95
Roza AM, 23
Ruben RA, 305
Rugtveit J, 225, 367
Rumessen JJ, 256
Rünzi M, 427
Rusche J, 374

Sagar G, 288
Sagar PM, 552
Sahmoud T, 811
Salam MA, 402
Salas A, 47
Saleh SM, 105
Salman W, 168
Saluja A, 427
Samuni A, 386
Sanderson T, 702
Sangaletti O, 210
Sano H, 544
Santo M, 77
Sarner M, 455 (LA)
Saunders JHB, 158 (C)
Savarino V, 445 (C)
Saverymuttu SH, 557
Savilahti E, 519
Scarpignato C, 457
Schaffalitzky de Muckadell OB, 805
Schlemper RJ, 199
Schmidt W, 524
Schneider T, 524
Schnell T, 168
Scholz T, 225
Schulzke I, 777
Schulzke J-D, 777
Scott BB, 445 (C)
Scott H, 367, 766
Scudamore CL, 235
Selmaier M, 309
Senesse P, 830
Sengupta A, 427
Shah K, 195
Sharpstone D, 623
Sheffield JP, 398
Sheu LF, 87
Shi G, 457
Shorrock CJ, 509
Shortis NP, 477
Silvennoinen JA, 71
Singh K, 158 (C)
Singh S, 737 (LA)
Sjödahl R, 380
Slattery J, 509
Slob AW, 361
Slomiany A, 589 (C)
Slomiany BL, 589 (C)
Smedh K, 380
Smit JWA, 654
Smith P, 702
Smith SJ, 177, 182
Smithson J, 623
Smyth CJ, 30
Soergel KH, 23
Sollböhmer M, 39
Sollid LM, 766
Somasundaram S, 623
Sontag S, 168
Soule JC, 811
Souza RF, 305
Spechler SJ, 305
Spencer J, 187
Spiers EM, 598
Spiller RC, 216
Stachura J, 749
Staël von Holstein CCS, 617
Starlinger M, 696
Stauber RE, 136
Steeb CB, 630
Steel SA, 639
Steele RJC, 465
Steer ML, 427
Stolte M, 39, 743
Sträter J, 819
Strickland GT, 105
Strohmeyer G, 361
Stronkhorst A, 361
Sturgess RP, 52, 593 (LA)
Sultan AH, 4 (LA)
Sun W-M, 643
Sun WM, 329
Sunderland D, 58
Sutherland LR, 668
Sutton DR, 639
Swain CP, 346
Sweidan WH, 639
Sylvester R, 811

Tagesson C, 380
Takacs T, 157 (C)
Talbot IC, 195, 398, 802
Tanner J, 702
Tanner MS, 590 (C)
Theodossi A, 279
Thomas DL, 105
Thomas HC, 449 (LA)
Thomas J, 100
Thompson DG, 17
Thompson WG, 298 (C)
Thornton E, 235
Tilg H, 108
Tillenburg B, 591 (C)
Tillmann H, 568
Tindale WB, 679
Top B, 758
Trahair JF, 630
Trauner M, 136
Trautwein C, 568
Trejdosiewicz LK, 660
Trimble KC, 7
Troncon LEA, 17
Tsai HH, 58
Tugnair A, 44
Tunio AM, 335
Turi S, 434
Turvill JL, 340
Tysk C, 394
Tytgat GNJ, 758

Ullrich R, 524

Vago L, 210
Vaillant JC, 712
Valla D, 292
Van Berge-Henegouwen GP, 654
van der Werf SDJ, 199
Van Erpecum KJ, 654
Van Someren RMN, 346
Vandenbroucke JP, 199
Varas MJ, 47

Varghese NM, 279
Verdú EF, 743
Vergani D, 406
Villanova MG, 589 (C)
Vincent R, 216
Vogel W, 108
Vullo C, 157 (C)

Waked IA, 105
Walker D, 568
Walt RP, 325
Walters JRF, 144, 220
Warlow CP, 509
Watson AJM, 165 (LA)
Weaver JB, 580
Weidenbach H, 434
Weisbruch JP, 23
Weissel M, 447 (C)
Welbourn CRB, 119, 576
Weldon MJ, 557
Wesenfelder L, 292
Wess L, 91
Wess TJ, 91
West AP, 44
Whelan A, 763
Whorwell PJ, 270
Wilder RL, 544
Wilkinson ML, 151
Willett WC, 298 (C)
Williams GT, 838, 840
Williams MH, 505
Williams R, 63, 296 (C)
Williamson MER, 552
Williamson R, 826
Wilmer A, 108
Windle HJ, 30
Wiste JA, 264, 499
Wood CM, 23
Woods HJ, 418
Wright J, 674
Wright NA, 205
Wych J, 270

Xia, 591 (C)
Xia HX, 30

Yamamura Y, 544
Yokosuka O, 721
Yu LG, 585
Yusuf SW, 465

Zietz M, 524

VOLUME 37: SUBJECT INDEX – MAIN HEADINGS

Absorption, Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, **623**
Acetic acid, Colitis and colonic mucosal barrier dysfunction, **530**
Acetic acid colitis, Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity, **247**
Achalasia, Heartburn in patients with achalasia, **305**
Acid base regulation, Defective acid base regulation by the gall bladder epithelium and its significance for gall stone formation, **127**
Adenocarcinoma, Ileostomy polyps, adenomas, and adenocarcinomas, **840**
Adenoma
Adenomas and a family history of colorectal cancer: *correspondence*, **297**
Ileostomy polyps, adenomas, and adenocarcinomas, **840**
Adenoma-carcinoma pathway, Family history of colorectal tumours and implications for the adenoma-carcinoma sequence, **830**
Adenomatous polyposis coli, Expression of the APC gene after transfection into a colonic cancer cell line, **826**
African iron overload, Hepatocellular carcinoma and African iron overload, **727**
AIDS
Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, **623**
Loss of CD4 lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood, **524**
Alcoholic hepatitis, Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables, **113**
Aminopeptidase-N, Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis, **422**
5-Aminosalicylic acid, Mesalazine induced exacerbation of ulcerative colitis, **838**
Aminotransferases, Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases, **274**
Amoxicillin, Intragastric acidity as a predictor of the success of *Helicobacter pylori* eradication: a study in peptic ulcer patients with omeprazole and amoxicillin, **39**
Anal continence, The perfect pelvic pouch – what makes the difference?, **552**
Anal endosonography, Anal endosonography in faecal incontinence: *leading article*, **4**
Anal fistula, Clinical course of perianal fistulas in Crohn's disease, **696**
Anal sphincter, High resolution magnetic resonance imaging of the anal sphincter using an internal coil, **284**
Anaphylaxis, Basal secretion and anaphylactic release of rat mast cell protease-II (RMCP-II) from ex vivo perfused rat jejunum: translocation of RMCP-II into the gut lumen and its relation to mucosal histology, **235**
Anorectal physiology, Acute diarrhoea induces rectal sensitivity in women but not men, **270**
Anti-HCV antibody, Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA, **721**
Antral motility
Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia, **488**
Evaluation of antral motility in humans using manometry and scintigraphy, **643**
Antral vascular ectasia, Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia, **488**
Antropyloroduodenal motility, Effect of drink temperature on antropyloroduodenal motility and gastric electrical activity in humans, **329**
APC gene, Expression of the APC gene after transfection into a colonic cancer cell line, **826**
Apoptosis
In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis, **819**
Necrosis and apoptosis in the gastrointestinal tract: *leading article*, **165**
Aspirin
Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats, **749**
Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer, **182**
Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin – analysis of gastrointestinal bleeding during the UK-TIA trial, **509**
Atrophic gastritis, Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to *Helicobacter pylori*, **199**
Attachment, Attachment of *Giardia lamblia* trophozoites to a cultured human intestinal cell line, **512**
Audit, Audit of upper gastrointestinal endoscopy: *correspondence*, **445**
Autoimmune hepatitis, Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease, **406**
Autoimmune thyroid disease, Coeliac disease and autoimmune thyroid disease: *correspondence*, **447**
Autonomic neuropathy, Highly variable gastric emptying in patients with insulin dependent diabetes mellitus, 23
Azathioprine, A controlled double blind study of azathioprine in the management of Crohn's disease, **674**

B cell lymphoma, Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma, **731**
Balloon expulsion, Intrarectal pressures and balloon expulsion related to evacuation proctography, **100**
Barrett's oesophagus
Alkaline gastro-oesophageal reflux: dual probe pH monitoring, **465**
Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus, **168**
Basic fibroblast growth factor, Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration, **610**
Benign gastroduodenal disease, Mortality after remote surgery for benign gastroduodenal disease, **617**
Bile
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia, **654**
Inhibition of methanogenesis by human bile, **418**
Biliary cholesterol, Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis, **422**
Biliary pancreatitis, Biochemical and morphological changes that characterise recovery from necrotising biliary pancreatitis in the opossum, **427**
Biliary stenting, Endoscopic biliary stenting in a district general hospital, **279**
Biliary stones, In vitro dissolution of cholesterol biliary stones: *correspondence*, **157**
Biofeedback, Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation, **95**
Biopsy, Is day case liver biopsy underutilised?, **574**
Bleeding peptic ulcer
Endoscopic intervention in bleeding peptic ulcer: *leading article*, **161**
Late mortality in elderly patients surviving acute peptic ulcer bleeding, **177**
Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer, **182**
Bone mineral density
A controlled study of bone mineral density in patients with inflammatory bowel disease, **71**
Coeliac disease and bone mineral density in adult female patients, **639**
Detection of low bone mineral density by dual energy *x* ray absorptiometry in unsuspected suboptimally treated coeliac disease, **220**
Book reviews
Baert AL. Medical radiology. Diagnostic imaging and radiation oncology. Radiology of the pancreas, **736**
Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, *editors*. Infections of the gastrointestinal tract, **447**
Broelsch CE, *editor*. Atlas of liver surgery, **159**
Brunelle F, Pariente D, Chaumont P, *editors*. Liver disease in children. An atlas of angiography and cholangiography, **851**
Cameron JL, *editor*. Atlas of biliary tract surgery, **159**
Castell DO, *editor*. The esophagus, 2nd ed, **852**
Farrell GC. Drug-induced liver disease, **447**
Haubrich WS, Schaffner F, Berk JE, *editors*. Bockus gastroenterology (5th ed), **849**
Janowitz HD. Indigestion, **852**
Janowitz HD. Your gut feelings (revised ed), **852**
Johnson LR, *editor*. Physiology of the gastrointestinal tract (3rd ed), **159**
Kirsch R, Robson S, Trey C, *editors*. Diagnosis and management of liver disease, **299**
Kirschner BS, Walker-Smith JA, *editors*. Paediatric gastroenterology, **299**

Lok Tio T. Gastrointestinal TNM cancer staging by endosonography, **851**
Mignon M, Jensen RT. Endocrine tumors of the pancreas: recent advances in research and management, **159**
Misiewicz JJ, Forbes A, Price AB, Shorvon PJ, Triger DR, Tytgat GNJ. Clinical gastroenterology CD-ROM version, **850**
Owen DA, Kelly JK. Atlas of gastrointestinal pathololgy, **158**
Payne-James J, Grimble G, Silk D, *editors*. Artificial nutrition support inclinical practice, **158**
Pounder RE, *editor*. Recent advances in gastroenterology (Vol 10), **851**
Rigas B, Spiro HM, *editors*. Clinical gastroenterology companion handbook, 4th ed, **850**
Wexner SD, Bartolo DCC, *editors*. Constipation. Etiology, evaluation and management, **849**
Wiedenmann B, Kvols LK, Arnold R, Riecken E-O, *editors*. Molecular and cell biological aspects of gastroenteropancreatic neuroendocrine tumor disease, **736**

Bootstrap, Identifying patients with a high risk of relapse in quiescent Crohn's disease, **811**

Bowel allograft, Small bowel transplantation in children: an immunohistochemical study of intestinal grafts, **783**

Bradykinin, Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis, **434**

Bran, Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study, **216**

Breath test
Breath hydrogen analysis in patients with ileoanal pouch anastomosis, **256**
Eradication rate of *Helicobacter pylori*: *correspondence*, **591**

British Society of Gastroenterology, Presidential review of the year's activity 1994-5, **848**

Butyrate, Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease, **536**

C reactive protein, C reactive protein and prealbumin as markers of disease activity in shigellosis, **402**

^{14}C threonine labelled mucin, Faecal mucinase activity assessed in inflammatory bowel disease using ^{14}C threonine labelled mucin substrate, **58**

^{14}C-urea breath test, Eradication rate of *Helicobacter pylori*: *correspondence*, **591**

CA 125, Increased CA 125 in tuberculous peritonitis: *correspondence*, **297**

Caco-2 cells, Attachment of *Giardia lamblia* trophozoites to a cultured human intestinal cell line, **512**

Caecocolonic junction, The caecocolonic junction in humans has a sphincteric anatomy and function, **493**

Calcium malabsorption, Detection of low bone mineral density by dual energy *x* ray absorptiometry in unsuspected suboptimally treated coeliac disease, **220**

Cancer mortality, Mortality after remote surgery for benign gastroduodenal disease, **617**

Carnitine, Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity, **140**

Catecholamines, Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis, **434**

CD4 cells, Loss of CD4 lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood, **524**

CD14 antigen, Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells, **367**

Cell death, Necrosis and apoptosis in the gastrointestinal tract: *leading article*, **165**

Cell proliferation, Cell proliferation and polyposis: *correspondence*, **446**

Cell separation, Isolation and longterm culture of human intestinal microvascular endothelial cells, **225**

Chemiluminescence, Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus, **168**

Chest pain, Oesophageal sensation assessed by electrical stimuli and brain evoked potentials – a new model for visceral nociception, **603**

Children
Age dependent hypergastrinaemia in children with *Helicobacter pylori* gastritis – evidence of early acquisition of infection, **35**
Small bowel transplantation in children: an immunohistochemical study of intestinal grafts, **783**

Cholecystectomy
Endoscopic sphincterotomy without cholecystectomy for gall stone pancreatitis, **119**
Helicobacter pylori and cholecystectomy: *correspondence*, **849**

Cholecystokinin
Cholecystokinin and transient lower oesophageal sphincter relaxation: *correspondence*, **298**
Eradication of *Helicobacter pylori* restores the inhibitory effect of cholecystokinin on postprandial gastrin release in duodenal ulcer patients, **482**

Cholelithiasis, Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis, **422**

Cholera toxin, Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and *Escherichia coli* enterotoxins, **340**

Cholestasis of pregnancy, Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid, **580**

Cholesterol biliary stones, In vitro dissolution of cholesterol biliary stones: *correspondence*, **157**

Cholestyramine, Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia, **654**

Chymase, Basal secretion and anaphylactic release of rat mast cell protease-II (RMCP-II) from ex vivo perfused rat jejunum: translocation of RMCP-II into the gut lumen and its relation to mucosal histology, **235**

Cimetidine, Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH, **325**

Cirrhosis
Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia, **488**
Copper associated childhood cirrhosis: *correspondence*, **590**
High prevalence of hepatitis C in Egyptian patients with chronic liver disease, **105**
Serum neopterin concentrations in chronic liver disease, **108**

Cl- secretion, Epithelial barrier and ion transport in coeliac sprue: electrical measurements on intestinal aspiration biopsy specimens, **777**

Coeliac disease
Coeliac disease and autoimmune thyroid disease: *correspondence*, **447**
Coeliac disease and bone mineral density in adult female patients, **639**
Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge, **52**
Detection of low bone mineral density by dual energy *x* ray absorptiometry in unsuspected suboptimally treated coeliac disease, **220**
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma, **766**
Immunohistochemical findings in jejunal specimens from patients with IgA deficiency, **519**
Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma, **731**
Neuroproliferation in the mucosa is a feature of coeliac disease and Crohn's disease, **763**

Coeliac sprue, Epithelial barrier and ion transport in coeliac sprue: electrical measurements on intestinal aspiration biopsy specimens, **777**

Coenzyme A, Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity, **140**

Colitis
Colitis and colonic mucosal barrier dysfunction, **530**
Oral efficacy of a leukotriene B_4 receptor antagonist in colitic cotton-top tamarins, **702**
Ranitidine, diarrhoea, and lymphocytic colitis, **708**

Collagen, Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy, **805**

Collagen content, Cross linking of collagen is increased in colonic diverticulosis, **91**

Collagenous colitis, Collagenous colitis in Örebro, Sweden, an epidemiological study 1984-1993, **394**

Colon
In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis, **819**
Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis, **684**

Colon motility
Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon, **264**
Hyperventilation, central autonomic control, and colonic tone in humans, **499**
Motor activity recorded in the unprepared colon of healthy humans, **649**

Colonic cancer cell line, Expression of the APC gene after transfection into a colonic cancer cell line, **826**

Colonic compliance, Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon, **264**

Colonic crypt cells, Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease, **536**
Colonic diverticulosis, Cross linking of collagen is increased in colonic diverticulosis, **91**
Colonic epithelial cell growth, Oestrogen and colonic epithelial cell growth: *leading article*, **737**
Colonic epithelial cells, Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis, **63**
Colonic mucosa, Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis, **544**
Colonic mucosal barrier dysfunction, Colitis and colonic mucosal barrier dysfunction, **530**
Colonic mucosal washings, Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis, **63**
Colonoscopy, The caecocolonic junction in humans has a sphincteric anatomy and function, **493**
Colorectal cancer (carcinoma)
Adenomas and a family history of colorectal cancer: *correspondence*, **297**
Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction, **87**
Family history of colorectal tumours and implications for the adenoma-carcinoma sequence, **830**
Overexpression of *nm23*-H1 and *nm23*-H2 genes in colorectal carcinomas and loss of *nm23*-H1 expression in advanced tumour stages, **712**
p53 expression in ulcerative colitis: a longitudinal study, **802**
Colorectal neoplasms, Flow cytometric analysis of DNA synthetic phase fraction of the normal appearing colonic mucosa in patients with colorectal neoplasms, **398**
Computed tomography, Endoscopy and computed tomography in the diagnosis and follow up of oesophageal leiomyoma, **288**
Constipation, Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation, **95**
Copper associated childhood cirrhosis, Copper associated childhood cirrhosis: *correspondence*, **590**
Corrections, **300**, **448**
Corticosteroids, Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers, **613**
Corticotropin releasing hormone, Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis, **544**
Cotton-top tamarins, Oral efficacy of a leukotriene B_4 receptor antagonist in colitic cotton-top tamarins, **702**
Crohn's disease
Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease, **242**
Clinical course of perianal fistulas in Crohn's disease, **696**
Colitis and colonic mucosal barrier dysfunction, **530**
Comparison of ^{99m}Technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-Indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess, **557**
Controlled double blind study of azathioprine in the management of Crohn's disease, **674**
Controlled study of bone mineral density in patients with inflammatory bowel disease, **71**
Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease, **361**
Identifying patients with a high risk of relapse in quiescent Crohn's disease, **811**
Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines, **798**
Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction, **660**
Neuroproliferation in the mucosa is a feature of coeliac disease and Crohn's disease, **763**
Phospholipase A_2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis, **380**
Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy, **805**
Transglutaminases in Crohn's disease, **690**
CYP2D6, Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease, **406**
Cytokines
Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge, **52**
Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma, **766**
Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines, **798**
Cytomegalovirus colitis, HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease, **148**
Cytoprotection, Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats, **749**

Densitometry, Coeliac disease and bone mineral density in adult female patients, **639**
Dental care, *Helicobacter pylori* infection and dental care, **44**
Dermatitis herpetiformis
Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma, **731**
Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis, **132**
Diabetes mellitus, Highly variable gastric emptying in patients with insulin dependent diabetes mellitus, 23
Diarrhoea
Acute diarrhoea induces rectal sensitivity in women but not men, **270**
Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, **623**
Ranitidine, diarrhoea, and lymphocytic colitis, **708**
Disease activity, Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease, **77**
Dissolution therapy, In vitro dissolution of cholesterol biliary stones: *correspondence*, **157**
Diverticular disease, Diverticular distraction: *correspondence*, **298**
DNA fingerprinting, Recrudescence of *Helicobacter pylori* after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting, **30**
DNA HPV, Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction, **87**
Drink temperature, Effect of drink temperature on antropyloroduodenal motility and gastric electrical activity in humans, **329**
Drug induced acute pancreatitis, Drug induced acute pancreatitis: incidence and severity, **565**
Dual energy *x* ray absorptiometry, Detection of low bone mineral density by dual energy *x* ray absorptiometry in unsuspected suboptimally treated coeliac disease, **220**
Duodenal mucosa, Loss of CD4 lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood, **524**
Duodenal ulcer
Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of *Helicobacter pylori* in duodenal ulcer patients. A controlled study, **210**
Epidermal growth factor in saliva and gastric juice: response to histamine, **335**
Eradication of *Helicobacter pylori* restores the inhibitory effect of cholecystokinin on postprandial gastrin release in duodenal ulcer patients, **482**
Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers, **205**
Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects, **319**
Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom, **314**
Dyspepsia
Does *Helicobacter pylori* infection increase gastric sensitivity in functional dyspepsia?, **47**
Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy, 17
Dysphagia, Quality of life measurement in patients with oesophageal cancer, **505**
Dysplasia-carcinoma sequence, p53 expression in ulcerative colitis: a longitudinal study, **802**

E-selectin, Leucocyte-endothelial cell adhesion in a model of intestinal inflammation, **374**
Early gastric carcinoma, Absence of ras gene mutations in early gastric carcinomas, **758**
Egypt, High prevalence of hepatitis C in Egyptian patients with chronic liver disease, **105**
Elderly patients
Late mortality in elderly patients surviving acute peptic ulcer bleeding, **177**
Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer, **182**
Electric stimulation, Oesophageal sensation assessed by electrical stimuli and brain evoked potentials – a new model for visceral nociception, **603**
Electrogastrogram, Effect of drink temperature on antropyloroduodenal motility and gastric electrical activity in humans, **329**

Electromyography, Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation, **95**
Embolotherapy, Embolotherapy for massive upper gastrointestinal haemorrhage secondary to metastatic renal cell carcinoma: report of three cases, **835**
Endoanal coil, High resolution magnetic resonance imaging of the anal sphincter using an internal coil, **284**
Endocytosis, Endocytosis of fluorescent microspheres by human oesophageal epithelial cells: comparison between normal and inflamed tissue, **598**
Endoscopic retrograde cholangiography, Selective preoperative endoscopic retrograde cholangiography with sphincterotomy avoids bile duct exploration during laparoscopic cholecystectomy, **576**
Endoscopic retrograde cholangiopancreatography, Factors influencing morbidity and mortality in acute pancreatitis: an analysis of 279 cases, **121**
Endoscopic sphincterotomy, Endoscopic sphincterotomy without cholecystectomy for gall stone pancreatitis, **119**
Endoscopy
Audit of upper gastrointestinal endoscopy: *correspondence*, **445**
Endoscopic biliary stenting in a district general hospital, **279**
Endoscopic intervention in bleeding peptic ulcer: *leading article*, **161**
Endoscopy and computed tomography in the diagnosis and follow up of oesophageal leiomyoma, **288**
The caecocolonic junction in humans has a sphincteric anatomy and function, **493**
Endosonography, Anal endosonography in faecal incontinence: *leading article*, **4**
Endotoxaemia, Intestinal permeability: *correspondence*, **589**
Endotoxin, A possible role for antibodies to tumour necrosis factor α and to endotoxin in the treatment of Reye's syndrome: *hypothesis*, **441**
Enteral nutrition, Diagnostic and therapeutic push type enteroscopy in clinical use, **346**
Enteroglucagon, Colonic short chain fatty acids mediate jejunal growth by increasing gastrin, **81**
Enteroscopy, Diagnostic and therapeutic push type enteroscopy in clinical use, **346**
Eosinophils
Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease, **242**
Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis, **132**
Epidemiology, Collagenous colitis in Örebro, Sweden, an epidemiological study 1984-1993, **394**
Epidermal growth factor
Epidermal growth factor in saliva and gastric juice: response to histamine, **335**
Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats, **749**
Epithelial barrier, Epithelial barrier and ion transport in coeliac sprue: electrical measurements on intestinal aspiration biopsy specimens, **777**
Epithelial cell growth, Oestrogen and colonic epithelial cell growth: *leading article*, **737**
Epithelial cells, Endocytosis of fluorescent microspheres by human oesophageal epithelial cells: comparison between normal and inflamed tissue, **598**
Epithelium, Administration of insulin-like growth factor-I peptides for three days stimulates proliferation of the small intestinal epithelium in rats, **630**
Escherichia coli, Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and *Escherichia coli* enterotoxins, **340**
Ethanol, Colitis and colonic mucosal barrier dysfunction, **530**
Ethanol metabolism, Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism, **413**
Europe, Gastroenterological training in Europe, **734**
Evacuation proctography, Intrarectal pressures and balloon expulsion related to evacuation proctography, **100**
Evoked potentials, Oesophageal sensation assessed by electrical stimuli and brain evoked potentials – a new model for visceral nociception, **603**

Factor XIII, Transglutaminases in Crohn's disease, **690**
Faecal incontinence, Anal endosonography in faecal incontinence: *leading article*, **4**
Faecal mucinase activity, Faecal mucinase activity assessed in inflammatory bowel disease using ^{14}C threonine labelled mucin substrate, **58**
Familial adenomatous polyposis
Expression of the APC gene after transfection into a colonic cancer cell line, **826**
Flow cytometric analysis of DNA synthetic phase fraction of the normal appearing colonic mucosa in patients with colorectal neoplasms, **398**
In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis, **819**
Family history, Family history of colorectal tumours and implications for the adenoma-carcinoma sequence, **830**
Famotidine, Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH, **325**
Fatty acid oxidation, Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis, **684**
Fetal mortality, Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid, **580**
Fibre, Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study, **216**
Fibroblast growth factor, Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration, **610**
Fistula, Clinical course of perianal fistulas in Crohn's disease, **696**
Flow cytometry, Flow cytometric analysis of DNA synthetic phase fraction of the normal appearing colonic mucosa in patients with colorectal neoplasms, **398**
Functional dyspepsia, Does *Helicobacter pylori* infection increase gastric sensitivity in functional dyspepsia?, **47**

Gall bladder, Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia, **654**
Gall bladder epithelium, Defective acid base regulation by the gall bladder epithelium and its significance for gall stone formation, **127**
Gall stone pancreatitis, Endoscopic sphincterotomy without cholecystectomy for gall stone pancreatitis, **119**
Gall stones
Biliary aminopeptidase-N and the cholesterol crystallisation defect in cholelithiasis, **422**
Defective acid base regulation by the gall bladder epithelium and its significance for gall stone formation, **127**
Selective preoperative endoscopic retrograde cholangiography with sphincterotomy avoids bile duct exploration during laparoscopic cholecystectomy, **576**
Gastric acid secretion, Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of *Helicobacter pylori* in duodenal ulcer patients. A controlled study, **210**
Gastric acidity, Effect of curing *Helicobacter pylori* infection on intragastric pH during treatment with omeprazole, **743**
Gastric adaptation, Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats, **749**
Gastric cancer (carcinoma)
Absence of ras gene mutations in early gastric carcinomas, **758**
Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom, **314**
Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to *Helicobacter pylori*, **199**
Gastric distension, Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy, 17
Gastric emptying
Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of *Helicobacter pylori* in duodenal ulcer patients. A controlled study, **210**
Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study, **216**
Highly variable gastric emptying in patients with insulin dependent diabetes mellitus, 23
Gastric first pass effect, Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism, **413**
Gastric inflammation, *Helicobacter pylori* infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects, **319**
Gastric lymphoma, Lymphocytic gastritis and *Helicobacter pylori* infection in gastric lymphoma, **471**
Gastric metaplasia
Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers, **205**
Gastric metaplasia and *Helicobacter pylori* infection: *correspondence*, **445**

Helicobacter pylori and gastric metaplasia of the duodenum: *correspondence*, **446**
Gastric mucus gel, Effect of *Helicobacter pylori* on the gastric mucus gel: *correspondence*, **296**
Gastric mucus viscosity, Gastric mucus viscosity and *Helicobacter pylori*: *correspondence*, **589**
Gastric pH-metry, Effect of curing *Helicobacter pylori* infection on intragastric pH during treatment with omeprazole, **743**
Gastric sensitivity, Does *Helicobacter pylori* infection increase gastric sensitivity in functional dyspepsia?, **47**
Gastric ulcer
Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs, **191**
Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration, **610**
Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers, **613**
Gastrin
Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of *Helicobacter pylori* in duodenal ulcer patients. A controlled study, **210**
Colonic short chain fatty acids mediate jejunal growth by increasing gastrin, **81**
Eradication of *Helicobacter pylori* restores the inhibitory effect of cholecystokinin on postprandial gastrin release in duodenal ulcer patients, **482**
Gastro-oesophageal reflux
Alkaline gastro-oesophageal reflux: dual probe pH monitoring, **465**
Heartburn in patients with achalasia, **305**
Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD, **7**, 7
Reflux related symptoms in patients with normal oesophageal exposure to acid, **457**
Gastroenterological training, Gastroenterological training in Europe, **734**
Gastroenterology service, Nutrition support teams: an integral part of developing a gastroenterology service: *leading article*, **740**
Gastrointestinal bleeding, Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin – analysis of gastrointestinal bleeding during the UK-TIA trial, **509**
Gastrointestinal disease, *Helicobacter pylori* and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom, **314**
Gastrointestinal endoscopy
Audit of upper gastrointestinal endoscopy: *correspondence*, **445**
Informed consent for upper gastrointestinal endoscopy, **151**
Gastrointestinal haemorrhage
Embolotherapy for massive upper gastrointestinal haemorrhage secondary to metastatic renal cell carcinoma: report of three cases, **835**
Value of laparotomy in the diagnosis of obscure gastrointestinal haemorrhage, **187**
Gastrointestinal mucosal integrity, Peptides and gastrointestinal mucosal integrity: *leading article*, **595**
Gastrointestinal tract, Reversible effect of phytohaemagglutinin on the growth and metabolism of rat gastrointestinal tract, **353**
Gastroscopy, Local anaesthetic sprays and pneumonia after gastroscopy: *correspondence*, **445**
Gender differences, Acute diarrhoea induces rectal sensitivity in women but not men, **270**
Gene therapy, Expression of the APC gene after transfection into a colonic cancer cell line, **826**
Giardia lamblia, Attachment of *Giardia lamblia* trophozoites to a cultured human intestinal cell line, **512**
Glucocorticoids, Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables, **113**
Glucose, Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis, **684**
Gluten, Epithelial barrier and ion transport in coeliac sprue: electrical measurements on intestinal aspiration biopsy specimens, **777**
Gluten free diet, Detection of low bone mineral density by dual energy *x* ray absorptiometry in unsuspected suboptimally treated coeliac disease, **220**
Growth, Reversible effect of phytohaemagglutinin on the growth and metabolism of rat gastrointestinal tract, **353**

H_2 receptor antagonist, Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH, **325**
Haemorrhage
Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin – analysis of gastrointestinal bleeding during the UK-TIA trial, **509**
Value of laparotomy in the diagnosis of obscure gastrointestinal haemorrhage, **187**
Heartburn, Heartburn in patients with achalasia, **305**
Helicobacter pylori
A reliable cure for *Helicobacter pylori* infection? *personal viewpoint*, **154**
Age dependent hypergastrinaemia in children with *Helicobacter pylori* gastritis – evidence of early acquisition of infection, **35**
Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of *Helicobacter pylori* in duodenal ulcer patients. A controlled study, **210**
Does *Helicobacter pylori* infection increase gastric sensitivity in functional dyspepsia?, **47**
Effect of curing *Helicobacter pylori* infection on intragastric pH during treatment with omeprazole, **743**
Effect of *Helicobacter pylori* on the gastric mucus gel: *correspondence*, **296**
Eradication of *Helicobacter pylori* restores the inhibitory effect of cholecystokinin on postprandial gastrin release in duodenal ulcer patients, **482**
Eradication rate of *Helicobacter pylori*: *correspondence*, **591**
Gastric metaplasia and *Helicobacter pylori* infection: *correspondence*, **445**
Gastric mucus viscosity and *Helicobacter pylori*: *correspondence*, **589**
Helicobacter pylori and cholecystectomy: *correspondence*, **849**
Helicobacter pylori and gastric metaplasia of the duodenum: *correspondence*, **446**
Helicobacter pylori infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects, **319**
Helicobacter pylori infection and dental care, **44**
Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom, **314**
Intragastric acidity as a predictor of the success of *Helicobacter pylori* eradication: a study in peptic ulcer patients with omeprazole and amoxicillin, **39**
Lymphocytic gastritis and *Helicobacter pylori* infection in gastric lymphoma, **471**
Omeprazole enhances efficacy of triple therapy in eradicating *Helicobacter pylori*, **477**
Recrudescence of *Helicobacter pylori* after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting, **30**
Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to *Helicobacter pylori*, **199**
Transmission of *Helicobacter pylori* infection: *leading article*, **1**
Heparin, 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis, **585**
Hepatic tuberculosis, Recurrent *Salmonella enteritidis* sepsis and hepatic tuberculosis, **136**
Hepatitis B, Clinical relevance of mutations in the precore genome of the hepatitis B virus, **568**
Hepatitis C virus infection
Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease, **406**
High prevalence of hepatitis C in Egyptian patients with chronic liver disease, **105**
Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases, **274**
The management of chronic hepatitis C virus infection: *leading article*, **449**
Hepatitis C virus RNA, Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA, **721**
Hepatocellular carcinoma, Hepatocellular carcinoma and African iron overload, **727**
Histamine stimulation, Epidermal growth factor in saliva and gastric juice: response to histamine, **335**
HIV
HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease, **148**
Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, **623**
Loss of CD4 lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood, **524**
HLA-DQ restriction, Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma, **766**
Human papillomavirus DNA, Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction, **87**

Hydatid disease, Hydatid disease: *correspondence*, **589**
Hydrogen breath tests, Breath hydrogen analysis in patients with ileoanal pouch anastomosis, **256**
5-Hydroxytryptamine, Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and *Escherichia coli* enterotoxins, **340**
Hyperbilirubinaemia, Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion, **144**
Hypergastrinaemia, Age dependent hypergastrinaemia in children with *Helicobacter pylori* gastritis – evidence of early acquisition of infection, **35**
Hypernephroma, Embolotherapy for massive upper gastrointestinal haemorrhage secondary to metastatic renal cell carcinoma: report of three cases, **835**
Hyperventilation, Hyperventilation, central autonomic control, and colonic tone in humans, **499**
Hypolactasia, Hypolactasia and protection against *Plasmodium* spp infection in *Homo sapiens*: *correspondence*, **157**

IgA, Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma, **731**
IgA deficiency, Immunohistochemical findings in jejunal specimens from patients with IgA deficiency, **519**
Ileal mucosa, Phospholipase A_2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis, **380**
Ileoanal pouch, Breath hydrogen analysis in patients with ileoanal pouch anastomosis, **256**
Ileostomy, Ileostomy polyps, adenomas, and adenocarcinomas, **840**
Immunohistochemistry, Small bowel transplantation in children: an immunohistochemical study of intestinal grafts, **783**
Immunosuppression, A controlled double blind study of azathioprine in the management of Crohn's disease, **674**
Indium-111
Comparison of ^{99m}Technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-Indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess, **557**
Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods, **679**
Indomethacin, Leucocyte-endothelial cell adhesion in a model of intestinal inflammation, **374**
Infection, Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, **623**
Infection density, *Helicobacter pylori* infection density and gastric inflammation in duodenal ulcer and non-ulcer subjects, **319**
Inflammatory bowel disease
Colitis and colonic mucosal barrier dysfunction, **530**
Comparison of ^{99m}Technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-Indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess, **557**
Controlled study of bone mineral density in patients with inflammatory bowel disease, **71**
Faecal mucinase activity assessed in inflammatory bowel disease using ^{14}C threonine labelled mucin substrate, **58**
HIV associated cytomegalovirus colitis as a mimic of inflammatory bowel disease, **148**
Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease, **77**
Inflammatory bowel disease in married couples: *correspondence*, **158**
Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease, **536**
Intestinal permeability: *correspondence*, **589**
Leucocyte-endothelial cell adhesion in a model of intestinal inflammation, **374**
Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease, **668**
Oral efficacy of a leukotriene B_4 receptor antagonost in colitic cotton-top tamarins, **702**
Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods, **679**
Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells, **367**
Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease, **260**
Informed consent, Informed consent for upper gastrointestinal endoscopy, **151**
Insulin-like growth factor, Administration of insulin-like growth factor-I peptides for three days stimulates proliferation of the small intestinal epithelium in rats, **630**
Interferon treatment, Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA, **721**
Interleukin 5
Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease, **242**
Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis, **132**
Interleukin 8, Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease, **536**
Intestinal grafts, Small bowel transplantation in children: an immunohistochemical study of intestinal grafts, **783**
Intestinal mucosa, Isolation and longterm culture of human intestinal microvascular endothelial cells, **225**
Intestinal permeability
Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea, **623**
Intestinal permeability: *correspondence*, **589**
Intestinal resection, Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease, **361**
Intestine, Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines, **798**
Intra-abdominal abscess, Comparison of ^{99m}Technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-Indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess, **557**
Intraepithelial lymphocyte, Lymphocytic gastritis and *Helicobacter pylori* infection in gastric lymphoma, **471**
Intragastric acidity, Intragastric acidity as a predictor of the success of *Helicobacter pylori* eradication: a study in peptic ulcer patients with omeprazole and amoxicillin, **39**
Intrahepatic cholestasis, Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion, **144**
Intrarectal pressure, Intrarectal pressures and balloon expulsion related to evacuation proctography, **100**
Ion transport, Epithelial barrier and ion transport in coeliac sprue: electrical measurements on intestinal aspiration biopsy specimens, **777**
Iron, Hepatocellular carcinoma and African iron overload, **727**
Irritable bowel syndrome, Hyperventilation, central autonomic control, and colonic tone in humans, **499**

Jejunal mucosa, Immunohistochemical findings in jejunal specimens from patients with IgA deficiency, **519**

L1 antigen, Respiratory burst of intestinal macrophages in inflammatory bowel disease in mainly caused by CD14+L1+ monocyte derived cells, **367**
Laparoscopic cholecystectomy, Selective preoperative endoscopic retrograde cholangiography with sphincterotomy avoids bile duct exploration during laparoscopic cholecystectomy, **576**
Laparotomy, Value of laparotomy in the diagnosis of obscure gastrointestinal haemorrhage, **187**
Lectin
Attachment of *Giardia lamblia* trophozoites to a cultured human intestinal cell line, **512**
Reversible effect of phytohaemagglutinin on the growth and metabolism of rat gastrointestinal tract, **353**
Leiomyoma, Endoscopy and computed tomography in the diagnosis and follow up of oesophageal leiomyoma, **288**
Leucocyte adhesiveness/aggregation test, Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease, **77**
Leucocyte-endothelial cell adhesion, Leucocyte-endothelial cell adhesion in a model of intestinal inflammation, **374**
Leukotriene B_4, Oral efficacy of a leukotriene B_4 receptor antagonost in colitic cotton-top tamarins, **702**
Lipids, Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia, **654**
Liver biopsy
Audit of percutaneous liver biopsy: *correspondence*, **296**
Is day case liver biopsy underutilised?, **574**
Liver disease
High prevalence of hepatitis C in Egyptian patients with chronic liver disease, **105**
Serum neopterin concentrations in chronic liver disease, **108**
Liver toxicity, Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity, **140**
Liver transplantation, Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation, **845**

Liver/kidney microsomal antibody type 1, Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease, **406**
Local anaesthetic sprays, Local anaesthetic sprays and pneumonia after gastroscopy: *correspondence*, **445**
Lower oesophageal sphincter relaxation, Cholecystokinin and transient lower oesophageal sphincter relaxation: *correspondence*, **298**
Lymphocytic colitis, Ranitidine, diarrhoea, and lymphocytic colitis, **708**
Lymphocytic gastritis, Lymphocytic gastritis and *Helicobacter pylori* infection in gastric lymphoma, **471**

Macrophages
Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines, **798**
Respiratory burst of intestinal macrophages in inflammatory bowel disease in mainly caused by CD14+L1+ monocyte derived cells, **367**
Magnetic resonance imaging, High resolution magnetic resonance imaging of the anal sphincter using an internal coil, **284**
Malignant oesophageal stenoses, Memory metal stents for palliation of malignant obstruction of the oesophagus and cardia, **309**
Malignant risk, Ornithine decarboxylase as a marker for premalignancy in the stomach, **13**
Malnutrition, Nutrition support teams: an integral part of developing a gastroenterology service: *leading article*, **740**
Manometry
Evaluation of antral motility in humans using manometry and scintigraphy, **643**
Motor activity recorded in the unprepared colon of healthy humans, **649**
Married couples, Inflammatory bowel disease in married couples: *correspondence*, **158**
Mast cell protease, Basal secretion and anaphylactic release of rat mast cell protease-II (RMCP-II) from ex vivo perfused rat jejunum: translocation of RMCP-II into the gut lumen and its relation to mucosal histology, **235**
Mesalazine, Mesalazine induced exacerbation of ulcerative colitis, **838**
Mesenteric vein thrombosis, Small intestinal stricture complicating superior mesenteric vein thrombosis. A study of three cases, **292**
Meta-analysis, Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease, **668**
Metal stents, Metal stents in the oesophagus: *leading article*, **593**
Metastases, Embolotherapy for massive upper gastrointestinal haemorrhage secondary to metastatic renal cell carcinoma: report of three cases, **835**
Methanogenesis, Inhibition of methanogenesis by human bile, **418**
Microvascular endothelial cells, Isolation and longterm culture of human intestinal microvascular endothelial cells, **225**
Misoprostol, Effect of longterm misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study, **195**
Mortality, Mortality after remote surgery for benign gastroduodenal disease, **617**
Motility
Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon, **264**
Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study, **216**
mRNA expression, Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge, **52**
Mucin substrate, Faecal mucinase activity assessed in inflammatory bowel disease using ^{14}C threonine labelled mucin substrate, **58**
Mucosa
In situ detection of enterocytic apoptosis in normal colonic mucosa and in familial adenomatous polyposis, **819**
Neuroproliferation in the mucosa is a feature of coeliac disease and Crohn's disease, **763**
Mucosal immunity, Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma, **766**
Mucosal integrity, Peptides and gastrointestinal mucosal integrity: *leading article*, **595**
Mucosal repair, Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs, **191**
Multinucleated giant cells, Inability of normal human intestinal macrophages to form multinucleated giant cells in response to cytokines, **798**
Muscular coordination training, Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation, **95**
Mycobacterium paratuberculosis
Effect of intestinal resection on serum antibodies to the mycobacterial 45/48 kilodalton doublet antigen in Crohn's disease, **361**
Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction, **660**

Necrosis, Necrosis and apoptosis in the gastrointestinal tract: *leading article*, **165**
Needle biopsy, Is day case liver biopsy underutilised?, **574**
Neopterin, Serum neopterin concentrations in chronic liver disease, **108**
Neovascularisation, Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs, **191**
Neuroproliferation, Neuroproliferation in the mucosa is a feature of coeliac disease and Crohn's disease, **763**
Neutrophils, 'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis, **585**
Nitric oxide
Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity, **247**
Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis, **434**
***nm23*-H1 and 2 genes**, Overexpression of *nm23*-H1 and *nm23*-H2 genes in colorectal carcinomas and loss of *nm23*-H1 expression in advanced tumour stages, **712**
Non-aspirin, Late mortality in elderly patients surviving acute peptic ulcer bleeding, **177**
Non-steroidal anti-inflammatory drugs
Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs, **191**
Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration, **610**
Effect of longterm misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study, **195**
Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defence against subsequent exposure to various strong irritants in rats, **749**
Late mortality in elderly patients surviving acute peptic ulcer bleeding, **177**
Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer, **182**
Non-ulcer dyspepsia
Epidermal growth factor in saliva and gastric juice: response to histamine, **335**
Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom, **314**
Notes, **160**, **300**, **448**, **592**, **736**, **852**
Nucleoside diphosphate kinases, Overexpression of *nm23*-H1 and *nm23*-H2 genes in colorectal carcinomas and loss of *nm23*-H1 expression in advanced tumour stages, **712**
Nutrition support teams, Nutrition support teams: an integral part of developing a gastroenterology service: *leading article*, **740**

Oesophageal achalasia, Heartburn in patients with achalasia, **305**
Oesophageal cancer
Combined radiochemotherapy for postoperative recurrence of oesophageal cancer, **174**
Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus, **168**
Quality of life measurement in patients with oesophageal cancer, **505**
Oesophageal exposure to acid, Reflux related symptoms in patients with normal oesophageal exposure to acid, **457**
Oesophageal innervation, Oesophageal sensation assessed by electrical stimuli and brain evoked potentials – a new model for visceral nociception, **603**
Oesophageal sensory thresholds, Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD, **7**
Oesophageal stenoses, Memory metal stents for palliation of malignant obstruction of the oesophagus and cardia, **309**
Oesophagitis
Alkaline gastro-oesophageal reflux: dual probe pH monitoring, **465**
Endocytosis of fluorescent microspheres by human oesophageal epithelial cells: comparison between normal and inflamed tissue, **598**
Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus, **168**
Oesophagus
Endoscopy and computed tomography in the diagnosis and follow up of oesophageal leiomyoma, **288**
Metal stents in the oesophagus: *leading article*, **593**
Oestrogen, Oestrogen and colonic epithelial cell growth: *leading article*, **737**

Omeprazole
Effect of curing *Helicobacter pylori* infection on intragastric pH during treatment with omeprazole, **743**
Intragastric acidity as a predictor of the success of *Helicobacter pylori* eradication: a study in peptic ulcer patients with omeprazole and amoxicillin, **39**
Omeprazole enhances efficacy of triple therapy in eradicating *Helicobacter pylori*, **477**
Oral contraceptives, Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease, **668**
Ornithine decarboxylase, Ornithine decarboxylase as a marker for premalignancy in the stomach, **13**
Osteoporosis
A controlled study of bone mineral density in patients with inflammatory bowel disease, **71**
Coeliac disease and bone mineral density in adult female patients, **639**
Outpatient, Is day case liver biopsy underutilised?, **574**
Oxygen consumption, Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
Oxygen delivery, Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
Oxygen free radicals, Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus, **168**
Oxygen reactive species, A stable nitroxide radical effectively decreases mucosal damage in experimental colitis, **386**

p53, p53 expression in ulcerative colitis: a longitudinal study, **802**
Pancreatic cancer, Mortality after remote surgery for benign gastroduodenal disease, **617**
Pancreatic inflammatory disease, Pancreatic inflammatory disease: *leading article*, **455**
Pancreatic vascular regulation, Pancreatic vascular regulation: *correspondence*, **849**
Pancreatitis
Biochemical and morphological changes that characterise recovery from necrotising biliary pancreatitis in the opossum, **427**
Drug induced acute pancreatitis: incidence and severity, **565**
Endoscopic sphincterotomy without cholecystectomy for gall stone pancreatitis, **119**
Factors influencing morbidity and mortality in acute pancreatitis: an analysis of 279 cases, **121**
Vasoactive mediators and the progression from oedematous to necrotising experimental acute pancreatitis, **434**
Partial gastric resection, Mortality after remote surgery for benign gastroduodenal disease, **617**
Pathergic arthritis, `Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis, **585**
Pelvic pouch, The perfect pelvic pouch – what makes the difference?, **552**
Pepsinogen
Behaviour of acid secretion, gastrin release, serum pepsinogen I, and gastric emptying of liquids over six months from eradication of *Helicobacter pylori* in duodenal ulcer patients. A controlled study, **210**
Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to *Helicobacter pylori*, **199**
Peptic ulcer
Endoscopic intervention in bleeding peptic ulcer: *leading article*, **161**
Intragastric acidity as a predictor of the success of *Helicobacter pylori* eradication: a study in peptic ulcer patients with omeprazole and amoxicillin, **39**
Late mortality in elderly patients surviving acute peptic ulcer bleeding, **177**
Morbidity and treatment in elderly patients surviving hospital admission with bleeding peptic ulcer, **182**
Peptic ulcer surgery, Mortality after remote surgery for benign gastroduodenal disease, **617**
Peptides, Peptides and gastrointestinal mucosal integrity: *leading article*, **595**
Percutaneous liver biopsy, Audit of percutaneous liver biopsy: *correspondence*, **296**
Perianal disease, Clinical course of perianal fistulas in Crohn's disease, **696**
Peritonitis
Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
Increased CA 125 in tuberculous peritonitis: *correspondence*, **297**
pH
Effect of curing *Helicobacter pylori* infection on intragastric pH during treatment with omeprazole, **743**
Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
Low dose famotidine and cimetidine in single postprandial doses: a placebo controlled comparative study of overnight pH, **325**
pH monitoring
Alkaline gastro-oesophageal reflux: dual probe pH monitoring, **465**
Reflux related symptoms in patients with normal oesophageal exposure to acid, **457**
Phospholipase A_2 gene expression, Phospholipase A_2 gene expression and activity in histologically normal ileal mucosa and in Crohn's ileitis, **380**
Phytohaemagglutinin, Reversible effect of phytohaemagglutinin on the growth and metabolism of rat gastrointestinal tract, **353**
***Plasmodium* spp**, Hypolactasia and protection against *Plasmodium* spp infection in *Homo sapiens*: *correspondence*, **157**
Pneumonia, Local anaesthetic sprays and pneumonia after gastroscopy: *correspondence*, **445**
Polymerase chain reaction
Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction, **87**
Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA, **721**
Mycobacterium paratuberculosis DNA not detected in Crohn's disease tissue by fluorescent polymerase chain reaction, **660**
Polyposis, Cell proliferation and polyposis: *correspondence*, **446**
Polyps, Ileostomy polyps, adenomas, and adenocarcinomas, **840**
Postoperative recurrence, Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease, **242**
Postprandial bloating, Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy, 17
Pouch anal anastomosis, Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation, **845**
Prealbumin, C reactive protein and prealbumin as markers of disease activity in shigellosis, **402**
Precore mutant, Clinical relevance of mutations in the precore genome of the hepatitis B virus, **568**
Prednisolone, Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy, **805**
Primary biliary cirrhosis, The ursodeoxycholic acid story in primary biliary cirrhosis: *leading article*, **301**
Procollagen, Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy, **805**
Proctocolectomy
Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation, **845**
The perfect pelvic pouch – what makes the difference?, **552**
Proctography, Intrarectal pressures and balloon expulsion related to evacuation proctography, **100**
Prognosis, Identifying patients with a high risk of relapse in quiescent Crohn's disease, **811**
Proliferation, Administration of insulin-like growth factor-I peptides for three days stimulates proliferation of the small intestinal epithelium in rats, **630**
Pyoderma gangrenosum, `Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis, **585**

Quality of life, Quality of life measurement in patients with oesophageal cancer, **505**

Radiochemotherapy, Combined radiochemotherapy for postoperative recurrence of oesophageal cancer, **174**
Ranitidine
Ranitidine, diarrhoea, and lymphocytic colitis, **708**
Ranitidine increases the bioavailability of postprandial ethanol by the reduction of first pass metabolism, **413**
Ras gene mutation, Absence of ras gene mutations in early gastric carcinomas, **758**
Reactive gastritis, Effect of longterm misoprostol coadministration with non-steroidal anti-inflammatory drugs: a histological study, **195**
Reactive oxygen species, Mucosal reactive oxygen species production in oesophagitis and Barrett's oesophagus, **168**
Recrudescence, Recrudescence of *Helicobacter pylori* after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting, **30**
Rectal sensitivity, Acute diarrhoea induces rectal sensitivity in women but not men, **270**
Relapse, Identifying patients with a high risk of relapse in quiescent Crohn's disease, **811**
Renal cell carcinoma, Embolotherapy for massive upper gastrointestinal haemorrhage secondary to metastatic renal cell carcinoma: report of three cases, **835**
Respiratory burst, Respiratory burst of intestinal macrophages in

inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells, **367**
Respiratory disease, Mortality after remote surgery for benign gastroduodenal disease, **617**
Reye's syndrome, A possible role for antibodies to tumour necrosis factor α and to endotoxin in the treatment of Reye's syndrome: *hypothesis*, **441**
RMCP-II, Basal secretion and anaphylactic release of rat mast cell protease-II (RMCP-II) from ex vivo perfused rat jejunum: translocation of RMCP-II into the gut lumen and its relation to mucosal histology, **235**

S phase fraction, Flow cytometric analysis of DNA synthetic phase fraction of the normal appearing colonic mucosa in patients with colorectal neoplasms, **398**
Salmonella enteritidis, Recurrent *Salmonella enteritidis* sepsis and hepatic tuberculosis, **136**
Schistosomiasis, High prevalence of hepatitis C in Egyptian patients with chronic liver disease, **105**
Scintigraphy
Effect of bran particle size on gastric emptying and small bowel transit in humans: a scintigraphic study, **216**
Evaluation of antral motility in humans using manometry and scintigraphy, **643**
Sensitivity, gastric, Does *Helicobacter pylori* infection increase gastric sensitivity in functional dyspepsia?, **47**
Sensory thresholds
Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD, **7**
Oesophageal sensation assessed by electrical stimuli and brain evoked potentials – a new model for visceral nociception, **603**
Sepsis, Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
***Shigella* spp**, C reactive protein and prealbumin as markers of disease activity in shigellosis, **402**
Short chain fatty acids
Colonic short chain fatty acids mediate jejunal growth by increasing gastrin, **81**
Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis, **684**
Sickle cell disease, Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion, **144**
Simvastatin, Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia, **654**
Skin disease, Linear IgA dermatosis, coeliac disease, and extraintestinal B cell lymphoma, **731**
Small intestine
Gut intramucosal pH and intraluminal PO_2 in a porcine model of peritonitis or haemorrhage, **791**
Small intestinal stricture complicating superior mesenteric vein thrombosis. A study of three cases, **292**
Smith, Paul, British Society of Gastroenterology: President 1995-96, **444**
Sphincter, The caecocolonic junction in humans has a sphincteric anatomy and function, **493**
Sphincterotomy, Selective preoperative endoscopic retrograde cholangiography with sphincterotomy avoids bile duct exploration during laparoscopic cholecystectomy, **576**
Stents
Memory metal stents for palliation of malignant obstruction of the oesophagus and cardia, **309**
Metal stents in the oesophagus: *leading article*, **593**
Stomach, Ornithine decarboxylase as a marker for premalignancy in the stomach, **13**
Stomach cancer, Mortality after remote surgery for benign gastroduodenal disease, **617**
Surgery, Mortality after remote surgery for benign gastroduodenal disease, **617**

T cell subset, Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma, **766**
Technetium-99m HMPAO, Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods, **679**
^{99m}Technetium, Comparison of ^{99m}Technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-Indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess, **557**
Temperature of drinks, Effect of drink temperature on antropyloroduodenal motility and gastric electrical activity in humans, **329**
TEMPOL, A stable nitroxide radical effectively decreases mucosal damage in experimental colitis, **386**
TGP-580, Basic fibroblast growth factor treatment for non-steroidal anti-inflammatory drug associated gastric ulceration, **610**
Thrombosis, Small intestinal stricture complicating superior mesenteric vein thrombosis. A study of three cases, **292**
Training, Gastroenterological training in Europe, **734**
Transaminases, Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases, **274**
Transglutaminase, Transglutaminases in Crohn's disease, **690**
Transmission, Transmission of *Helicobacter pylori* infection: *leading article*, **1**
Trefoil peptides, Expression of trefoil peptides pS2 and human spasmolytic polypeptide in gastric metaplasia at the margin of duodenal ulcers, **205**
Trinitrobenzene sulphonic acid colitis
A stable nitroxide radical effectively decreases mucosal damage in experimental colitis, **386**
Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity, **247**
Triple therapy
Eradication rate of *Helicobacter pylori*: *correspondence*, **591**
Omeprazole enhances efficacy of triple therapy in eradicating *Helicobacter pylori*, **477**
Tuberculosis, Recurrent *Salmonella enteritidis* sepsis and hepatic tuberculosis, **136**
Tuberculous peritonitis, Increased CA 125 in tuberculous peritonitis: *correspondence*, **297**
Tumour necrosis factor, Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease, **260**
Tumour necrosis factor alpha, A possible role for antibodies to tumour necrosis factor α and to endotoxin in the treatment of Reye's syndrome: *hypothesis*, **441**

Ulcerative colitis
Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis, **63**
Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis, **544**
Ileostomy polyps, adenomas, and adenocarcinomas, **840**
Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis, **684**
Mesalazine induced exacerbation of ulcerative colitis, **838**
Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation, **845**
'Sticky' neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis, **585**
Ulcerative colitis associated colorectal carcinoma, p53 expression in ulcerative colitis: a longitudinal study, **802**
Ultrasound, Comparison of ^{99m}Technetium hexamethylpropylene-amine oxime labelled leucocyte with 111-Indium tropolonate labelled granulocyte scanning and ultrasound in the diagnosis of intra-abdominal abscess, **557**
Upper gastrointestinal haemorrhage, Late mortality in elderly patients surviving acute peptic ulcer bleeding, **177**
Ursodeoxycholic acid
Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid, **580**
The ursodeoxycholic acid story in primary biliary cirrhosis: *leading article*, **301**

Vagotomy, Relations between upper abdominal symptoms and gastric distension abnormalities in dysmotility like functional dyspepsia and after vagotomy, **17**
Valproate, Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity, **140**
Vascular endothelium, Isolation and longterm culture of human intestinal microvascular endothelial cells, **225**
Visceral nociception, Oesophageal sensation assessed by electrical stimuli and brain evoked potentials – a new model for visceral nociception, **603**
Visceral sensation, Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD, **7**

Wheat peptide, Cytokine mRNA expression in the mucosa of treated coeliac patients after wheat peptide challenge, **52**

VOLUME 37: AUTHOR INDEX – SUPPLEMENTS 1 AND 2

Abbass Z, Suppl.2.A24
Abdi Y, Suppl.1.A30
Abrignani S, Suppl.1.A51
Ackerman SK, Suppl.1.A52
Acuña R, Suppl.1.A41
Adam A, Suppl.2.A4
Adamek RJ, Suppl.1.A41, A43
Addolorato G, Suppl.1.A96
Adler G, Suppl.1. A20, A73
Ahmed HA, Suppl.1. A75, Suppl.2.A19
Ahmed MM, Suppl.2.A26
Akashi H, Suppl.1.A19
Akin S, Suppl.1.A26
Akopyants NS, Suppl.1. A1, A61
Al-Assi MT, Suppl.1.A89
Al Kawas F, Suppl.1.A5
Alarcón T, Suppl.1.A15, A72, A97
Alderson D, Suppl.2.A4, A5, A21
Aldous JC, Suppl.1.A88
Aleljung P, Suppl.1.A93
Aleotti A, Suppl.1.A72
Alison MR, Suppl.2.A33
Alkout AH, Suppl.1. A21, A22
Allan E, Suppl.1. A22, A23
Allardyce RA, Suppl.1. A93, A95
Allen-Mersh TG, Suppl.2.A36
Ally R, Suppl.2.A29
Alvarex I, Suppl.1.A30
Alvarez Baleriola I, Suppl.1.A47
Alvisi V, Suppl.1.A72
Amorim MN, Suppl.1.A27
Anand BS, Suppl.1.A10
Andersen LP, Suppl.1.A2, A14, A27, A95
Anderson JT, Suppl.1.A84
Anderson K, Suppl.2.A25
Anderson LE, Suppl.2.A20
Anderson NH, Suppl.2.A16
Andrade AM, Suppl.1.A71
Andreb H-J, Suppl.1.A9
Andriulli A, Suppl.1.A11
Andrutis KA, Suppl.1. A30, A48
Ang L, Suppl.2.A42
Angeletti S, Suppl.2.A7
Anggiansah A, Suppl.2.A46
Annese V, Suppl.1.A11
Annibale B, Suppl.2.A7
Anzai H, Suppl.1.A8
Aranda-Michel J, Suppl.1.A90
Ardill J, Suppl.1.A9
Aricò B, Suppl.1.A51
Armitage NC, Suppl.2.A5, A49
Armitage NCM, Suppl.2.A5
Armuzzi A, Suppl.1.A37, A71, A96
Aromaa A, Suppl.1.A26
Arthur MJP, Suppl.2.A26
Aruin LI, Suppl.1.A29
Asaka M, Suppl.1.A7
Asante M, Suppl.1.A16, Suppl.2.A6
Asante MA, Suppl.1.A75
Ascencio F, Suppl.1.A74
Ashorn M, Suppl.1.A24
Askew JN, Suppl.2.A20
Aspinall GO, Suppl.1.A17
Atherton JC, Suppl.1.A3, A69, A75
Attardo L, Suppl.1.A10
Atzei A, Suppl.1.A68
Aubert E, Suppl.1.A86
Avunduk C, Suppl.1.A38
Axon ATR, Suppl.1.A12, A25, A39, A44, A46, A53, A54, Suppl.2.A7, A32, A45
Aygen S, Suppl.1.A25, A54
Aynilian G, Suppl.1.A14
Azuma T, Suppl.1.A7
Azzarone P, Suppl.1.A40

Babbs C, Suppl.1.A87
Babin P, Suppl.1.A66
Baborie A, Suppl.2.A30
Backman VEM, Suppl.1.A53
Baczako K, Suppl.1.A29, A35
Badve S, Suppl.2.A6
Baestlein E, Suppl.1.A54
Baggaley R, Suppl.2.A41
Bagnolo F, Suppl.1.A82
Bagshaw J, Suppl.1.A50, A63, A92
Bagshaw PF, Suppl.1.A93, A95
Bailey R, Suppl.1.A42
Bailie AG, Suppl.1.A70
Baillon M-LA, Suppl.1.A63
Bains MA, Suppl.2.A36
Bais R, Suppl.2.A29
Baker JE, Suppl.2.A26
Bakios TJ, Suppl.1.A94
Bakir A, Suppl.2.A30
Baldini L, Suppl.1.A37, A71, A96
Bamford K, Suppl.1.A55
Bamford KB, Suppl.1.A11, A70
Bampton P, Suppl.1.A59
Banatvala N, Suppl.1.A30
Banerjee S, Suppl.1.A11
Bansi D, Suppl.2.A25
Bansi DS, Suppl.2.A14
Baoku Y, Suppl.2.A26
Barba M, Suppl.1.A25
Barbara L, Suppl.1.A40
Barbi G, Suppl.1.A34
Barbosa W, Suppl.1.A35
Bardhan KD, Suppl.1.A5, A54, A85
Bargiggia S, Suppl.1.A41
Barham CP, Suppl.2. A3, A4
Barnes S, Suppl.2.A30
Baron JH, Suppl.1.A8, A19, A73, A74, A88, Suppl.2.A39, A44
Barr H, Suppl.2. A3, A4
Barrera C, Suppl.1.A31
Barrison I, Suppl.2.A7
Barrowclough S, Suppl.2.A32
Barton S, Suppl.2.A37
Barton SGRG, Suppl.1.A80, Suppl.2.A44
Basso D, Suppl.1. A15, A57
Bastlein E, Suppl.1.A39
Bästlein E, Suppl.1.A44, A89
Basumani P, Suppl.2.A34
Batchelder M, Suppl.1.A52
Bate CM, Suppl.2.A45
Bates S, Suppl.2.A34
Bateson MC, Suppl.2.A30
Battaglia G, Suppl.1.A47, A57, A76
Battisitini B, Suppl.2.A52
Bauerfeind P, Suppl.1.A65, A66
Bautista L, Suppl.1.A15
Baxter ST, Suppl.2.A53
Bayerdoerffer E, Suppl.1.A54
Bayerdörffer E, Suppl.1.A4, A9, A38, A39, A44, A81
Bayerdörffer R, Suppl.1.A89
Bazzoli F, Suppl.1.A5, A37, A61
Beales I, Suppl.1.A37, A84
Beales ILP, Suppl.1.A80, A90, Suppl.2.A17, A18, A40, A44
Beath SV, Suppl.2.A30
Beattie S, Suppl.1.A61
Beatty ER, Suppl.2. A15, A22
Becker T, Suppl.1.A43
Beckett CG, Suppl.2.A42
Beckly D, Suppl.2.A5
Beil W, Suppl.1.A32, A82
Belcher JC, Suppl.1.A30
Beliaeva OI, Suppl.1.A27
Bell GD, Suppl.2.A6
Bell JD, Suppl.2.A28, A34
Bell JI, Suppl.2.A21
Bell JM, Suppl.1.A88
Belluzzi A, Suppl.2.A49
Ben-Ari Z, Suppl.2.A34
Benaissa M, Suppl.1.A66
Benger J, Suppl.2.A2
Bennett Clark S, Suppl.1.A72
Benvenuti ME, Suppl.1.A47, A76
Benyon RC, Suppl.2.A26
Berg DE, Suppl.1.A1, A23, A50, A61
Bergamasco Mm, Suppl.1.A76
Bermejo F, Suppl.1.A47
Bernardi R, Suppl.2.A13
Besherdas K, Suppl.2.A10
Bettany GEA, Suppl.2.A43
Bettini L, Suppl.2.A27
Bhalla AK, Suppl.2.A42
Bhattacharya S, Suppl.2.A36
Bianchi Porro G, Suppl.1.A23, A41
Biancone L, Suppl.1.A52, A78
Bilgin Y, Suppl.1.A26
Birac C, Suppl.1.A25, A67
Birkholz S, Suppl.1.A32, A79
Bischoff SC, Suppl.1.A32
Blackshaw PE, Suppl.2.A47
Blackwell CC, Suppl.1.A21, A22
Blanchard TG, Suppl.1.A31
Blanchard W, Suppl.1.A56
Blaser M, Suppl.1.A84, Suppl.2.A40
Blaser MJ, Suppl.1.A1, A3, A23, A50, A69, A75, A79
Blazeby JM, Suppl.2.A5
Blomberg B, Suppl.1.A3
Bloom SL, Suppl.2.A22
Blum AL, Suppl.1.A8, A93
Boberg K, Suppl.2.A25
Bode G, Suppl.1.A20, A72, A73
Boixeda D, Suppl.1.A25, A30, A47
Boldeoku J, Suppl.2.A24
Bölin I, Suppl.1.A22
Bolle KH, Suppl.1.A44
Bollen A, Suppl.1.A57, A69
Bologna P, Suppl.1.A82
Bolton C, Suppl.2.A6
Boni M, Suppl.1.A85
Bonnevie O, Suppl.1.A27
Bontems P, Suppl.1.A57
Bonvicini F, Suppl.1.A37, A71, A96
Booth IW, Suppl.2.A30
Borriello SP, Suppl.1.A64
Börsch G, Suppl.1.A6, A8, A25, A28, A41, A43, A54
Bottomley JR, Suppl.1.A16
Bouchard S, Suppl.1.A71, A91
Bouchier IAD, Suppl.2.A25, A27, A28
Boulton R, Suppl.1.A90, Suppl.2.A20
Boulton RA, Suppl.2.A20, A33
Bovo P, Suppl.2.A29
Boxall E, Suppl.2.A26
Boyanova L, Suppl.1.A71
Bozzola L, Suppl.1.A82
Bradbury J, Suppl.2.A46
Bradford I, Suppl.2.A14, A43
Braganza JM, Suppl.2.A29
Bramble MG, Suppl.2.A10, A35, A38
Bramley P, Suppl.2.A14, A37
Bramley PN, Suppl.2.A8, A50
Branciforte G, Suppl.1.A41
Brannigan K, Suppl.2.A36
Bray MJ, Suppl.2.A43
Brejeaud L, Suppl.1.A35
Bresalier RS, Suppl.1.A75
Breuer N, Suppl.2.A25
Bridger S, Suppl.2.A39
Bright NF, Suppl.2.A46
Brignola C, Suppl.2.A49
Britton BJ, Suppl.2.A3
Broglia F, Suppl.1.A87
Broome U, Suppl.2.A25
Broutet N, Suppl.1.A78
Brown C, Suppl.2.A6
Brown D, Suppl.2.A1
Brugmann D, Suppl.1.A71
Brummer R-JM, Suppl.2.A32
Brunori MP, Suppl.2.A29
Brunt PW, Suppl.2.A37, A50
Bryant DJ, Suppl.2.A28, A34
Buchanan KD, Suppl.1.A9
Buck FJ, Suppl.1.A93
Buckels JAC, Suppl.2.A34
Buckley M, Suppl.1.A55, A61, A91
Buizza M, Suppl.1.A82
Bunce M, Suppl.2.A21
Bures J, Suppl.1.A33
Burette A, Suppl.1.A56, A57, A59, A69, A89
Burke D, Suppl.2.A36
Burnham WR, Suppl.2.A1, A37
Burns BP, Suppl.1.A20
Burns KE, Suppl.2.A9
Burroni D, Suppl.1.A51, A94
Burroughs AK, Suppl.2.A28, A34, A36, A48
Buset M, Suppl.1.A96
Butruk E, Suppl.1.A42
Butzler J-P, Suppl.1.A56, A57, A59, A69, A79
Bykova O, Suppl.1.A71
Byrd JC, Suppl.1.A75
Bzeizi K, Suppl.2.A48
Bzeizi KI, Suppl.2.A8

Cadranel S, Suppl.1.A57, A58, A79
Calam J, Suppl.1.A9, A37, A80, A83, A84, A90, Suppl.2.A17, A18, A40, A44, A45
Callanan K, Suppl.2.A4
Calnan D, Suppl.2.A20
Caló G, Suppl.1.A71
Camacho-Hubner C, Suppl.2.A43
Cameron IC, Suppl.2.A1
Cammarota G, Suppl.1.A96
Campbell J, Suppl.1.A48, A52
Campieri M, Suppl.2.A49
Cantet F, Suppl.1.A78
Cantón R, Suppl.1.A25
Capriati G, Suppl.1.A37
Carbone F, Suppl.1.A91
Cardaci G, Suppl.1.A90
Carè M, Suppl.2.A13
Carll G, Suppl.1.A5
Caroli A, Suppl.1.A85
Caroli M, Suppl.1.A60
Carswell N, Suppl.1.A39
Carter AM, Suppl.1.A25, A53
Carter DC, Suppl.2.A3
Carty E, Suppl.2.A37
Carvalho SD, Suppl.1.A26
Casadei A, Suppl.1.A40
Caselli M, Suppl.1.A72
Cassaro M, Suppl.1.A15
Castro FJ, Suppl.1.A71
Castro LP, Suppl.1.A71
Catalano F, Suppl.1.A41
Catanzaro R, Suppl.1.A41
Cattani L, Suppl.1.A82
Catto AJ, Suppl.1.A25, A53
Cavallini G, Suppl.2.A29
Caviglia R, Suppl.2.A7
Cayla R, Suppl.1.A55, A91, A92
Celestin LR, Suppl.1.A85
Cenatiempo Y, Suppl.1.A66
Censini S, Suppl.1.A51
Certo M, Suppl.1.A96
Chalk P, Suppl.1.A16
Chalk PA, Suppl.1. A17, A18, A67
Chalmers DM, Suppl.1.A39
Chalybäus C, Suppl.1.A38
Chan EC, Suppl.1.A29
Changani KK, Suppl.2.A34
Chapman R, Suppl.2.A25
Chapman RW, Suppl.2.A14
Chapman RWG, Suppl.2.A45
Chaussade S, Suppl.1.A55
Chausson Y, Suppl.1.A71
Chawla M, Suppl.2.A7
Chen CY, Suppl.1.A12
Chen FC, Suppl.2.A53
Chen L, Suppl.1.A9
Chen LT, Suppl.1.A12
Chen M, Suppl.1.A48
Chen MH, Suppl.1.A38, A78
Chesner IM, Suppl.2.A49
Chevalier C, Suppl.1.A65
Chiba N, Suppl.2.A31
Chin J, Suppl.2.A48
Ching CK, Suppl.1.A42
Chintu C, Suppl.1.A36
Chmiela M, Suppl.1.A32
Choi H, Suppl.1.A40
Choudari C, Suppl.2.A38
Chuah SY, Suppl.1.A97
Chung SCS, Suppl.1.A6
Ciclitira PJ, Suppl.2.A19, A41, A42
Ciociola AA, Suppl.1.A5
Claeys D, Suppl.1.A93
Clarithromycin European *H. pylori* Study Group, Suppl.1.A4, A5
Clarke AR, Suppl.2.A18
Clarridge JE, Suppl.1.A67
Clayton C, Suppl.1.A16, A65
Clayton CL, Suppl.1.A18, A67
Clements L, Suppl.1.A30
Clifton S, Suppl.1.A61
Cockayne A, Suppl.1.A63, A64
Coelho LGV, Suppl.1.A71
Cogliandro L, Suppl.1.A37
Cole A, Suppl.2.A22
Cole AT, Suppl.2.A15
Cole RA, Suppl.1.A13
Coleman TJ, Suppl.1.A24
Colla C, Suppl.1.A87
Collins C, Suppl.2.A42
Collins CE, Suppl.2.A21
Collins JSA, Suppl.1.A9, A55
Colombo E, Suppl.1.A41, A82
Coman G, Suppl.1.A71
Constantinidou C, Suppl.1.A63
Cooper BT, Suppl.2.A13, A32
Cooper P, Suppl.2.A51
Copass M, Suppl.1.A94
Corless DJ, Suppl.1.A77
Corlett M, Suppl.1.A4
Correa P, Suppl.1.A27
Corthésy-Theulaz I, Suppl.1.A93
Corvaglia L, Suppl.1.A57, A58
Cotton RGH, Suppl.2.A19
Cottrill MRB, Suppl.1.A45
Coughlin B, Suppl.1.A38
Coutts GA, Suppl.2.A28
Covacci A, Suppl.1.A14, A30, A37, A51, A83
Cover TL, Suppl.1.A3, A69

Cowan RE, Suppl.2.A10
Cox IJ, Suppl.2.A28
Cox MA, Suppl.2.A13, A32
Cox PT, Suppl.1.A2
Cox S, Suppl.1.A52
Crabtree JE, Suppl.1.A3, A6, A14, A30, A31, A33, A37, A46, A80, A83
Craft JC, Suppl.1.A43
Craig A-M, Suppl.1.A47
Cripps NPJ, Suppl.2.A23
Crisp W, Suppl.2.A4
Crowe H, Suppl.1.A15
Crowe J, Suppl.2.A45
Crowe JP, Suppl.1.A54
Crowe SE, Suppl.1.A31, A50
Cuccurullo F, Suppl.1.A91
Cugia L, Suppl.1.A68
Cull A, Suppl.2.A9
Cummings JH, Suppl.2.A15, A22
Cummings M, Suppl.2.A18
Curtis D, Suppl.2.A20
Cutler AF, Suppl.1.A12, A13
Czinn S, Suppl.1.A33
Czinn SJ, Suppl.1.A31

Dal Bo' N, Suppl.1.A15, A47, A57
Dalla Livera M, Suppl.1.A5
Dallai R, Suppl.1.A94
Dallaire C, Suppl.1.A5
Dalzell AM, Suppl.1.A70
D'Ambra G, Suppl.2.A7
Danielsson D, Suppl.1.A3
Dankert J, Suppl.1.A68
D'Apolito M, Suppl.1.A94
Darmaillac V, Suppl.1.A91
Daskalopoulos G, Suppl.1.A20
Dattilo M, Suppl.1.A46
Dave K, Suppl.2.A1
Davey PG, Suppl.1.A47
Davidson BR, Suppl.2.A34, A36
Davies E, Suppl.2.A26
Davies GR, Suppl.1.A30, A33, Suppl.2.A8
Davies M, Suppl.1.A39
Davis T, Suppl.2.A19
Davison AA, Suppl.1.A18
Dawodu JB, Suppl.1.A3
De Fanis C, Suppl.1.A42
de Graaf J, Suppl.1.A68
De Koster E, Suppl.1.A36, A90, A96
De Magistris MT, Suppl.1.A51
de Mascarel A, Suppl.1.A92
de Rafael L, Suppl.1.A30, A47
De Reuck M, Suppl.1.A90
de Reuse H, Suppl.1.A65
De Tavonatti M, Suppl.2.A27
de Ungria MCA, Suppl.1.A2
De Wolf-Peeters C, Suppl.1.A40
Deakin M, Suppl.2.A36
DeBartolo M, Suppl.1.A43, A85
deBruine A, Suppl.1.A14
Del Bianco T, Suppl.1.A47
Del Valle J, Suppl.1.A84, Suppl.2.A17, A18, A40
Delchier JC, Suppl.1.A30, A55
Delle Fave G, Suppl.2.A7
Dell'Olio D, Suppl.2.A42
Deltenre M, Suppl.1.A36, A90, A96
Dennison N, Suppl.1.A9
Dent J, Suppl.1.A46
Deprez C, Suppl.1.A36, A89
Deren J, Suppl.1.A28
Dewhirst FE, Suppl.1.A26, A30
Dhillon AP, Suppl.2.A36
Dhir NK, Suppl.1.A19
Di Francesco V, Suppl.2.A29
di Giovine FS, Suppl.2.A17
Di Leo A, Suppl.1.A78
Di Mario F, Suppl.1.A15, A47, A57, A76, A82, A85
Di Tommaso A, Suppl.1.A51
Di Virgilio M, Suppl.1.A42
Dillon J, Suppl.2.A2, A25, A48
Dillon JF, Suppl.2.A33
Diss TC, Suppl.1.A6
Dixey J, Suppl.2.A42
Dixon M, Suppl.1.A51
Dixon MF, Suppl.1.A7, A39, A42, A54
Dockray GJ, Suppl.2.A19, A51
Doermann HP, Suppl.1.A25
Doidge C, Suppl.1.A93
Dollinger M, Suppl.2.A48
Domingo D, Suppl.1.A15, A72, A97
Dominguez-M JE, Suppl.1.A58
Dominguez-Muñoz E, Suppl.1.A60
Domizio P, Suppl.1.A74, A76, Suppl.2.A16, A44
Domschke W, Suppl.1.A6, Suppl.2.A23
Doninguez-Muñoz JE, Suppl.1.A53
Donisi PM, Suppl.1.A76
Donnelly C, Suppl.1.A63
Doppl WE, Suppl.1.A26
Dore MP, Suppl.1.A68
Dore S, Suppl.1.A11
Dorsch M, Suppl.1.A20
Douglas S, Suppl.2.A46
Drake IM, Suppl.1.A39
Drazek ES, Suppl.1.A61
Driessen A, Suppl.1.A40
Drilleau MF, Suppl.1.A66
Dronfield MW, Suppl.2.A45
Dubois A, Suppl.1.A50
Duff GW, Suppl.2.A17
Duggan AE, Suppl.1.A5, A42, A58
Dunn BE, Suppl.1.A19, A40
Dunphy J, Suppl.2.A42
DuPont HB, Suppl.1.A36
Dür S, Suppl.1.A9
Duval-Arujo I, Suppl.1.A35
Dworkin B, Suppl.1.A72

Earlam S, Suppl.2.A36
Eaton KA, Suppl.1.A48
Eckelmann S, Suppl.1.A18
Ectors N, Suppl.1.A40
Edmonds A, Suppl.1.A85
Efskind PS, Suppl.1.A86
Eidt S, Suppl.1.A40
Eisold H, Suppl.1.A5
Ekevall E, Suppl.2.A25
El-Nujumi A, Suppl.1.A83
El-Omar E, Suppl.1.A8, A11, A82, A83, A86, Suppl.2.A6, A39
El-Zaatari FAK, Suppl.1.A10, A59, A80
El-Zimaity H, Suppl.1.A4, A13, A36
El-Zimaity HMT, Suppl.1.A59, A80
Elamine I, Suppl.1.A55
Elder J, Suppl.1.A4
Elder JB, Suppl.2.A36
Elfant A, Suppl.1.A68
Elia M, Suppl.2.A16
Elias E, Suppl.2.A26, A28, A33, A34
Elliot T, Suppl.2.A33
Elliott T, Suppl.2.A39
Ellis B, Suppl.2.A23
Ellul J, Suppl.2.A4
Elsborg L, Suppl.1.A2
Emery PW, Suppl.2.A43
Emmanuel A, Suppl.2.A7
Enders G, Suppl.1.A9
Enders GA, Suppl.1.A81
Engstrand L, Suppl.1.A10, A24
Enno A, Suppl.1.A7
Enroth H, Suppl.1.A24
Epifanio G, Suppl.1.A37
Erlandsson KIM, Suppl.1.A53
Ermak TH, Suppl.1.A52, A94
Ernst PB, Suppl.1.A31, A50
Evans AE, Suppl.1.A11, A70
Evans DF, Suppl.2.A3, A52
Evans DG, Suppl.1.A10, A67
Evans RC, Suppl.2.A49
Eyre D, Suppl.1.A14

Fabrello R, Suppl.1.A82
Falco F, Suppl.2.A13
Falkow S, Suppl.1.A1
Faller G, Suppl.1.A33, A34
Fan XG, Suppl.1.A7
Fan XJ, Suppl.1.A7
Fanning G, Suppl.2.A22
Faragher IG, Suppl.2.A19
Farmery SM, Suppl.1.A3
Farris PC, Suppl.2.A29
Farthing MJG, Suppl.1.A74, A76, Suppl.2.A9, A12, A16, A40, A41, A44, A47, A52
Farup PG, Suppl.1.A45
Farzam F, Suppl.1.A21
Fasanella C, Suppl.1.A37
Fauchere JL, Suppl.1.A66
Fauconnier A, Suppl.1.A57, A69
Fedeli G, Suppl.1.A96
Federlin K, Suppl.1.A26
Fedorak R, Suppl.1.A5
Feinauer B, Suppl.1.A39
Fell JME, Suppl.2.A23
Feller M, Suppl.1.A68
Fennerty B, Suppl.1.A56
Ferhat M, Suppl.1.A36
Fernandes E, Suppl.1.A96
Fernandes MLM, Suppl.1.A71
Fernandez B, Suppl.1.A66
Ferrana M, Suppl.1.A47, A57
Ferraz-Neto B, Suppl.2.A33
Ferraz-Neto B-H, Suppl.2.A26
Ferrero RL, Suppl.1.A51, A65
Ferretti M, Suppl.2.A49
Feyerabend C, Suppl.2.A40
Fiala N, Suppl.1.A50
Figueroa G, Suppl.1.A41
Figura N, Suppl.1.A31, A37, A46, A51, A68, A71
Filippini M, Suppl.2.A29
Finlayson C, Suppl.1.A75, Suppl.2.A6
Finlayson NDC, Suppl.2.A48
Fiocca R, Suppl.1.A84, A87
Fisahn M, Suppl.2.A23
Fischer R, Suppl.1.A40
Fitch D, Suppl.1.A5
Fixa B, Suppl.1.A71, A33
Flamm R, Suppl.1.A67
Flejou J-F, Suppl.1.A35
Fleming DM, Suppl.2.A50
Fleming K, Suppl.2.A25
Fleming KA, Suppl.2.A14
Fletcher J, Suppl.2.A35
Flury R, Suppl.1.A28
Foerster EC, Suppl.1.A6
Fordy C, Suppl.2.A36
Forestier S, Suppl.1.A78, A92
Forget A-M, Suppl.2.A52
Forman D, Suppl.1.A4, A77
Forrest EH, Suppl.2.A3, A25, A33
Fortunato A, Suppl.1.A82
Fossi S, Suppl.1.A5, A37, A61
Fowler AL, Suppl.2.A3
Fox J, Suppl.1.A94
Fox JG, Suppl.1.A10, A27, A30, A48, A52
Franceschi M, Suppl.1.A82
Francis CY, Suppl.2.A46
Franco JMM, Suppl.1.A71
Franzin G, Suppl.1.A6
Fraser A, Suppl.2.A37, A50
Fraser AG, Suppl.1.A26
Fraser GJ, Suppl.1.A30
Fregonese D, Suppl.2.A5
Fried H, Suppl.1.A68
Fried M, Suppl.1.A28
Frulloni L, Suppl.2.A29
Fryer AA, Suppl.2.A36
Fuertes A, Suppl.1.A25
Fujioka T, Suppl.1.A37, A75
Fukuda S, Suppl.1.A95
Fukuda Y, Suppl.1.A19
Fuller BJ, Suppl.2.A34
Futagawa S, Suppl.1.A8

Galand P, Suppl.1.A96
Gallacher C, Suppl.1.A84
Galloway A, Suppl.2.A8
Galvin A, Suppl.2.A15
Gao Y-T, Suppl.1.A77
García Buey ML, Suppl.1.A34
García I, Suppl.1.A72
García Plaza A, Suppl.1.A25, A47
García-Rodríguez J, Suppl.2.A6
Garden OJ, Suppl.2.A3
Gardiner KR, Suppl.2.A16
Garlick NM, Suppl.2.A15
Garner R, Suppl.1.A65, Suppl.1.A66
Garofalo R, Suppl.1.A50
Gasbarrini G, Suppl.1.A37, A71, A96, Suppl.2.A13
Gatti NRA, Suppl.1.A71
Gatto M, Suppl.1.A40
Gaudin M, Suppl.1.A93
Gaylor J, Suppl.2.A25
Gazzard BG, Suppl.2.A12, A41
Gearty JC, Suppl.2.A32
Gebel M, Suppl.1.A82
Geboes K, Suppl.1.A40
Geerling BJ, Suppl.2.A32
Gemmell CG, Suppl.1.A3
Genta RM, Suppl.1.A4, A10, A13, A36, A59, A80, A89
George DK, Suppl.2.A8
Georgokopoulos K, Suppl.1.A94
Georgopoulos S, Suppl.1.A85
Germana B, Suppl.1.A47
Gernow A, Suppl.1.A14
Geypens B, Suppl.1.A11
Ghiara P, Suppl.1.A51
Ghironzi GC, Suppl.1.A37, A71
Ghoos Y, Suppl.1.A11
Gianikaki L, Suppl.1.A85
Gibbons AH, Suppl.1.A9, A83, A90, Suppl.2.A44
Gilchrist PJ, Suppl.2.A47
Gillen D, Suppl.1.A8, Suppl.2.A39
Gillon KRW, Suppl.1.A54
Gilman RH, Suppl.1.A10
Gion M, Suppl.1.A76
Gionchetti P, Suppl.2.A49
Giorcelli W, Suppl.1.A40
Giorgio I, Suppl.1.A78
Girardi LS, Suppl.1.A46
Gisbert JP, Suppl.1.A25, A30, A47
G.I.S.U. (Interdisciplinary Group for Ulcer Study), Suppl.1.A86
Giulianelli G, Suppl.1.A71
Glaxo *H. pylori* Study Group, Suppl.2.A6
Gleeson D, Suppl.2.A17, A34
Globe J, Suppl.2.A1
Glober G, Suppl.1.A7
Glupczynski Y, Suppl.1.A56, A57, A59, A69, A79, A89
Go MF, Suppl.1.A66, A67, A77
Goddard AF, Suppl.1.A88, A96, Suppl.2.A31
Godfroid E, Suppl.1.A57, A69
Goebell H, Suppl.2.A25
Goeral V, Suppl.1.A26
Goggins M, Suppl.1.A7
Goh KL, Suppl.1.A97
Goldfain D, Suppl.1.A55
Golding M, Suppl.2.A33
Gomborone JE, Suppl.2.A47
Gong F, Suppl.2.A1, A3, A52
Goodeve A, Suppl.2.A20
Goodison S, Suppl.2.A24
Goodwin A, Suppl.1.A66
Gorard DA, Suppl.2.A47
Gordon M, Suppl.2.A17, A34
Gorduna C, Suppl.1.A25
Gosciniak G, Suppl.1.A95
Goudie BM, Suppl.2.A9, A24
Gough AC, Suppl.2.A31, A36, A40
Gourley WK, Suppl.1.A50
Goutier S, Suppl.1.A56, A59, A69
Goyens Ph, Suppl.1.A57
Graffeo M, Suppl.1.A6
Graham DY, Suppl.1.A4, A7, A10, A13, A50, A59, A66, A67, A71, A77, A80, A89
Graham J, Suppl.2.A9
Grainger SL, Suppl.2.A10
Grant MH, Suppl.2.A25
Grant P, Suppl.1.A25, A53
Grasso GA, Suppl.1.A47, A57, A85
Greaves RRSH, Suppl.2.A52
Greaves S, Suppl.1.A4
Green R, Suppl.1.A14
Green WB, Suppl.1.A48
Greenslade L, Suppl.2.A48
Gregory WM, Suppl.2.A9
Griffin SM, Suppl.2.A2, A4, A7, A10, A35, A45
Grootscholten C, Suppl.2.A50
Grübel P, Suppl.1.A83
Grundman MJ, Suppl.2.A35
Gruppo Italiano Gabesato Endoscopia Digestiva (GRIGED), Suppl.2.A29
Guan R, Suppl.2.A32
Guedes LM, Suppl.1.A71
Gullini S, Suppl.1.A5
Gummett Pa, Suppl.1.A8, A88
Gunasena H, Suppl.1.A31
Günbey S, Suppl.1.A26
Gunson BK, Suppl.2.A34
Gurer IE, Suppl.1.A4
Gusmaroli R, Suppl.1.A40

H. pylori Ulcer Group, Suppl.1.A5
Haas R, Suppl.1.A1, A21
Häberle H, Suppl.1.A31, A50
Hachem CY, Suppl.1.A67
Hackelsberger A, Suppl.1.A35
Häivä V-M, Suppl.1.A12
Hall C, Suppl.2.A21
Halter F, Suppl.1.A9, A38
Hamilton H, Suppl.1.A61
Hamlet AK, Suppl.1.A53
Hampf F, Suppl.1.A38
Han SW, Suppl.1.A10
Handt L, Suppl.1.A52
Handt LK, Suppl.1.A48
Handwerker J, Suppl.1.A27
Häninen M-L, Suppl.1.A49
Hanley S, Suppl.1.A22
Hänninen M-L, Suppl.1.A92
Hansky J, Suppl.1.A83
Hansson H-A, Suppl.1.A74
Happonen I, Suppl.1.A49
Hardcastle JD, Suppl.2.A37
Hardwick R, Suppl.2.A4
Harison DJ, Suppl.2.A18
Härkönen M, Suppl.1.A26
Harridence A, Suppl.2.A10

Harris AW, Suppl.1.A8, A73, A74, Suppl.2.A39, A44
Harrison DJ, Suppl.2.A33
Hasegawa H, Suppl.1.A54
Hastings L, Suppl.2.A6
Hastings M, Suppl.2.A26
Hatz R, Suppl.1.A39, A44, A89
Hatz RA, Suppl.1.A9, A81
Hauer ACh, Suppl.2.A16
Haug JB, Suppl.1.A16, A86
Hauge T, Suppl.1.A86
Havard TJ, Suppl.1.A76
Hawkey CJ, Suppl.1.A58, A64, A79, A88, Suppl.2.A15, A18, A22, A31
Hawkins PN, Suppl.2.A27
Hawley PR, Suppl.2.A21
Hayashi T, Suppl.1.A19
Haydon GH, Suppl.2.A2, A27, A28
Hayes N, Suppl.2.A7, 10, A35
Hayes P, Suppl.2.A48
Hayes PC, Suppl.2.A2, A3, A8, A25, A27, A28, A33, A48
Haylett KR, Suppl.2.A50
Haynes WG, Suppl.2.A51
Hayward A, Suppl.1.A48, A52
Hazell S, Suppl.1.A63
Hazell SL, Suppl.1.A19, A20, A38, A78, A88
Heading RC, Suppl.2.A46
Heald RJ, Suppl.2.A23
Heaton KW, Suppl.2.A51
Hebden JM, Suppl.2.A47
Hector M, Suppl.2.A52
Hegels K, Suppl.1.A4
Heidt H, Suppl.1.A44
Heinonen OP, Suppl.1.A11, A26
Helander HF, Suppl.1.A29
Heldwein W, Suppl.1.A44
Hele C, Suppl.1.A89
Hellyer TJ, Suppl.1.A63
Helske T, Suppl.1.A13
Henderson J, Suppl.1.A40
Henderson N, Suppl.2.A48
Hendricks K, Suppl.1.A65
Hendrickse C, Suppl.2.A36
Henin D, Suppl.1.A35
Hennemann O, Suppl.1.A25, A54
Henriksen M, Suppl.1.A86
Heppell RM, Suppl.1.A25, A53
Hepworth CC, Suppl.2.A1, A3, A37, A52
Hershman M, Suppl.2.A12
Hershman MJ, Suppl.2.A5
Heuermann D, Suppl.1.A21
Hewett PW, Suppl.2.A18
Hewin DF, Suppl.2.A21
Hickman JA, Suppl.2.A20
Hill MJ, Suppl.2.A35
Hippensteel R, Suppl.1.A43
Hirai M, Suppl.1.A7
Hirakawa R, Suppl.1.A44
Hirata I, Suppl.1.A49
Ho KY, Suppl.2.A32
Höchter W, Suppl.1.A44, A89
Hodgson HJF, Suppl.2.A20, A26, A27, A33
Hoffman PS, Suppl.1.A66
Holcombe C, Suppl.1.A81
Hole J, Suppl.2.A45
Holt H, Suppl.2.A50
Hooley INM, Suppl.2.A30
Hopkins RJ, Suppl.1.A46
Hopkirk N, Suppl.1.A26
Hopwood D, Suppl.1.A84
Hoshiya S, Suppl.1.A49
Hossack M, Suppl.1.A62
Hotz J, Suppl.1.A34
Houben P, Suppl.1.A14
Houghton LA, Suppl.2.A46, A51
Hovell CJ, Suppl.2.A26
Howard A, Suppl.2.A17, A20
Howe B, Suppl.1.A68
Howlett R, Suppl.1.A51
Hu PJ, Suppl.1.A38, A78
Huang MS, Suppl.1.A12
Huber F, Suppl.1.A44
Huerre M, Suppl.1.A51
Hughes NJ, Suppl.1.A18
Hughes RD, Suppl.2.A48
Hull MA, Suppl.2.A18
Hülskath H, Suppl.1.A39
Hultén K, Suppl.1.A10
Humphreys S, Suppl.2.A47
Hunt R, Suppl.1.A5
Hunt RH, Suppl.1.A56, Suppl.2.A31
Hurlimann S, Suppl.1.A9, A38
Hurtado A, Suppl.1.A64
Hussain F, Suppl.2.A45
Hussaini SH, Suppl.2.A14
Hyde D, Suppl.1.A55, A91
Hyvärinen H, Suppl.1.A13

Ichinose M, Suppl.1.A7
Idle N, Suppl.2.A35, A38
Idström JP, Suppl.1.A4, A8, A41, A55
Imeneo M, Suppl.1.A52, A78
Inaba Y, Suppl.1.A8
Inauen W, Suppl.1.A9
Incecik ET, Suppl.1.A50
Iqbal TH, Suppl.2.A13, A32
Isaacson PG, Suppl.1.A6
Isakov VA, Suppl.1.A29
Italian Helicobacter Pylori Study Group, Suppl.1.A53
Ito S, Suppl.1.A7
Itoh T, Suppl.1.A49
Ivey KJ, Suppl.1.A84

Jackson CJ, Suppl.1.A18
Jackson NA, Suppl.2.A51
Jacobs E, Suppl.2.A37
Jacyna MR, Suppl.1.A8
Jalan R, Suppl.2.A28, A48
Jalava K, Suppl.1.A49
James RFI, Suppl.1.A60
Jamieson CP, Suppl.2.A11
Jan CM, Suppl.1.A12
Järvinen P, Suppl.1.A13
Jarvis LM, Suppl.2.A27, A28, A33
Jaseph C, Suppl.1.A60
Jatzwauk P, Suppl.1.A39
Jaup BH, Suppl.1.A43
Jazrawi RP, Suppl.2.A19, A27
Jenkins D, Suppl.1.A79, Suppl.2.A15, A22
Jennings G, Suppl.2.A16
Jewell DP, Suppl.2.A14, A15, A21, A22, A24, A50
Jiesong H, Suppl.1.A94
John TG, Suppl.2.A3
Johnsen J, Suppl.1.A66
Johnson C, Suppl.1.A15
Johnson CD, Suppl.2.A28, A31, A40
Johnson SG, Suppl.2.A30
Johnson TE, Suppl.2.A30
Johnston BJ, Suppl.2.A35, A38
Johnston BT, Suppl.2.A45
Johnston CF, Suppl.1.A9
Johnston D, Suppl.2.A14
Jonas C, Suppl.1.A90
Jones A, Suppl.1.A63, Suppl.2.A19, A51
Jones AC, Suppl.1.A23
Jones AF, Suppl.2.A49
Jones AR, Suppl.2.A46
Jones LS, Suppl.2.A20
Jones MN, Suppl.2.A19
Jones PH, Suppl.2.A6
Jones R, Suppl.2.A30
Jones RA, Suppl.2.A35, A38
Jonkers D, Suppl.1.A14
Jorgensen M, Suppl.1.A20
Jorgensen R, Suppl.2.A25
Jorgensen T, Suppl.1.A27
Josenhans C, Suppl.1.A62
Joubert-Collin M, Suppl.1.A92
Justin T, Suppl.2.A52
Justin TA, Suppl.2.A37
Juutinen K, Suppl.1.A12

Kaartinen M, Suppl.1.A49
Kadirkamanathan SS, Suppl.2.A1, A3, A52
Kahn MA, Suppl.2.A24
Kaise R, Suppl.1.A8
Kang JY, Suppl.2.A32, A53
Kansau I, Suppl.1.A51, A65
Kantola S, Suppl.1.A13
Kapoor H, Suppl.1.A45
Kaps MF, Suppl.1.A81
Kapur K, Suppl.1.A56
Kapur V, Suppl.1.A66
Karameris A, Suppl.1.A76
Karat D, Suppl.2.A4, A7, A10, A35
Karim QN, Suppl.1.A19, Suppl.2.A6
Karita M, Suppl.1.A1, A49
Kärkkäinen P, Suppl.1.A92
Karlicek R, Suppl.1.A33
Karttunen R, Suppl.1.A35, A50
Karttunen T, Suppl.1.A35
Karttunen TJ, Suppl.1.A36, A59, A77, A80, A89
Kasapidis P, Suppl.2.A12
Katelaris PH, Suppl.1.A74, A76
Kato S, Suppl.1.A54
Kato T, Suppl.1.A7
Kaup W, Suppl.1.A79
Kaur S, Suppl.1.A77, Suppl.2.A36
Kayser St, Suppl.1.A28
Kazembe F, Suppl.2.A41

Keane CT, Suppl.1.A55
Keane E, Suppl.2.A41
Keele AM, Suppl.2.A43
Keeling PWN, Suppl.1.A7, Suppl.2.A45
Keenan JI, Suppl.1.A93, A95
Kekki M, Suppl.1.A69
Kelleher D, Suppl.1.A7, A50
Kelly DA, Suppl.2.A30
Kelly DJ, Suppl.1.A18
Kelly P, Suppl.2.A12, A41
Kelly SM, Suppl.2.A11
Kench SM, Suppl.1.A24
Kennedy HJ, Suppl.2.A11
Kenyon A, Suppl.2.A23
Keppens E, Suppl.1.A58
Kerola T, Suppl.1.A35, A36
Kerr MA, Suppl.1.A80, Suppl.2.A16
Kersten A, Suppl.1.A21
Kersulyte D, Suppl.1.A1, A61
Kettlewell MGW, Suppl.2.A15, A19, A24
Khulusi S, Suppl.1.A16
Kibler K, Suppl.1.A67
Kihira K, Suppl.1.A44
Kikuchi S, Suppl.1.A8
Kikuichi M, Suppl.1.A8
Kim JG, Suppl.1.A77
Kimura K, Suppl.1.A44
Kirchner Th, Suppl.1.A33, A34
Kirk SJ, Suppl.2.A16
Kiss J, Suppl.1.A30
Kist M, Suppl.1.A21
Klann H, Suppl.1.A44
KLarttunen R, Suppl.1.A80
Kleanthous C, Suppl.1.A16
Kleanthous H, Suppl.1.A48, A52, A94
Klein PD, Suppl.1.A10
Klör HU, Suppl.1.A26
Knekt P, Suppl.1.A26
Knifton A, Suppl.1.A58
Knight T, Suppl.1.A4
Knipp U, Suppl.1.A32, A79
Knoishi T, Suppl.1.A8
Kobayashi O, Suppl.1.A8
Kobori O, Suppl.1.A8
Koch O, Suppl.1.A6
Koch P, Suppl.1.A6
Kodama R, Suppl.1.A37, A75
Köhl H, Suppl.1.A28
Kohli Y, Suppl.1.A7
Koizuka H, Suppl.1.A19
Kolesnikow T, Suppl.1.A2
Komarkova O, Suppl.1.A33
Kopp R, Suppl.1.A9
Korhonen H, Suppl.1.A92
Korri UM, Suppl.1.A13
Kosunen TU, Suppl.1.A11, A26, A58, A92
Kraehenbuhl J-P, Suppl.1.A93
Krakowka S, Suppl.1.A48
Krämling H-J, Suppl.1.A81
Krasilnikoff PA, Suppl.1.A14
Kubba AK, Suppl.2.A38
Kubin M, Suppl.1.A50
Kubo T, Suppl.1.A8
Kubota T, Suppl.1.A37, A75
Kucharzik T, Suppl.2.A23
Kühl P, Suppl.1.A29
Kumar D, Suppl.2.A24
Kuriyama M, Suppl.1.A7
Kurosawa M, Suppl.1.A8
Kusstatscher S, Suppl.1.A47, A57, A85

Labenz J, Suppl.1.A6, A8, A25, A28, A41, A43, A54
Labigne A, Suppl.1.A23, A51, A62, A65, A67, A79
Lage AP, Suppl.1.A57, A69
Lahaie RG, Suppl.1.A13
Lai T, Suppl.2.A21
Laino G, Suppl.1.A47
Lamarque D, Suppl.1.A30
Lambert JR, Suppl.1.A59, A83, A88, A90
Lamireau T, Suppl.1.A25
Lamouliatte H, Suppl.1.A55, A67, A78, A91, A92
Landi F, Suppl.1.A40
Langworthy H, Suppl.2.A7
Lanzini A, Suppl.2.A27
Larkins A, Suppl.1.A60
Larm O, Suppl.1.A74
Larsson H, Suppl.1.A49
Laterza F, Suppl.1.A91
Laws SAM, Suppl.2.A36
Lawson F, Suppl.1.A11
Le Roux PH, Suppl.1.A73, A74, Suppl.2.A44
Leandro G, Suppl.1.A57, A76

Lebovics E, Suppl.1.A72
Lecis PE, Suppl.1.A47, A76
Leddin D, Suppl.1.A56
Lee A, Suppl.1.A2, A7, A20, A38, A48, A51, A93, Suppl.2.A48
Lee C, Suppl.1.A94
Lee CA, Suppl.1.A45
Lee CK, Suppl.1.A45, A52
Lee E, Suppl.2.A32
Lee FD, Suppl.2.A21
Lee G, Suppl.1.A48
Lee SC, Suppl.1.A12
Lee SH, Suppl.2.A50
Legon S, Suppl.1.A9, A83, Suppl.2.A17, A44
Lehn N, Suppl.1.A9, A38, A39, A44, A54, A89
Leicester RJ, Suppl.2.A23
Lella F, Suppl.1.A82
Leong SO, Suppl.2.A32
Lerang F, Suppl.1.A16, A86
Lerwill RJ, Suppl.2.A10
Lessels A, Suppl.2.A4
Leung VKS, Suppl.1.A6
Levi J, Suppl.1.A10
Levi S, Suppl.2.A38
Levy J, Suppl.1.A16, A75
Levy JH, Suppl.2.A27
Levy L, Suppl.1.A14
Lewis KO, Suppl.2.A13
Lewis SJ, Suppl.2.A13, A51
Leyh S, Suppl.1.A39
Li H, Suppl.1.A29
Li X, Suppl.1.A48, A52
Li YY, Suppl.1.A38, A78
Libby GW, Suppl.2.A47
Liberti A, Suppl.1.A41
Lilius E-M, Suppl.1.A92
Lim AG, Suppl.2.A27
Limia A, Suppl.1.A15
Lin HL, Suppl.1.A38
Lin L, Suppl.1.A74, A76, Suppl.2.A16
Lin SK, Suppl.1.A83
Lin YL, Suppl.1.A29
Lind T, Suppl.1.A4
Lindley IJD, Suppl.1.A31, A33
Lindner B, Suppl.1.A16
Lindor K, Suppl.2.A25
Linehan IP, Suppl.2.A9
Ling TKW, Suppl.1.A6
Linke A, Suppl.1.A53, A58
Linkholm C, Suppl.1.A22
Linn J, Suppl.1.A48
Linsalata M, Suppl.1.A78
Liston R, Suppl.2.A13
Liu DQ, Suppl.1.A38
Ljungh , Suppl.1.A61
Lloyd R, Suppl.1.A75
Lo YL, Suppl.1.A97
Logan RFA, Suppl.1.A58, Suppl.2.A11
Logan RPH, Suppl.1.A4, A19, A58, A64, A85, A88, Suppl.2.A6
Lombard M, Suppl.2.A12
Long A, Suppl.1.A7
Lopez-Brea M, Suppl.1.A15
López-Brea M, Suppl.1.A72, A97
Lopez M, Suppl.2.A9, A24
Lorini GP, Suppl.2.A27
Losowsky MS, Suppl.2.A14
Louis E, Suppl.2.A15, A22
Louw JA, Suppl.1.A42, Suppl.2.A39
Lovat LB, Suppl.2.A27
Lowy A, Suppl.1.A72
Lu JH, Suppl.1.A12
Luca MG, Suppl.2.A19, A51
Lucke W, Suppl.2.A39
Lügering N, Suppl.2.A23
Luinetti O, Suppl.1.A87
Luke CJ, Suppl.1.A63
Luman W, Suppl.1.A21, A22, Suppl.2.A4, A51
Lund JN, Suppl.2.A5, A49
Lundström A, Suppl.1.A22
Lungu F, Suppl.2.A41
Lupetti P, Suppl.1.A94
Lupinacci G, Suppl.1.A40
Luthra R, Suppl.1.A50
Luzza F, Suppl.1.A52, A78
Luzzi I, Suppl.2.A7
Lye WC, Suppl.2.A32
Lynch DAF, Suppl.1.A54

Maaroos H-I, Suppl.1.A72
McAlindon ME, Suppl.2.A18
McBride PDP, Suppl.1.A80, Suppl.2.A16
McCallion WA, Suppl.1.A70
McCloy RF, Suppl.2.A50
McColl KEL, Suppl.1.A8, A11,

A62, A82, A83, A86, Suppl.2.A6, A39
McColm AA, Suppl.1.A50, A63, A92
McCormick C, Suppl.1.A55
McCormick PA, Suppl.2.A48
McCrum EE, Suppl.1.A11, A70
McCullough S, Suppl.1.A26
McDevitt DG, Suppl.1.A90
MacDonald TM, Suppl.1.A90
MacDonald TT, Suppl.2.A16, A23
McDougall NI, Suppl.2.A45
McDowell SR, Suppl.1.A62
McFarlane XA, Suppl.2.A42
MacFie J, Suppl.2.A1, A14, A43
MacGilchrist AJ, Suppl.2.A3
McGilchrist MM, Suppl.1.A90
McGoogan E, Suppl.2.A3
McGovern JJ, Suppl.1.A16
Maciel CD, Suppl.1.A71
McIntyre N, Suppl.2.A48
McKeown PA, Suppl.2.A8
McKinlay A, Suppl.2.A37
McKnight G, Suppl.2.A8, A37, A50
McLaren A, Suppl.1.A50, A62, A63, A92
McLaughlan J, Suppl.1.A79
McLaughlan JM, Suppl.2.A15
McLaughlin JT, Suppl.2.A19, A51
McMaster P, Suppl.2.A26, A34
McNulty C, Suppl.1.A63
McNulty CAM, Suppl.1.A15, A46, Suppl.2.A31
Maconi G, Suppl.1.A23, A41
McSorley DJ, Suppl.1.A5
McWhirter JP, Suppl.2.A43
McWilliam D, Suppl.2.A22
Madhoo S, Suppl.2.A27
Maes B, Suppl.1.A11
Magnago AGP, Suppl.1.A26, A35, A92
Magnarini C, Suppl.1.A42
Maguire C, Suppl.2.A21
Mahida YR, Suppl.2.A18
Mahl M, Suppl.2.A25
Mahmoud AEA, Suppl.2.A28, A33
Mai UEH, Suppl.1.A32, A82
Maiolo P, Suppl.1.A40
Maitland B, Suppl.2.A6
Mäki M, Suppl.1.A24
Makin AJ, Suppl.2.A48
Malatjalian D, Suppl.1.A56
Malaty H, Suppl.1.A10
Malaty HM, Suppl.1.A71, A7, A36
Malek M, Suppl.1.A47
Maletta M, Suppl.1.A52, A78
Malfertheiner P, Suppl.1.A3, A18, A29, A35, A53, A58, A60
Malhotra R, Suppl.2.A13
Mamtora H, Suppl.2.A51
Mancey-Jones B, Suppl.2.A1
Mancini L, Suppl.1.A55
Manegold C, Suppl.1.A39
Manetti R, Suppl.1.A51, A94
Manheller I, Suppl.1.A18
Mani V, Suppl.2.A40
Manika Z, Suppl.1.A85
Mannes GA, Suppl.1.A54, A89
Manns M, Suppl.1.A32, A82
Mansfield JC, Suppl.2.A2
Mapstone N, Suppl.1.A39
Mapstone NP, Suppl.1.A39
Marcheggiano A, Suppl.1.A78
Marchetti M, Suppl.1.A51
Marchini A, Suppl.1.A51, A94
Marcon N, Suppl.1.A68
Marignani M, Suppl.2.A7
Marini RP, Suppl.1.A48, A52
Marks IN, Suppl.2.A39
Marnila P, Suppl.1.A92
Marotta F, Suppl.1.A34
Martin de Argila C, Suppl.1.A25, A30, A47
Martin DF, Suppl.2.A12
Martinez MJ, Suppl.1.A15
Martinez MJ, Suppl.1.A72, A97
Marxer M, Suppl.1.A21
Mashentseva EV, Suppl.1.A28
Mason R, Suppl.2.A4
Massardi B, Suppl.1.A40
Massarelli G, Suppl.1.A68
Massari P, Suppl.1.A51, A94
Masson J, Suppl.2.A8, A37, A50
Masubuchi N, Suppl.1.A49
Matsukura N, Suppl.1.A54
Matsumoto S, Suppl.1.A49
Matsumoto Y, Suppl.1.A49
Matsuoka K, Suppl.1.A49
Matthewson K, Suppl.2.A2
Matysiak-Budnik T, Suppl.1.A71
Matzen P, Suppl.1.A14
Mauch F, Suppl.1.A20, A72, A73
Maxwell JD, Suppl.2.A6, A42
Mayberry JF, Suppl.2.A9, A41
Mayer AD, Suppl.2.A34
Mazzucchelli L, Suppl.1.A9
Meadows D, Suppl.1.A24
Mee AS, Suppl.2.A30
Meekison LA, Suppl.2.A46
Mégraud F, Suppl.1.A25, A35, A55, A67, A71, A78, A91, A92, A94
Meikle D, Suppl.2.A10
Meining A, Suppl.1.A39, A44, A54
Melchers K, Suppl.1.A2, A17, A21
Meli V, Suppl.1.A82
Melichar B, Suppl.1.A33
Mellgård B, Suppl.1.A29, A49
Mellor N, Suppl.2.A26
Mendall MA, Suppl.1.A10, A16, A69, A75, Suppl.2.A6
Mendes EN, Suppl.1.A26, A27, A92
Méndez L, Suppl.1.A68
Mendz GL, Suppl.1.A19, A20, A88
Menegatti M, Suppl.1.A40
Mentis A, Suppl.1.A85
Merigo F, Suppl.2.A29
Merritt AJ, Suppl.2.A20
Mesheikes A, Suppl.2.A26
Messa C, Suppl.1.A78
Michaeli D, Suppl.2.A37
Michetti P, Suppl.1.A93
Middleton S, Suppl.2.A1
Midolo P, Suppl.1.A59, A83
Midolo PD, Suppl.1.A88
Miederer SE, Suppl.1.A83
Miehlke S, Suppl.1.A54, A77, A89
Miettinen A, Suppl.1.A24, A77
Miglio F, Suppl.1.A37, A71
Miglioli M, Suppl.1.A40, Suppl.2.A49
Mikami T, Suppl.1.A95
Miki K, Suppl.1.A7, A8
Milesi F, Suppl.1.A40
Millar AD, Suppl.2.A11
Miller GG, Suppl.1.A75
Milne S, Suppl.1.A26
Minguzzi M, Suppl.1.A23
Miranda D, Suppl.1.A92
Miranda SC, Suppl.1.A71
Mirza D, Suppl.2.A33
Mirza DF, Suppl.2.A34
Misiewicz JJ, Suppl.1.A8, A19, A73, A74, A88, Suppl.2.A39
Mitchell CJ, Suppl.2.A1, A14, A43
Mitchell HM, Suppl.1.A38, A78
Mix H, Suppl.1.A32
Mixiewicz JJ, Suppl.2.A44
Mizobuchi N, Suppl.1.A8
Mizuki I, Suppl.1.A95
Moayeddi P, Suppl.1.A41
Moayyedi P, Suppl.1.A12, A25, A44, A46, A53, Suppl.2.A7, A32
Mobley H, Suppl.1.A65
Mobley HLT, Suppl.1.A66
Moe B, Suppl.1.A45
Mohamed R, Suppl.2.A34
Mohammadi M, Suppl.1.A33
Mokhashi MS, Suppl.1.A3, Suppl.2.A8
Molineaux N, Suppl.1.A10
Monath T, Suppl.1.A94
Monath TP, Suppl.1.A52
Moniz C, Suppl.2.A26
Montalto M, Suppl.1.A96
Monteiro MA, Suppl.1.A17
Moran A, Suppl.2.A49
Moran AP, Suppl.1.A2, A16, A17, A31
Moretzsohn LD, Suppl.1.A71
Morgan AG, Suppl.1.A14
Morgan-Capner P, Suppl.1.A24
Mori K, Suppl.1.A8
Moriarty KJ, Suppl.2.A13
Morris AJ, Suppl.2.A8
Morris J, Suppl.2.A46
Morris P, Suppl.2.A20
Morris TM, Suppl.2.A37
Mortensen NJMcC, Suppl.2.A5, A15, A24, A47
Moum B, Suppl.1.A16, A86
Mountford R, Suppl.2.A13
Mountford RA, Suppl.2.A45
Moura SB, Suppl.1.A26, A27, A92
Mourad FH, Suppl.2.A52
Mowat NAG, Suppl.2.A8, A37, A50
Moxon D, Suppl.2.A1, A2
Mulder CJJ, Suppl.1.A68
Mulè P, Suppl.1.A40
Mulholland G, Suppl.2.A45
Mulla R, Suppl.1.A77
Mulla RJ, Suppl.1.A90
Mullany P, Suppl.1.A22, A23
Mullins JGLI, Suppl.2.A17
Murakami K, Suppl.1.A37, A75
Murchan PM, Suppl.2.A1, A14, A43
Murphy JC, Suppl.1.A48, A52
Murray F, Suppl.1.A47
Murray FE, Suppl.1.A80, A84, A90, Suppl.2.A16
Murray LJ, Suppl.1.A11, A70
Musser JM, Suppl.1.A66
Mutimer DJ, Suppl.2.A26, A34
Myers G, Suppl.1.A94
Myoga A, Suppl.1.A8

Nachamkin I, Suppl.1.A28
Nagawa H, Suppl.1.A8
Nair P, Suppl.1.A15, A46, Suppl.2.A31, A38
Nakajima T, Suppl.1.A8
Nakamuta K, Suppl.2.A22
Nakshabendi IM, Suppl.1.A3, Suppl.2.A8
Namavar F, Suppl.1.A68
Nasu M, Suppl.1.A37, A75
Navab F, Suppl.1.A38
Navaglia F, Suppl.1.A15
Navratil E, Suppl.1.A35
Nazarina AR, Suppl.1.A97
Nedrud J, Suppl.1.A33
Nedrud JG, Suppl.1.A31
Negrini R, Suppl.1.A6
Neilly PJD, Suppl.2.A16
Nelufer JM, Suppl.2.A42
Neubauer A, Suppl.1.A38, A39
Neubauer B, Suppl.1.A38, A39
Neuberger JM, Suppl.2.A34
Neumann CS, Suppl.2.A32
Newcombe R, Suppl.2.A40
Newell D, Suppl.1.A4
Newell DG, Suppl.1.A77
Newland R, Suppl.2.A45
Newton M, Suppl.2.A37
Ng EKW, Suppl.1.A6
Nicolaysen K, Suppl.1.A86
Nielsen H, Suppl.1.A2, A95
Niemelä S, Suppl.1.A35, A36
Nietert M, Suppl.1.A82
Nightingale JMD, Suppl.2.A41
Nilius M, Suppl.1.A3, A18, A29, A35
Nilsson H-O, Suppl.1.A93
Nilsson I, Suppl.1.A96
Ninomiya H, Suppl.1.A49
Nord CE, Suppl.1.A63
Norgaard A, Suppl.1.A2
Norrby A, Suppl.1.A43
Northfield TC, Suppl.1.A10, A16, A69, A75, Suppl.2.A6, A11, A19, A27
Nuutinen H, Suppl.1.A58

Obeidat W, Suppl.2.A21
Odenbreit S, Suppl.1.A1, A21
O'Donnell C, Suppl.1.A67
O'Donnell LJD, Suppl.2.A52
O'Donoghue D, Suppl.2.A45
O'Donohue J, Suppl.2.A26
O'Dorisio T, Suppl.1.A68
O'Grady J, Suppl.2.A14
O'Hanlon D, Suppl.2.A4
O'Hanlon DM, Suppl.2.A7, A10, A35
Ohlin B, Suppl.1.A42
Okamoto N, Suppl.1.A8
Olbe L, Suppl.1.A53
Oldroyd B, Suppl.2.A14
Oliveira AMR, Suppl.1.A26, A27, A92
Oliveira CA, Suppl.1.A92
Olivieri R, Suppl.1.A51
Olson C, Suppl.1.A43, A52, A85
O'Malley C, Suppl.1.A50
O'Morain C, Suppl.1.A4, A42, A61, A91
O'Morain CA, Suppl.1.A54, A55
Onda M, Suppl.1.A54
Ong KK, Suppl.1.A97
Oona M, Suppl.1.A72
Opekun AR, Suppl.1.A10
Opferkuch W, Suppl.1.A79
Oppenheim D, Suppl.1.A28
Oppenheim E, Suppl.2.A17
Orefice R, Suppl.2.A7
O'Reilly DPJ, Suppl.1.A11, A70
O'Rourke J, Suppl.1.A7, A51
Ortmann M, Suppl.1.A40
O'Shea C, Suppl.2.A38
Osman E, Suppl.2.A34
Otani R, Suppl.1.A8
Ottway J, Suppl.2.A5
Oura S, Suppl.1.A8
Owen RJ, Suppl.1.A64
Owen WA, Suppl.2.A46
Owen WJ, Suppl.2.A46
Ozmen MM, Suppl.2.A31, A40

Pærregaard A, Suppl.1.A14
Paetow A, Suppl.1.A32
Page J, Suppl.2.A11
Påhlsson C, Suppl.1.A24
Paikov VL, Suppl.1.A27
Pain JA, Suppl.2.A11
Pajares JM, Suppl.1.A34
Pallone F, Suppl.1.A52, A78
Palmer D, Suppl.2.A14, A43
Palmer K, Suppl.1.A21, A22, A85
Palmer KR, Suppl.2.A4, A38, A51
Pan L, Suppl.1.A6
Panagou M, Suppl.2.A34
Pannuti F, Suppl.1.A40
Pantaleone U, Suppl.1.A42
Paoletti M, Suppl.2.A7
Papa A, Suppl.1.A96
Pappo J, Suppl.1.A10, A52, A94
Parasakthi N, Suppl.1.A97
Parente F, Suppl.1.A23, A41
Park J, Suppl.2.A17, A18, A40
Pasechnikov VD, Suppl.1.A28
Pasi J, Suppl.1.A45
Pasini M, Suppl.1.A76
Paspatis GA, Suppl.2.A11
Pasquino M, Suppl.1.A76
Passos MCF, Suppl.1.A71
Paster BJ, Suppl.1.A26, A30
Patch D, Suppl.2.A34, A48
Patchett SE, Suppl.1.A74, A76, Suppl.2.A16, A40, A44
Patel AC, Suppl.2.A45
Patel P, Suppl.1.A16, A69, A75, Suppl.2.A6
Paterson Brown S, Suppl.2.A3
Paykov V, Suppl.1.A71
Pazianas M, Suppl.2.A42
Pazzi P, Suppl.1.A5
Peacock RA, Suppl.1.A54
Peake I, Suppl.2.A20
Pearson J, Suppl.2.A32
Pederzoli P, Suppl.2.A29
Peek RM, Suppl.1.A3, A69, A75
Peeters M, Suppl.1.A11
Peh SC, Suppl.1.A97
Peichl P, Suppl.1.A33
Peikin S, Suppl.1.A68
Peitz U, Suppl.1.A6, A8, A25, A28, A41, A43, A54
Penn CW, Suppl.1.A63
Pennington CR, Suppl.2.A9, A24, A43
Pepys MB, Suppl.2.A27
Pere A, Suppl.1.A12
Perez-Perez G, Suppl.1.A50
Perez-Perez GI, Suppl.1.A34, A69, A79
Perkins AC, Suppl.2.A47
Perkins S, Suppl.1.A10
Perng DS, Suppl.1.A12
Perrett D, Suppl.2.A16, A40, A44
Perri F, Suppl.1.A11
Perry S, Suppl.1.A3, A33
Persey MR, Suppl.2.A27
Peterson WL, Suppl.1.A5
Petronelli A, Suppl.1.A40
Pettersson AB, Suppl.1.A53
Phadnis SH, Suppl.1.A19, A40
Phillips RKS, Suppl.2.A21
Phull PS, Suppl.1.A8
Pianko S, Suppl.1.A83
Pica R, Suppl.2.A7
Pigozzi MG, Suppl.2.A27
Pilotto A, Suppl.1.A82
Pisanu G, Suppl.1.A68
Pitcher MCL, Suppl.2.A15, A22
Pizza MG, Suppl.1.A51
Pizzicannella G, Suppl.1.A42
Plasterk RHA, Suppl.1.A68
Plebani M, Suppl.1.A15, A57
Plebania M, Suppl.1.A47
Plein K, Suppl.1.A34
Plevris JN, Suppl.2.A48
Pobee JOM, Suppl.2.A41
Pollak PT, Suppl.1.A45
Polos G, Suppl.1.A7
Pomme E, Suppl.1.A58
Pond CL, Suppl.2.A23
Poniewierka E, Suppl.1.A95
Popova N, Suppl.1.A96
Porta N, Suppl.1.A93
Portell DP, Suppl.1.A41
Post L, Suppl.1.A84, Suppl.2.A17, A18, A40
Potten CS, Suppl.2.A20

Potts L, Suppl.2.A13
Pounder RE, Suppl.1.A42, A45, Suppl.2.A50
Powell KU, Suppl.2.A6
Powell-Tuck J, Suppl.2.A43
Poxon V, Suppl.1.A87
Pozzato P, Suppl.1.A5, A37, A61
Prach AT, Suppl.1.A80, A90, Suppl.2.A16
Prasad VM, Suppl.1.A12, A13
Preston T, Suppl.1.A62
Pretolani S, Suppl.1.A37, A71, A96
Prichard PJ, Suppl.1.A59
Prifti S, Suppl.1.A71
Primrose JN, Suppl.2.A36
Privitera U, Suppl.1.A41
Pronovost A, Suppl.1.A15
Protheroe S, Suppl.2.A30
Prytherch D, Suppl.2.A23
Przemioslo R, Suppl.2.A42
Przondo-Mordarska A, Suppl.1.A95
Pugh S, Suppl.1.A56
Puglisi A, Suppl.1.A85

Quarrell O, Suppl.2.A20
Queiroz DMM, Suppl.1.A26, A27, A35, A92
Quellard N, Suppl.1.A66
Quirke P, Suppl.1.A42

Rabello ALT, Suppl.1.A27
Radcliff FJ, Suppl.1.A48
Ragnhildstveit E, Suppl.1.A16, A86
Rägo T, Suppl.1.A72
Ragunath K, Suppl.2.A40
Raimes S, Suppl.2.A35
Rajgopal C, Suppl.2.A38
Ramdani B, Suppl.1.A89
Ramirez AJ, Suppl.2.A9
Rampton DS, Suppl.1.A80, Suppl.2.A21, A44
Ramsay M, Suppl.1.A88
Ramus SJ, Suppl.2.A19
Rappuoli R, Suppl.1.A14, A23, A32, A51, A94
Rathbone B, Suppl.1.A87
Rathbone BJ, Suppl.1.A60, Suppl.2.A41
Rautelin H, Suppl.1.A26, A92
Rauws EAJ, Suppl.1.A68
Ray KC, Suppl.1.A69
Read MWR, Suppl.2.A29
Realdi G, Suppl.1.A68
Reddy R, Suppl.1.A67
Redhead DN, Suppl.2.A3
Redline R, Suppl.1.A33
Reed PI, Suppl.1.A85, Suppl.2.A35, A38
Rees E, Suppl.2.A33
Reggiani A, Suppl.2.A27
Rehnberg-Laiho L, Suppl.1.A92
Reijman IL, Suppl.1.A36
Reilly TG, Suppl.1.A87, Suppl.2.A39
Rejchrt S, Suppl.1.A33
Reltmayer R, Suppl.1.A85
Rembacken B, Suppl.1.A31
Reyes VE, Suppl.1.A31, A50
Reymunde A, Suppl.1.A28
Reynolds DJ, Suppl.1.A63
Rhodes J, Suppl.2.A40
Rhodes JM, Suppl.2.A49, A53
Ricard N, Suppl.1.A13
Ricci C, Suppl.1.A40
Ricci V, Suppl.1.A84
Richards MA, Suppl.2.A9
Richardson PDI, Suppl.2.A45
Rieder G, Suppl.1.A81
Riepponen P, Suppl.1.A12
Rigo L, Suppl.2.A29
Riley S, Suppl.2.A45
Ringnér M, Suppl.1.A61
Rizzello F, Suppl.2.A49
Roberts NB, Suppl.2.A53
Robertson BR, Suppl.1.A20
Robertson DAF, Suppl.2.A42
Robertson JFR, Suppl.2.A37
Robins A, Suppl.1.A64, A79, Suppl.2.A15
Robins RA, Suppl.2.A22
Robinson G, Suppl.2.A37
Rocha GA, Suppl.1.A26, A27, A92
Rockall TA, Suppl.2.A11
Roda A, Suppl.1.A61
Roda E, Suppl.1.A5, A37, A61
Rodi M, Suppl.1.A40
Roe B, Suppl.1.A61
Rogers J, Suppl.2.A1, A2, A21
Rokkas T, Suppl.1.A76
Rolles K, Suppl.2.A28, A36
Roman F, Suppl.2.A14
Romano M, Suppl.1.A84
Romanos J, Suppl.2.A24, A47
Romeo MA, Suppl.1.A41
Rose S, Suppl.1.A15
Rosen-Bronson S, Suppl.2.A19, A41
Rosenstock SJ, Suppl.1.A27
Ross PE, Suppl.1.A84
Ross R, Suppl.1.A77
Rotondi A, Suppl.2.A27
Rousseau M, Suppl.1.A35
Roussomoustakaki M, Suppl.2.A15, A22
Rowlands BJ, Suppl.2.A16
Ruckwell A, Suppl.1.A17
Rudnicka W, Suppl.1.A32
Rudolph B, Suppl.1.A38, A39
Ruffett I, Suppl.2.A38
Rufo R, Suppl.1.A48
Rugge M, Suppl.1.A15
Ruina M, Suppl.1.A72
Ruiz del Arbol L, Suppl.1.A25
Russell MAH, Suppl.2.A40
Russell RI, Suppl.1.A3, Suppl.2.A8, A21
Russo F, Suppl.1.A78
Rutgeerts P, Suppl.1.A11
Ruuska T, Suppl.1.A24
Ryott J, Suppl.2.A35

Saari S, Suppl.1.A49
Safran P, Suppl.1.A34
Saggioro A, Suppl.1.A60
Saifuku K, Suppl.1.A44
Saito S, Suppl.1.A49
Sakagami T, Suppl.1.A51
Salandin S, Suppl.1.A47, A57
Saletti G, Suppl.1.A51
Sallerin V, Suppl.1.A35
Salmon RL, Suppl.1.A24
Salomaa A, Suppl.1.A26
Samloff IM, Suppl.1.A11
Sanchez I, Suppl.1.A15
Sánchez Romero I, Suppl.1.A97
Saniour P, Suppl.1.A68
Santograde P, Suppl.1.A12
Sanz JC, Suppl.1.A15, A72, A97
Saraga E, Suppl.1.A93
Sargentoni J, Suppl.2.A28
Sarsfield P, Suppl.1.A76, Suppl.2.A40
Sato T, Suppl.1.A8
Satoh K, Suppl.1.A44
Satsangi J, Suppl.2.A15, A21, A22, A50
Sauerbruch T, Suppl.1.A3, A18, A53, A58, A60
Saunders DSA, Suppl.2.A39
Saunders M, Suppl.2.A4
Savage J, Suppl.1.A59
Savage K, Suppl.2.A36
Savio A, Suppl.1.A6
Scagliarini R, Suppl.1.A5
Scagnelli M, Suppl.1.A82
Scaillon M, Suppl.1.A57
Schäfer KP, Suppl.1.A2, A17, A21
Schalm SW, Suppl.2.A27
Schauer DB, Suppl.1.A27, A30, A48
Scheiman J, Suppl.1.A84, Suppl.2.A40
Schmitt W, Suppl.1.A21, A44
Schmitz A, Suppl.1.A62
Schneider T, Suppl.1.A32
Schoengold R, Suppl.1.A60
Schoeppner H, Suppl.1.A75
Schofield D, Suppl.2.A29
Scholefield JH, Suppl.2.A5, A49
Schönfeld J.v., Suppl.2.A25, A52
Schorah CJ, Suppl.1.A39
Schrier W, Suppl.1.A60
Schrumpf E, Suppl.2.A25
Schulz H, Suppl.1.A44
Schulz TB, Suppl.1.A42
Schuppert U, Suppl.1.A3
Schütze K, Suppl.1.A42
Schwab P, Suppl.1.A9
Schwartz H, Suppl.1.A5
Schwarz SM, Suppl.1.A72
Sciampa G, Suppl.1.A42
Scott BB, Suppl.2.A22
Scott D, Suppl.2.A7, A35
Scrigner M, Suppl.1.A15
Segal ED, Suppl.1.A1
Segal I, Suppl.2.A29
Seidl G, Suppl.1.A9
Seifert E, Suppl.1.A38
Selden C, Suppl.2.A20, A26, A33
Sen C, Suppl.1.A26
Senior BW, Suppl.1.A80, Suppl.2.A16
Seppälä K, Suppl.1.A58
Sercombe JC, Suppl.1.A45
Seth R, Suppl.1.A79, Suppl.2.A15, A22
Sgarbi D, Suppl.2.A29
Shames B, Suppl.1.A30, A52
Shanaghan K, Suppl.2.A7
Sharma TK, Suppl.1.A13
Sharp R, Suppl.2.A11
Shaw-Smith CJ, Suppl.2.A17
Shen Z-Z, Suppl.2.A35
Shepherd N, Suppl.2.A4
Shidrawi RG, Suppl.2.A19, A41
Shimoyama T, Suppl.1.A19, A51, A95
Shingaki M, Suppl.1.A49
Sidebotham RL, Suppl.1.A19
Siepman N, Suppl.1.A14, A52
Sierla K, Suppl.1.A3
Silcock JG, Suppl.2.A10
Silk DBA, Suppl.2.A43
Sillis AJ, Suppl.2.A6
Simmonds P, Suppl.2.A27, A28
Simon T, Suppl.1.A44
Simoni P, Suppl.1.A5, A61
Simpson J, Suppl.2.A46
Simpson KJ, Suppl.2.A2, A28, A33
Simpson M, Suppl.2.A14
Sinclair TS, Suppl.2.A37, A50
Singh SD, Suppl.2.A46
Sinha L, Suppl.2.A13
Sipponen P, Suppl.1.A11, A13, A58, A69, A72
Siurala M, Suppl.1.A11, A69
Skandalis N, Suppl.1.A85
Slater C, Suppl.1.A62
Sloan JM, Suppl.1.A55
Small S, Suppl.1.A67
Small SM, Suppl.1.A77
Smith GD, Suppl.2.A51
Smith K, Suppl.2.A52
Smith MA, Suppl.2.A14
Smith MD, Suppl.2.A25
Smithson JAJ, Suppl.2.A12, A41
Snider L, Suppl.1.A34
Soffiati G, Suppl.1.A82
Solcia E, Suppl.1.A84, A87
Sollböhmer M, Suppl.1.A6
Sommer A, Suppl.1.A44, A89
Sommi P, Suppl.1.A84
Sontag SJ, Suppl.1.A5
Sorbara R, Suppl.2.A27
Sottili S, Suppl.1.A5, A37
Soule J-C, Suppl.1.A35
Souza EMM, Suppl.1.A71
Soveny C, Suppl.1.A83
Sowdi R, Suppl.2.A1
Spadaccini A, Suppl.1.A42
Spanò C, Suppl.2.A13
Spencer J, Suppl.2.A23
Sperti C, Suppl.1.A85
Spiegel T, Suppl.1.A68
Spiegelhalder C, Suppl.1.A21
Spiliadis C, Suppl.1.A85
Spiller RC, Suppl.1.A4, A96, Suppl.2.A31, A47
Srinivasan S, Suppl.1.A19, A84, Suppl.2.A40
Stage L, Suppl.1.A53
Stalis IH, Suppl.1.A48
Stallmach A, Suppl.1.A32
Stambolos P, Suppl.1.A85
Stanley A, Suppl.2.A8
Stanton SL, Suppl.2.A24
Steele RJC, Suppl.2.A5, A52
Steephens A, Suppl.1.A36
Steer HW, Suppl.1.A76
Stefanelli ML, Suppl.1.A37, A71
Steinhilber W, Suppl.1.A2, A17, A21
Steininger H, Suppl.1.A33, A34
Stephens JC, Suppl.1.A60
Stewart SP, Suppl.2.A14
Stobberingh E, Suppl.1.A14
Stockbrügger R, Suppl.1.A14
Stockbrügger RW, Suppl.2.A32
Stoddard CJ, Suppl.2.A1
Stoll R, Suppl.2.A23
Stolte M, Suppl.1.A6, A8, A9, A25, A28, A34, A38, A39, A40, A43, A44, A54, A81, A89
Stone MA, Suppl.2.A9
Stoschus B, Suppl.1.A60
Strachan D, Suppl.1.A10
Strange RC, Suppl.2.A36
Sturgess RP, Suppl.2.A12
Su YC, Suppl.1.A12
Sue-Ling HM, Suppl.2.A14
Suen R, Suppl.1.A6
Suerbaum S, Suppl.1.A62
Sugino T, Suppl.2.A24
Sunderland D, Suppl.1.A81
Sung JY, Suppl.1.A6
Susi D, Suppl.1.A91
Sutton R, Suppl.2.A53
Suvakovic Z, Suppl.2.A35, A38
Svennerholm A-M, Suppl.1.A22, A53
Swain CP, Suppl.2.A1, A3, A11, A37, A52
Swift J, Suppl.1.A56
Sykes DL, Suppl.1.A5
Syväoja E-L, Suppl.1.A92

Tabaqchali S, Suppl.1.A22, A23, A74, A76, Suppl.2.A16
Tahara E, Suppl.2.A24
Takahashi S, Suppl.1.A49
Takami S, Suppl.1.A19
Takimoto T, Suppl.1.A44
Talamini G, Suppl.2.A29
Talbi P, Suppl.1.A55, A91, A92
Talija I, Suppl.1.A96
Tam C-Y, Suppl.1.A42
Tamassy K, Suppl.1.A71
Tammaru M, Suppl.1.A96
Tamura T, Suppl.1.A19
Tan B, Suppl.2.A4
Tan CC, Suppl.2.A32
Tanaki Y, Suppl.1.A44
Taniguchi Y, Suppl.1.A44
Tankovic J, Suppl.1.A30
Tanner S, Suppl.2.A20
Tanton R, Suppl.1.A56
Tarin D, Suppl.2.A24
Tawara S, Suppl.1.A49
Tay A, Suppl.1.A67
Taylor DE, Suppl.1.A23
Taylor G, Suppl.2.A46
Taylor HW, Suppl.2.A9
Taylor MD, Suppl.2.A45
Taylor N, Suppl.1.A10
Taylor-Robinson S, Suppl.2.A34
Taylor-Robinson SD, Suppl.2.A28
Tebaldi M, Suppl.2.A29
Tebaldi P, Suppl.2.A27
Telford JL, Suppl.1.A51, A94
Teng CH, Suppl.2.A53
Terrés AM, Suppl.1.A34
Tessiore S, Suppl.1.A35
Testoni PA, Suppl.1.A82
Tham KT, Suppl.1.A3
Tham TCK, Suppl.1.A9, A55, Suppl.2.A45
Theodossi A, Suppl.1.A85
Thiberge JM, Suppl.1.A51, A79
Thiede C, Suppl.1.A39
Thillainavagam AV, Suppl.2.A30
Thillainayajain AV, Suppl.2.A12
Thiruchelvam T, Suppl.2.A53
Thomas DRh, Suppl.1.A24
Thomas GAO, Suppl.1.A56, Suppl.2.A40
Thomas MG, Suppl.2.A12
Thompson DG, Suppl.2.A19, A51
Thompson JA, Suppl.2.A23
Thompson MH, Suppl.2.A2
Thompson MR, Suppl.2.A23
Thompson NP, Suppl.2.A50
Thompson RPH, Suppl.2.A17
Thompson SA, Suppl.1.A75
Tian D, Suppl.1.A35
Tibbitts T, Suppl.1.A94
Tiemann M, Suppl.1.A6
Till M, Suppl.1.A1
Tillenburg B, Suppl.1.A6, A8, A25, A28, A41, A43, A54
Tittobello A, Suppl.2.A29
Toge T, Suppl.2.A24
Toh SKC, Suppl.2.A28
Tokieda M, Suppl.1.A37
Tokunaga A, Suppl.1.A54
Tolás P, Suppl.1.A86
Toledo MS, Suppl.1.A41
Toma A, Suppl.1.A15
Tomkins DS, Suppl.1.A54
Tompkins D, Suppl.1.A63
Tompkins DS, Suppl.1.A44, Suppl.2.A7, A32
Tompkins LS, Suppl.1.A1
Tonge KA, Suppl.1.A88
Tonokatsu Y, Suppl.1.A19
Torsoli A, Suppl.2.A7
Townsend S, Suppl.2.A43
Travers P, Suppl.2.A19
Treacy PJ, Suppl.2.A1, A29
Trespi E, Suppl.1.A87
Trinchieri G, Suppl.1.A50
Troncoso M, Suppl.1.A41
Trudgill N, Suppl.2.A45
Trust TJ, Suppl.1.A23
Tummuru MKR, Suppl.1.A1
Turbitt M, Suppl.2.A45
Turner S, Suppl.2.A29

Turney EA, Suppl.1.A46
Turnidge J, Suppl.1.A88
Tursi A, Suppl.1.A96
Turvill JL, Suppl.2.A12
Tytgat GNJ, Suppl.1.A68

Uff JS, Suppl.1.A15, Suppl.2.A31
Uhlenberg W, Suppl.1.A39
Uibo R, Suppl.1.A38, A96
Underwood B, Suppl.1.A90
Underwood JCE, Suppl.2.A34
Unge P, Suppl.1.A4

v. Streitberg U, Suppl.1.A34
Vaidya K, Suppl.2.A9, A24
Vaira D, Suppl.1.A31, A40, A68
Vakil N, Suppl.1.A5, A56
Valerio G, Suppl.1.A82
Vales P, Suppl.2.A50
Valkonen K, Suppl.1.A2
Valle J, Suppl.1.A69
Valori R, Suppl.1.A15, Suppl.2.A31
Valsecchi C, Suppl.2.A27
van Buuren HR, Suppl.2.A27
Van den Borre C, Suppl.1.A56, A59
van der Ende A, Suppl.1.A68
van der Walt JD, Suppl.2.A2
van Doorn NEM, Suppl.1.A68
Van Gossum M, Suppl.1.A90
Van Horn K, Suppl.1.A72
van Kempen L, Suppl.1.A68
van Rees EP, Suppl.1.A68
Vandenborre C, Suppl.1.A79
Vane JR, Suppl.2.A52
Vaona B, Suppl.2.A29
Varai E, Suppl.1.A49
Varga L, Suppl.1.A9, A38
Varro A, Suppl.2.A37
Vautier G, Suppl.2.A22
Veldhuyzen van Zanten S, Suppl.1.A56, A66
Veldhuyzen van Zanten SJO, Suppl.1.A4, A45
Venables T, Suppl.2.A45
Ventrua U, Suppl.1.A84
Venturi A, Suppl.2.A49
Verdú E, Suppl.1.A8
Vergura M, Suppl.1.A40
Verma A, Suppl.2.A19, A27
Versalovic J, Suppl.1.A67
Vesey D, Suppl.2.A26, A33
Vianello F, Suppl.1.A47, A57
Vieira WLS, Suppl.1.A71
Vila T, Suppl.1.A30
Villani L, Suppl.1.A87
Vipond MN, Suppl.2.A21
Virtanen S, Suppl.1.A92
Viviani G, Suppl.2.A27
Voland P, Suppl.1.A2
von Blohn G, Suppl.1.A32
Vorobjova T, Suppl.1.A38, A96

Wada O, Suppl.1.A8
Wadhera V, Suppl.2.A2
Wadström T, Suppl.1.A2, A32, A61, A74, A93, A96
Wagner A, Suppl.2.A19, A41
Wagner S, Suppl.1.A32, A82
Wakefield AJ, Suppl.2.A50
Walker MM, Suppl.1.A73, A74, Suppl.2.A39, A44
Walker SJ, Suppl.2.A53
Walker-Smith JA, Suppl.2.A16, A23
Wallace PG, Suppl.1.A88
Waller JM, Suppl.1.A73, A74
Wallington EJ, Suppl.1.A63
Wallis J, Suppl.1.A63, A92
Walsh EJ, Suppl.1.A16, A17
Walt RP, Suppl.1.A87, Suppl.2.A39
Walters JRF, Suppl.2.A17
Wang J, Suppl.2.A46
Wang JT, Suppl.1.A70
Wang TH, Suppl.1.A70
Wang WM, Suppl.1.A12
Wang X, Suppl.1.A93
Wängler S, Suppl.1.A21
Want SV, Suppl.1.A90
Warburton V, Suppl.1.A20
Waring RH, Suppl.2.A22
Warland D, Suppl.1.A39
Warren BF, Suppl.2.A24
Warren CW, Suppl.1.A36
Washington N, Suppl.2.A52
Washizuka Y, Suppl.1.A49
Wastell C, Suppl.1.A77
Watanabe H, Suppl.1.A8
Watkinson A, Suppl.2.A4
Watson AJM, Suppl.2.A20
Watson BE, Suppl.1.A15, Suppl.2.A31
Watson RGP, Suppl.1.A55, Suppl.2.A45
Watson SA, Suppl.2.A37
Watts DA, Suppl.2.A45
Webb DD, Suppl.1.A5
Webb DJ, Suppl.2.A51
Webb PM, Suppl.1.A77
Wee A, Suppl.2.A53
Weinbaum G, Suppl.1.A28
Weingart J, Suppl.1.A44, A89
Weir DM, Suppl.1.A21, A22
Weitzenegger T, Suppl.1.A21
Welsh K, Suppl.2.A22
Welsh KI, Suppl.2.A21
Weltzin R, Suppl.1.A52
West KP, Suppl.2.A41
Wetterhus S, Suppl.1.A45
Wewer V, Suppl.1.A14
Whalley SA, Suppl.2.A9
White G, Suppl.1.A90
White KLM, Suppl.1.A39
White PJ, Suppl.1.A18
Whitehead RH, Suppl.2.A19
Whittle BJR, Suppl.1.A30
Whorwell PJ, Suppl.2.A46, A51
Wicks ACW, Suppl.2.A38, A41
Wigmore SJ, Suppl.2.A3
Wilkinson JM, Suppl.2.A31
Wilks AF, Suppl.2.A19
Wilks M, Suppl.1.A74, A76, Suppl.2.A16
Williams C, Suppl.1.A62
Williams G, Suppl.2.A40
Williams H, Suppl.2.A2
Williams JAR, Suppl.2.A29
Williams MH, Suppl.2.A5
Williams NS, Suppl.2.A21
Williams R, Suppl.2.A26, A48
Willis KD, Suppl.2.A30
Willoughby CP, Suppl.2.A9
Wills A, Suppl.1.A81
Willson PD, Suppl.2.A1, A2
Wilson A, Suppl.1.A4
Wilson C, Suppl.2.A35, A38
Wilson CG, Suppl.2.A47
Windle H, Suppl.1.A7
Windle HJ, Suppl.1.A50
Wingate DL, Suppl.2.A25, A52
Winn G, Suppl.2.A30
Winrow VR, Suppl.1.A80, Suppl.2.A44
Wirth HP, Suppl.1.A28
Wirz A, Suppl.1.A3, A11, A82, A86, Suppl.2.A6
Wolfhagen FHJ, Suppl.2.A27
Wolters U, Suppl.1.A28
Wong NW, Suppl.1.A97
Wotherspoon AC, Suppl.1.A6
Wrangstadh M, Suppl.1.A4
Wright T, Suppl.2.A45
Wu DC, Suppl.1.A12
Wuscher N, Suppl.1.A51
Wyatt JI, Suppl.1.A4, A33, A36, Suppl.2.A8
Wyeth J, Suppl.1.A45

Xia HX, Suppl.1.A55, A91
Xiang Z, Suppl.1.A51

Yamada T, Suppl.1.A84, Suppl.2.A17, A18, A40
Yamahatsu J, Suppl.1.A54
Yamamoto I, Suppl.1.A19
Yamashita K, Suppl.1.A54
Yamazaki T, Suppl.1.A8
Yan L, Suppl.1.A10, A30, A48, A52
Yanagawa Y, Suppl.1.A49
Yang CK, Suppl.1.A70
Yang JC, Suppl.1.A70
Yapp T, Suppl.1.A56
Yates N, Suppl.1.A26
Yazaki E, Suppl.2.A52
Yazaki FR, Suppl.1.A71
Ye G, Suppl.1.A31
Yeoh KG, Suppl.2.A32
Yeung PKF, Suppl.1.A45
Yoffe B, Suppl.1.A59
Yoshida K, Suppl.2.A24
Yoshida Y, Suppl.1.A44, A95
Young GO, Suppl.2.A39
Yousfi MM, Suppl.1.A13, A80
Yu M, Suppl.1.A77
Yuan J-M, Suppl.1.A77
Yunker C, Suppl.1.A75

Zagari RM, Suppl.1.A5, A37, A61
Zambelli A, Suppl.1.A40
Zamboni G, Suppl.1.A6
Zeitz M, Suppl.1.A32
Zerbib F, Suppl.1.A55, A91, A92
Zeyen R, Suppl.1.A39
Zhang OB, Suppl.1.A3
Zhang ZW, Suppl.2.A16, A40, A44
Zimmermann A, Suppl.1.A38
Zoli G, Suppl.2.A13
Zoller WG, Suppl.1.A44
Zverkov IV, Suppl.1.A29ß

VOLUME 37: SUBJECT INDEX – SUPPLEMENTS 1 AND 2

Acetyl CoA carboxylase, Acetyl CoA carboxylase activity in *Helicobacter pylori* and the requirement of increased carbon dioxide for growth, Suppl.1.A20
Acetyl-SER-ASP-LYS-PRO, Inhibition of DNA synthesis in mitogen stimulated rate hepatocytes by the peptide acetyl-SER-ASP-LYS-PRO, Suppl.2.A20
Acid-peptic disorders, Suppl.2.A30-32
Acyl chain length, CCK release by fatty acid is a function of acyl chain length but not saturation, Suppl.2.A19
Adenocarcinoma, Lack of association between the presence of the *cagA* gene in *Helicobacter pylori* and gastric adenocarcinoma, Suppl.1.A77
Adherence, Development of a quantitative assay for adherence of *H.l pylori*, Suppl.1.A64
Adherence-induced expression, Adherence-induced expression of a novel *Helicobacter pylori* gene and correlation with peptic ulceration, Suppl.1.A75
Adhesin-receptor, Adhesin-receptor specificity of *Helicobacter* sp, Suppl.1.A64
Adhesion, *Helicobacter pylori* strain variability in adhesion, cytotoxicity and IL-8 release, Suppl.1.A3
Adolescents, Viral markers for mode of transmission in *Helicobacter pylori* infected adolescents, Suppl.1.A70
Adrenaline, A controlled study of adrenaline injection in peptic ulcer bleeding within a specialised unit, Suppl.2.A37
Age, Association between gastric cancer and *H. pylori* with reference to age, Suppl.1.A8
AgNOR method, Evaluations of inflammatory, metaplastic, preneoplastic and neoplastic changes in the gastric surface epithelium by the AgNOR method, Suppl.1.A34
AgNORs, Argyrophilic nucleolar organizer region-associated proteins in surface mucous cells and *Helicobacter pylori* infection, Suppl.1.A73
AIDS, Suppl.2.A40-41
A randomized controlled trial of albendazole for treatment of diarrhoea in Africans with AIDS, Suppl.2.A41
Intralesional chemotherapy in the treatment of gastric Kaposi's sarcoma in AIDS, Suppl.2.A41
Albendazole, A randomized controlled trial of albendazole for treatment of diarrhoea in Africans with AIDS, Suppl.2.A41
Alcohol intake
A study of the relationship between alcohol intake and gastric luminal antioxidant concentrations, Suppl.2.A40
Serum carbohydrate-deficient transferrin remains a reliable marker of high alcohol intake in acute abdominal inflammatory conditions, Suppl.2.A28
Alcoholism, Investigation of micronutrient antioxidant status as a potential determinant of susceptibility to chronic pancreatitis among alcoholics at Soweto, Suppl.2.A29
Alkaline phosphatase vectors, Identification of genes encoding exported protein sequences in *Helicobacter pylori* using alkaline phosphatase vectors, Suppl.1.A22
Amoxicillin
A decision analysis of healthcare costs following eradication of *H. pylori* with omeprazole in combination with either amoxycillin or clarithromycin, Suppl.1.A47
A randomised comparison of 3 omeprazole-based eradication regimens in an inner-city area, Suppl.1.A90
Amoxicillin plus omeprazole versus triple therapy for the eradication of *H. pylori* and healing of duodenal ulcers, Suppl.1.A6
An increasing dose of omeprazole combined with amoxicillin improves the cure of *Helicobacter pylori* infection, Suppl.1.A89
Clarithromycin or amoxicillin dual and triple therapies in *H. pylori* eradication: a meta-analysis, Suppl.2.A31
Comparison of omeprazole+amoxicillin *versus* OM+clarithromycin in the eradication of *Helicobacter pylori* – results from a randomized study involving 120 patients, Suppl.1.A55
Double-blind trial of 80 mg omeprazole and 2250 mg amoxicillin for cure of *Helicobacter pylori* infection in gastric ulcer patients, Suppl.1.A44
Dual therapy versus triple therapy: high dose of lansoprazole plus amoxicillin in combination or not with clarithromycin for *Helicobacter pylori* infection, Suppl.1.A92
Efficacy of amoxycillin compared with classical triple therapy in the eradication of *H. pylori* after pre-treatment with lansoprazole, Suppl.1.A41
Efficacy of ten days of clarithromycin, amoxycillin and omeprazole in eradicating *Helicobacter pylori* infection, Suppl.1.A44
Eradication of *Helicobacter pylori* infection: is a double therapy still suitable?, Suppl.1.A85
Eradication of *Helicobacter pylori* using clarithromycin, omeprazole and amoxycillin for one week, Suppl.1.A88
Evolution of the resistance to several antibiotics in *H. pylori* over a 4 year period, Suppl.1.A97
GR122311X (ranitidine bismuth citrate) with amoxycillin for the eradication of *Helicobacter pylori*, Suppl.1.A42
High efficacy of a clarithromycin-amoxycillin-omeprazole association for *H. pylori* eradication and treatment of ulcer-like or reflux-like dyspeptic symptoms, Suppl.1.A87
Omeprazole+amoxicillin+clarithromycin therapy for *H. pylori* infection, Suppl.1.A89
Omeprazole based therapies for eradication of *Helicobacter pylori*, Suppl.1.A90
Omeprazole and clarithromycin vs. omeprazole and amoxicillin: a comparison of one-week and two-week treatments, Suppl.1.A91
Omeprazole has no effect on the gastric mucosal bioavailability of amoxycillin, Suppl.1.A90
One-week treatment with omeprazole, amoxycillin and clarithromycin or metronidazole for cure of *Helicobacter pylori* infection, Suppl.1.A43
Preliminary report on the impact of the Suffolk GP-based *Helicobacter pylori* eradication programme on the prescribing of ulcer healing drugs in general practice, Suppl.2.A6
The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and amoxycillin, Suppl.1.A42
Time-course of histological changes in *Helicobacter pylori* associated gastritis during the early phase of cure therapy with omeprazole and amoxycillin in duodenal ulcer patients, Suppl.1.A34
Triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for *Helicobacter pylori* eradication, Suppl.1.A91
Ampullary carcinoma, Laser ablation of ampullary carcinoma. The effects and outcome of endoscopic treatment, Suppl.2.A3
Amylase, Amylase and lipase levels in the diagnosis of acute pancreatitis, Suppl.2.A29
Amyloidosis, Amyloidosis and the liver, Suppl.2.A27
Anal anastomosis, Cytokine gene polymorphisms in patients with an ileal pouch anal anastomosis for ulcerative colitis, Suppl.2.A15
Anal fissure
Long term sequelae after sphincterotomy for anal fissure, Suppl.2.A49
The use of glyceryl trinitrate in the treatment of anal fissure, Suppl.2.A5
Ankylosing spondylitis, Crohn's disease patients suffering from peripheral arthritis or ankylosing spondylitis reveal restricted T cell receptor Vβ regions in different temporal phases of disease, Suppl.2.A23
Anti-CagA serum IgG, Association of *Helicobacter pylori* and anti-CagA serum IgG with gastroduodenal endoscopic lesions in the population of San Marino, Suppl.1.A71
Anti-*Helicobacter* therapies
Quantitative computer-aided evaluation of *Helicobacter pylori* gastritis: effect of anti-*HP* therapy on inflammatory cell infiltration and acquired MALT, Suppl.1.A96
Screening of anti-*Helicobacter* therapies in mice colonised with *H. pylori*, Suppl.1.A92
Antibiotics
Evolution of the resistance to several antibiotics in *H. pylori* over a 4 year period, Suppl.1.A97
Proton pump inhibitor pretreatment affects *Helicobacter pylori* sensitivity to antibiotics, Suppl.1.A18
Screening of anti-*Helicobacter* therapies in mice colonised with *H. pylori*, Suppl.1.A92
Antibodies
Prevalence of *H. pylori* antibodies in children and young adults living in the southeast of Turkey, Suppl.1.A26
Prevalence of *Helicobacter* antibodies in 1973 and 1994 in the adult population of Vammala, Finland, Suppl.1.A26
Antibody response
Isotypic pattern of *Helicobacter pylori* antibody response in gastric mucosa, saliva and serum. Relation to ulcer, gastritis and intragastric extent of *H. pylori*, Suppl.1.A78
Specific antibody response to *Helicobacter pylori* in asymptomatic adults in China and Australia compared with patient groups, Suppl.1.A78
Antigastric autoantibodies, Antigastric autoantibodies in *Helicobacter pylori* gastritis. Prevalence, in situ binding sites and positive correlation with gastric atrophy and hypergastrinemia, Suppl.1.A33
Antigen expression, Evaluation of media for growth and antigen expression by *Helicobacter pylori*, Suppl.1.A17
Antigen recognition, *Helicobacter felis* surface antigen recognition by three strains of immune mice, Suppl.1.A95

Antigens
Local antibodies to *Helicobacter pylori* antigens, Suppl.1.A32
The inhibition of antigen- or mitogen-induced response to T cells by *H. pylori* bacteria and their products, Suppl.1.A32
Antimicrobial therapy, Evaluation of large gastric folds in patients with *Helicobacter pylori* infection by endoscopic ultrasound before and after antimicrobial therapy, Suppl.1.A38
Antineutrophil cytoplasmic antibody(ies)
Antineutrophil cytoplasmic antibodies in inflammatory bowel disease distinguish between ulcerative colitis and Crohn's disease, Suppl.2.A14
Detection of antineutrophil cytoplasmic antibody in primary sclerosing cholangitis: comparison of the alkaline phosphatase and immunofluorescent techniques, Suppl.2.A25
Antiproteases, Are salivary antiproteases important in oesophageal protection?, Suppl.2.A53
Antral phase 3, *H. pylori* colonization of the gastric mucosa is likely to be found in dyspeptic patients without antral phase 3 of migrating motor complex, Suppl.1.A82
Antral tumours, *Helicobacter pylori* infection is significantly more common in association with tumours of the gastric antrum than tumours of cardia, Suppl.2.A7
Anxiety, Anxiety, depression and intestinal transit, Suppl.2.A47
APC, Co-operativity between APC and p53 in murine pancreatic cancer, Suppl.2.A18
Arbitrary primers-PCR, AP-PCR as typing method in clinical isolates of *Helicobacter pylori*, Suppl.1.A72
Argyrophilic nucleolar organizer region-associated proteins, Argyrophilic nucleolar organizer region-associated proteins in surface mucous cells and *Helicobacter pylori* infection, Suppl.1.A73
Arthritis, Crohn's disease patients suffering from peripheral arthritis or ankylosing spondylitis reveal restricted T cell receptor Vβ regions in different temporal phases of disease, Suppl.2.A23
Ascites, Management of refractory ascites with TIPSS, Suppl.2.A3
Ascorbyl radical, The ascorbyl radical is increased in *H. pylori* associated gastritis, Suppl.1.A39
Aspirates, Molecular characterisation of immunoglobulins in gastric aspirates of *Helicobacter pylori* infected patients, Suppl.1.A80
ATP regeneration, 31P-ATP regeneration following storage and reperfusion of the donor pig liver, Suppl.2.A34
Atrophic gastritis
antibodies to Cag A protein in patients with *H. pylori* infection and atrophic gastritis, Suppl.1.A37
Host's genetic analysis in patients with atrophic gastritis or gastric carcinoma harboring *Helicobacter pylori*, Suppl.1.A7
Prevalence of gastric atrophy, the precursor lesion of gastric carcinoma, is dependent of the prevalence of Hp infection: evidence that while *Hp* infection may be the major determining factor for gastric cancer it is not for gastric atrophy, Suppl.1.A7
Audit
A safe and cost effective transfusion policy in gastrointestinal haemorrhage, Suppl.2.A8
Audit of a specialised *Helicobacter pylori* treatment clinic, Suppl.2.A31
Open access gastroscopy – effects of pretreatment – closing the audit cycle, Suppl.2.A7
Reducing the gastric biopsy histopathology workload through audit, Suppl.2.A8
Australia, Specific antibody response to *Helicobacter pylori* in asymptomatic adults in China and Australia compared with patient groups, Suppl.1.A78
Auto-antibodies, Immunization with *H. pylori* urease do not induce serum auto-antibodies against the gastric mucosa in mice, Suppl.1.A93
Autoimmune hepatitis, Autoimmune hepatitis: application of International Group criteria and clinical experience in a single centre, Suppl.2.A34
Autoimmunity, Are autoimmunity and endotoxin sensitivity part of the spectrum of *Helicobacter*-induced disease?, Suppl.1.A51

B7, Modulation of the expression of B7, ICAM-1 and LFA3 on the surface of gastric epithelial cells following exposure to *H. pylori* and cytokines, Suppl.1.A31
B-cell gastric lymphoma
Gastric B-cell lymphomas induced in a single mouse strain by various isolates of *Helicobacter heilmannii*: similarities and differences, Suppl.1.A7
Serum response to *Helicobacter pylori* in primary B-cell gastric lymphoma, Suppl.1.A6
Bacterial interaction, The role of *H. pylori* surface structures in bacterial interaction with macrophages, Suppl.1.A32
Bacterial load, Gastric acid output, bacterial load and gastritis in *Helicobacter pylori* positive patients with duodenal ulcer, Suppl.1.A73
Bacterial overgrowth, Positive glucose hydrogen breath tests for small bowel bacterial overgrowth in residents of elderly peoples homes, Suppl.2.A13
Barrett's oesophagus
Continuous treatment of patients with Barrett's oesophagus with omeprazole 20 mg daily over 3 years, Suppl.2.A32
Nd-YAG laser: ineffective therapy for Barrett's oesophagus, Suppl.2.A4
bcl-2
Glandular proliferation and homeostasis of specific cells are differentially affected in gastric corpus and antrum in *Helicobacter pylori* induced gastritis, Suppl.1.A38
Immunohistochemical analysis of p53 and bcl-2 in primary gastric non-Hodgkin's lymphomas, Suppl.1.A40
Belgium
Frequency of *cagA* in *Helicobacter pylori* strains isolated from Belgian and Moroccan patients, Suppl.1.A69
Serum reactivity to *Helicobacter pylori* antigens assessed by Helico Blot 2.0 in *H. pylori*-positive children from different ethnic groups, Suppl.1.A79
Surveillance of *Helicobacter pylori* resistance to antimicrobial agents in Belgium from 1989 to 1994, Suppl.1.A56
β-carotene, *H. pylori* infection is associated with decreased gastric juice β-carotene concentration, Suppl.2.A44
Bile acid malabsorption, Idiopathic bile acid malabsorption and response to cholestyramine therapy, Suppl.2.A13
Bile canalicular membrane, Demonstration and partial characterisation of phospholipid methyltransferase activity in bile canalicular membrane from hamster liver, Suppl.2.A19
Bile duct calculi, Preoperative detection of bile duct calculi – results of an aggressive approach, Suppl.2.A11
Bile reflux, Bile reflux and gastric cell proliferation, Suppl.1.A96
Biliary atresia, Malnutrition, essential fatty acids deficiency and intake threshold in biliary atresia, Suppl.2.A30
Biliary cirrhosis, New genetic association of an interleukin-1 beta gene variation with primary biliary cirrhosis, Suppl.2.A17
Biliary microflora, Biliary microflora and its relation to biliary sepsis after liver transplantation, Suppl.2.A33
Biliary strictures, A prospective evaluation of cytology from biliary strictures, Suppl.2.A2
Biopsy(ies)
Comparison of PCR to other routine invasive methods in the diagnosis of *Helicobacter pylori* infection, Suppl.1.A57
Confirmation of successful therapy of *H. pylori* infection: number and site of biopsies vs. a rapid urease test, Suppl.1.A59
Detection of *Helicobacter pylori* in gastric biopsies by in situ hybridization, Suppl.1.A59
Importance of obtaining biopsies from gastric body in the follow-up after *H. pylori* eradication therapy, Suppl.1.A47
Validity of a new biopsy urease test and a simplified 13C-urea breath test for diagnosis of *Helicobacter pylori* infection and estimation of severity of gastritis, Suppl.1.A54
Birth cohorts, Rate of *H. pylori* infection in different birth cohorts, Suppl.1.A11
Bismuth carbomer enemas, Bismuth carbomer enemas in treatment of chronic unremitting pouchitis, Suppl.2.A49
Bleeding peptic ulcer
A controlled study of adrenaline injection in peptic ulcer bleeding within a specialised unit, Suppl.2.A37
Early feeding in patients with bleeding peptic ulcer and a visible vessel, Suppl.2.A37
Blood group antigens
Binding of biotinylated blood group antigens to isolates of *Helicobacter pylori* with reference to disease, blood group and secretor status, Suppl.1.A22
Identification of surface components of *Helicobacter pylori* that bind H type 2 and Lewis blood group antigens, Suppl.1.A21
Bone mineral density, Bone mineral density and bone turnover in treated coeliac disease, Suppl.2.A42
Bone turnover, Bone mineral density and bone turnover in treated coeliac disease, Suppl.2.A42
Branched chain amino acids, Evaluation of the role of branched chain amino acids in the treatment of protein malnutrition in infants with liver disease, Suppl.2.A30
Brazil, Factors involved in reinfection by *H. pylori* in Brazil, Suppl.1.A71
Breath tests
Analysis of the accuracy of the ^{13}C-urea breath test for the detection of *H. pylori* infection by using different test meals, Suppl.1.A58
Citric acid solution is an optimal test meal in the ^{13}C-urea breath test for the diagnosis of *H. pylori* infection, Suppl.1.A53
Comparison of culture, histology, and ^{13}C-urea breath tests for detection of *H. pylori*, Suppl.1.A52
Positive glucose hydrogen breath tests for small bowel bacterial overgrowth in residents of elderly peoples homes, Suppl.2.A13

Quantitative noninvasive testing for *H. pylori* does not predict gastroduodenal ulcer disease, Suppl.1.A13
Simple rapid and highly reliable capsule-based ^{14}C-urea breath test for diagnosis of *Helicobacter pylori* infection, Suppl.1.A53
Simplified, reliable urea breath test, Suppl.1.A61
Standardisation of the 13-C-urea breath test in children, Suppl.1.A58
The ^{13}C-urea breath test for early assessment of *Helicobacter pylori* eradication, Suppl.1.A61
Validation of a non-fasting ^{13}carbon urea breath test to diagnose *Helicobacter pylori* infection, Suppl.1.A12
Validity of a new biopsy urease test and a simplified ^{13}C-urea breath test for diagnosis of *Helicobacter pylori* infection and estimation of severity of gastritis, Suppl.1.A54

British physicians, *H. pylori*-associated gastroduodenal disease: survey of British physicians' views, Suppl.1.A87

Broth microdilution, Discrepancies between the results of antimicrobial susceptibility testing of *Helicobacter pylori* using E-test compared to broth microdilution or disk diffusion, Suppl.1.A67

Budd-Chiari syndrome, Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis, Suppl.2.A28

Burnout, Do senior gastroenterologists experience more 'burnout' and psychiatric disorder than other hospital consultants, Suppl.2.A9

Burns, Port site skin burns and diathermy in surgical laparoscopy, Suppl.2.A2

Butyrate enemas, Butyrate enemas are less effective than prednisolone enemas in treating distal or left sided ulcerative colitis, Suppl.2.A41

^{13}C-urea breath test
Analysis of the accuracy of the ^{13}C-urea breath test for the detection of *H. pylori* infection by using different test meals, Suppl.1.A58
Citric acid solution is an optimal test meal in the ^{13}C-urea breath test for the diagnosis of *H. pylori* infection, Suppl.1.A53
Comparison of culture, histology, and ^{13}C-urea breath tests for detection of *H. pylori*, Suppl.1.A52
Quantitative noninvasive testing for *H. pylori* does not predict gastroduodenal ulcer disease, Suppl.1.A13
Simplified, reliable urea breath test, Suppl.1.A61
Standardisation of the 13-C-urea breath test in children, Suppl.1.A58
The ^{13}C-urea breath test for early assessment of *Helicobacter pylori* eradication, Suppl.1.A61
Validation of a non-fasting ^{13}carbon urea breath test to diagnose *Helicobacter pylori* infection, Suppl.1.A12
Validity of a new biopsy urease test and a simplified ^{13}C-urea breath test for diagnosis of *Helicobacter pylori* infection and estimation of severity of gastritis, Suppl.1.A54

^{14}C-urea breath test, A simple rapid and highly reliable capsule-based ^{14}C-urea breath test for diagnosis of *Helicobacter pylori* infection, Suppl.1.A53

Caecal mucosa, Isolation of *Helicobacter* species from mouse caecal mucosa, Suppl.1.A20

***cagA* antibodies**
Presence of CagA antibodies is related to the extent of premalignant histological change in the stomach, Suppl.1.A76
Presence of CagA antibodies in patients attending for upper gastrointestinal endoscopy, Suppl.1.A74

***cagA* gene**
Distribution of the *cagA* gene in *Helicobacter pylori* strains isolated from children, Suppl.1.A25
Expression of *cag*A gene and nonopsonic neutrophil activation by *Helicobacter pylori*, Suppl.1.A3
Identification of a *cagA* gene in *Helicobacter mustelae* strains, Suppl.1.A30
Lack of association between the presence of the *cagA* gene in *Helicobacter pylori* and gastric adenocarcinoma, Suppl.1.A77

***cagA* protein**
Antibodies to Cag A protein in patients with *H. pylori* infection and atrophic gastritis, Suppl.1.A37
Detection of *Helicobacter pylori* cytotoxin-associated protein by small format polyacrylamide gel electrophoresis and application to identifying potentially ulcerogenic strains, Suppl.1.A64
Frequency of *cagA* in *Helicobacter pylori* strains isolated from Belgian and Moroccan patients, Suppl.1.A69
Genotypic analysis of *vacA* and *cagA* in *Helicobacter pylori* isolates from the U.S., Thailand, Peru and China, Suppl.1.A69
Growth phase and pH-related regulation of *cag*A, *cag*C and *ure*A expression in *H. pylori*, Suppl.1.A1
H. pylori-induced disturbance of gastric acid secretion is unrelated to bacterial CagA status, Suppl.1.A83
Helicobacter pylori gastritis with cytotoxin associated protein antibodies (CagA) in a population at high risk for gastric cancer: a semiquantitative and computer aided morphological study, Suppl.1.A37
Immunological adhesion molecules on gastric mucosa. Does *H. pylori*, and specifically Cag A+ strains influence its expression, Suppl.1.A34
Infection by a mixed population, including for *cagA*, of *Helicobacter pylori*, Suppl.1.A68
Poor correlation between serum IgG titers to CagA and mucosal inflammation, Suppl.1.A80
Reactive oxygen metabolite production by gastric antral mucosa infected with *Helicobacter pylori*: relationship to CagA seropositivity, Suppl.1.A30
Serological evaluation of *Helicobacter pylori* eradication using recombinant CagA protein, Suppl.1.A14
Systemic IgG antibodies to *Helicobacter pylori* CagA protein in blood donors with asymptomatic duodenal ulcers, Suppl.1.A31

cagC, Growth phase and pH-related regulation of *cag*A, *cag*C and *ure*A expression in *H. pylori*, Suppl.1.A1

cagII
CagII, a new multigene locus associated with virulence in *Helicobacter pylori*, Suppl.1.A1
DNA sequence of *cagII*, a new multigene locus implicated in *H. pylori* virulence, Suppl.1.A61

Calcium absorption, Fractional calcium absorption is reduced in treated coeliac disease, Suppl.2.A42

Calcium signalling, The role of plasma factors in the abnormal calcium signalling of platelets from patients with cirrhosis, Suppl.2.A33

Capsaicin, Mechanism of gastro protection by epidermal growth factor in the rat: influence of capsaicin desensitisation and close arterial infusion of a calcitonin gene-related peptide antagonist on gastric mucosal blood flow, Suppl.2.A53

Carbohydrate-deficient transferrin, Serum carbohydrate-deficient transferrin remains a reliable marker of high alcohol intake in acute abdominal inflammatory conditions, Suppl.2.A28

Carbon dioxide, Acetyl CoA carboxylase activity in *Helicobacter pylori* and the requirement of increased carbon dioxide for growth, Suppl.1.A20

Cardia tumours, *Helicobacter pylori* infection is significantly more common in association with tumours of the gastric antrum than tumours of cardia, Suppl.2.A7

Cardiovascular risk factors, *Helicobacter pylori* infection: relation with cardiovascular risk factors, ischaemic heart disease and social class, Suppl.1.A11

Carvedilol, Actions of carvedilol, a vasodilating beta-blocker, upon splanchnic and renal haemodynamics in patients with cirrhosis, Suppl.2.A25

Cats
Characterization of feline *Helicobacter pylori* strains and associated gastritis in a colony of domestic cats, Suppl.1.A48
Helicobacter pylori induced gastritis in the domestic cat, Suppl.1.A52
Public health implication of *H. pylori* in cats: presence of *H. pylori* in cat saliva, gastric juice, and feces, Suppl.1.A10

CCK release
CCK release by fatty acid is a function of acyl chain length but not saturation, Suppl.2.A19
Fat induced CCK release and effects on antral and gallbladder motility are dependent on meal composition, Suppl.2.A51

CD44
Disturbed CD44 gene activity in colorectal carcinoma – a new abnormality with clinical diagnostic potential, Suppl.2.A24
Helicobacter pylori gastritis is associated with expression of variant forms of CD44 on gastric epithelial cells: implications for gastric cancer, Suppl.1.A7

Cell proliferation
Bile reflux and gastric cell proliferation, Suppl.1.A96
Characterization of a cell proliferation inhibiting factor produced by *Helicobacter pylori*, Suppl.1.A79
Glandular proliferation and homeostasis of specific cells are differentially affected in gastric corpus and antrum in *Helicobacter pylori* induced gastritis, Suppl.1.A38
H. pylori infection increase gastric antrum mucosal cell proliferation, Suppl.1.A75
Increased gastric epithelial cell proliferation in *H. pylori* associated follicular gastritis, Suppl.1.A76

Cell vacuolation, An acidic environment inhibits *H. pylori* toxin-dependent cell vacuolation in vitro, Suppl.1.A84

cGMP, Role of cGMP on haemodynamic changes during liver transplantation, Suppl.2.A48

Characterisation, The cloning and characterisation of chemotaxis genes in *Helicobacter pylori*, Suppl.1.A18

Chemoattractant, Production of a chemoattractant by *Helicobacter pylori*, Suppl.1.A28

Chemokine genes, Multiple chemokine genes are expressed in liver

tissue from patients with chronic hepatitis C infection, Suppl.2.A33
Chemotaxid genes, The cloning and characterisation of chemotaxis genes in *Helicobacter pylori*, Suppl.1.A18
Children
Antral and bulbar micronodular pattern in young children infected with *Helicobacter pylori*, Suppl.1.A57
Cohort study of *Helicobacter pylori* colonisation in children, Suppl.1.A72
Distribution of the *cagA* gene in *Helicobacter pylori* strains isolated from children, Suppl.1.A25
Helicobacter pylori and gastric cancer: an endoscopic survey of healthy children in high and low risk areas for gastric cancer in China, Suppl.1.A38
High seroconversion for *Helicobacter pylori* in children, Suppl.1.A27
Household living conditions and *Helicobacter pylori* infection in children undergoing elective day surgery, Suppl.1.A70
Mother's *Helicobacter pylori* positivity as a risk factor of infant infection, Suppl.1.A27
Prevalence of *H. pylori* antibodies in children and young adults living in the southeast of Turkey, Suppl.1.A26
Serum reactivity to *Helicobacter pylori* antigens assessed by Helico Blot 2.0 in *H. pylori*-positive children from different ethnic groups, Suppl.1.A79
Chile, Long term *H. pylori* eradication after antibiotic therapy in duodenal ulcer patients in Chile, Suppl.1.A41
China
Helicobacter pylori and gastric cancer: an endoscopic survey of healthy children in high and low risk areas for gastric cancer in China, Suppl.1.A38
Prospective investigation of the association between *H. pylori* infection and gastric cancer in China, Suppl.1.A77
Specific antibody response to *Helicobacter pylori* in asymptomatic adults in China and Australia compared with patient groups, Suppl.1.A78
Cholera toxin, Effect of the sigma ligand JO 1784 on cholera toxin induced jejunal secretion, Suppl.2.A12
Cholestyramine, Idiopathic bile acid malabsorption and response to cholestyramine therapy, Suppl.2.A13
Chronic active gastritis, Infection by a mixed population, inlcuding for *cagA*, of *Helicobacter pylori*, Suppl.1.A68
Chronic hepatitis C virus infection
Disease severity in chronic hepatitis C virus infection is related to mode of transmission, Suppl.2.A28
Interferon vs interferon+tauro-ursodeoxycholic acid for treatment of chronic active hepatitis C, Suppl.2.A27
Cirrhosis
Actions of carvedilol, a vasodilating beta-blocker, upon splanchnic and renal haemodynamics in patients with cirrhosis, Suppl.2.A25
Combination ursodeoxycholic acid and immunosuppressive therapy for the treatment of primary biliary cirrhosis, Suppl.2.A27
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography, Suppl.2.A34
The role of plasma factors in the abnormal calcium signalling of platelets from patients with cirrhosis, Suppl.2.A33
Vitamin D and markers of bone formation in primary biliary cirrhosis, Suppl.2.A26
Cirrhotic explant livers, Pre-operative hepatic arterial lipiodol for the detection of hepatocellular cancers in cirrhotic explant livers, Suppl.2.A36
Citric acid cycle, The citric acid cycle of *Helicobacter pylori*, Suppl.1.A19
Clarithromycin
A cost-effective, European approach to *H. pylori* eradication, Suppl.1.A91
A decision analysis of healthcare costs following eradication of *H. pylori* with omeprazole in combination with either amoxycillin or clarithromycin, Suppl.1.A47
Clarithromycin or amoxicillin dual and triple therapies in *H. pylori* eradication: a meta-analysis, Suppl.2.A31
Clarithromycin in combination with omeprazole for healing duodenal ulcers, prevention of DU recurrence, and eradication of *H. pylori* in two European studies, Suppl.1.A4
Clarithromycin and omeprazole in the prevention of duodenal ulcer recurrence and eradication of *H. pylori*, Suppl.1.A85
Clarithromycin in the treatment and eradication of *Helicobacter pylori* in duodenal ulcer patients, Suppl.1.A97
Comparison of omeprazole+amoxicillin *versus* OM+clarithromycin in the eradication of *Helicobacter pylori* – results from a randomized study involving 120 patients, Suppl.1.A55
Dual therapy of clarithromycin and omeprazole for treatment of patients with duodenal ulcers associated with *H. pylori* infection, Suppl.1.A5
Dual therapy versus triple therapy: high dose of lansoprazole plus amoxicillin in combination or not with clarithromycin for *Helicobacter pylori* infection, Suppl.1.A92
Duodenal ulcer healing and *Helicobacter pylori* eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole, Suppl.1.A41
Effect of omeprazole and clarithromycin plus tinidazole on the eradication of *Helicobacter pylori* and the recurrence of duodenal ulcer, Suppl.1.A5
Effect of smoking on *H. pylori* eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole, Suppl.1.A85
Effects of antibiotic-resistance on clarithromycin-combined triple therapy for *Helicobacter pylori*, Suppl.1.A55
Efficacy of low doses of clarithromycin for one week in eradicating *H. pylori*, Suppl.1.A47
Efficacy of ten days of clarithromycin, amoxycillin and omeprazole in eradicating *Helicobacter pylori* infection, Suppl.1.A44
Eradication of *Helicobacter pylori* using clarithromycin, omeprazole and amoxycillin for one week, Suppl.1.A88
Evaluation of the efficacy of clarithromycin in the eradication of *Helicobacter pylori*, Suppl.1.A85
Evolution of the resistance to several antibiotics in *H. pylori* over a 4 year period, Suppl.1.A97
Factors affecting the eradication success in gastric and duodenal ulcer patients, Suppl.1.A44
GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of *Helicobacter pylori*, Suppl.1.A42
High efficacy of a clarithromycin-amoxycillin-omeprazole association for *H. pylori* eradication and treatment of ulcer-like or reflux-like dyspeptic symptoms, Suppl.1.A87
Mutations in 23S ribosomal RNA confer clarithromycin resistance in *Helicobacter pylori*, Suppl.1.A67
Omeprazole+amoxicillin+clarithromycin therapy for *H. pylori* infection, Suppl.1.A89
Omeprazole based therapies for eradication of *Helicobacter pylori*, Suppl.1.A90
Omeprazole and clarithromycin vs. omeprazole and amoxicillin: a comparison of one-week and two-week treatments, Suppl.1.A91
Omeprazole plus clarithromycin: efficacy of two treatment regimens on *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A41
One-week treatment with omeprazole, amoxycillin and clarithromycin or metronidazole for cure of *Helicobacter pylori* infection, Suppl.1.A43
Patient factors that predict failure of omeprazole, clarithromycin and tinidazole to eradicate *Helicobacter pylori*, Suppl.1.A46
Pre and post-treatment clarithromycin resistance of *Helicobacter pylori* strains: a key fctor of treatment failure, Suppl.1.A55
Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of *Helicobacter pylori* and prevention of duodenal ulcer relapse, Suppl.1.A5
The safety of dual therapy with clarithromycin and omeprazole in the treatment of patients with duodenal ulcer, Suppl.1.A43
The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin, Suppl.1.A5
Triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for *Helicobacter pylori* eradication, Suppl.1.A91
Cloning, The cloning and characterisation of chemotaxis genes in *Helicobacter pylori*, Suppl.1.A18
ClpB heat shock protein, Identification and characterisation of the *Helicobacter pylori* gene encoding a homologue of the ClpB heat shock protein of *Escherichia coli*, Suppl.1.A23
Coccoid forms
Do viable but non-culturable coccoid forms of *Helicobacter pylori* exist?, Suppl.1.A24
Fine structure and antigens of coccoid forms of *Helicobacter pylori*, Suppl.1.A66
Coccoidal forms, Evidence of the viability of non culturable coccoidal forms of *Helicobacter felis*, Suppl.1.A94
Coeliac disease
A three dimensional model of the HLA DQ2 peptide binding motif in coeliac disease, Suppl.2.A19
Bone mineral density and bone turnover in treated coeliac disease, Suppl.2.A42
Characterisation of gluten peptide HLA DQ2 binding in coeliac disease, Suppl.2.A41
Fractional calcium absorption is reduced in treated coeliac disease, Suppl.2.A42
Measurement of lactulose and mannitol in serum and the development of a serum test for assessing small intestinal permeability: preliminary results in untreated coeliac disease, Suppl.2.A13
Nitric oxide in the small intestinal mucosa of patients with coeliac disease, Suppl.2.A42
Th2 cytokines, interleukin-4 and interleukin-10 in the small intestine of patients with coeliac disease, Suppl.2.A42
Colon cancer, cDNA deletion associated with abnormal DNA mismatch repair in HNPCC? Suppl.2.A19

Colon pouches, Do ambulatory pouch and anal motility patterns in colon pouches explain poor functional results? Suppl.2.A47
Colon, radiolabelled resin, Colonic distribution of daily dosed, radiolabelled resin: right-sided reservoir and left-sided conduit? Suppl.2.A47
Colonic adenomas, *Helicobacter pylori* and colonic adenomas, Suppl.1.A83
Colonic epithelium, The distribution of somatostatin receptor subtypes in normal and malignant colonic epithelium, Suppl.2.A36
Colorectal cancer (carcinoma), Suppl.2.A23-24
Determination of *Helicobacter pylori* exposure, serum gastrin and gastrin releasing peptide in patients with colorectal carcinoma, Suppl.1.A68
Evidence for reciprocity of *bcl-2* and *p53* expression in colorectal adenomas and carcinomas, Suppl.2.A20
Follow-up after surgery for colorectal cancer, Suppl.2.A9
Gastrimmune reduces lung metastases in a human colorectal model, Suppl.2.A37
Glutathione-S-transferase (GST theta 1) genotypes and susceptibility to gastric and colorectal carcinoma, Suppl.2.A36
Colorectal liver metastases, Tumour response to regional chemotherapy depends upon tumour vascularity in colorectal liver metastases, Suppl.2.A36
Colostrum, Specific immune colostrum in the prevention of *Helicobacter felis* infection in mice, Suppl.1.A92
Colporrhaphy, The posterior colporrhaphy: a cosmetic or a therapeutic procedure?, Suppl.2.A24
Columnar-lined oesophagus, Regression of columnar-lined oesophagus following laser ablation and acid suppression, Suppl.2.A4
Commercial tests
A comparison of five commercial serological tests for *Helicobacter pylori* detection, Suppl.1.A15
Evaluation of a physician's office rapid serology test which detects *Helicobacter pylori* IgG antibodies with whole blood samples, Suppl.1.A15
False negative serological EIA results in *Helicobacter pylori* infected children, Suppl.1.A15
Computerised recording, Computerised recording and display of oesophageal manometry with video barium swallow, Suppl.2.A50
Consent, Consent – how much to tell?, Suppl.2.A10
Coronary heart disease, *Helicobacter pylori* infection and coronary heart disease, Suppl.1.A25
Corticosteroid resistance, Treatment of corticosteroid resistant ulcerative colitis with heparin, Suppl.2.A49
Costs
A cost-effective, European approach to *H. pylori* eradication, Suppl.1.A91
A decision analysis of healthcare costs following eradication of *H. pylori* with omeprazole in combination with either amoxycillin or clarithromycin, Suppl.1.A47
Decision analysis of the economic impact of *H. pylori* eradication regimens, Suppl.1.A56
Crohn's disease
Crohn's disease: a national study of prevalence and incidence, Suppl.2.A50
Crohn's disease patients suffering from peripheral arthritis or ankylosing spondylitis reveal restricted T cell receptor Vβ regions in different temporal phases of disease, Suppl.2.A23
Effect of oral glutamine on intestinal permeability and nutritional status in Crohn's disease, Suppl.2.A13
Platelet aggregate formation in the mesenteric microcirculation in Crohn's disease: further evidence for their role in pathogenesis, Suppl.2.A21
Cryptolytic lesions, The significance of cryptolytic lesions in inflammatory bowel disease, Suppl.2.A21
Cynomolgus monkey, Long-term infection of *Helicobacter pylori* promotes gastric mucosal atrophy in Cynomolgus monkey, Suppl.1.A49
Cytokine gene polymorphism
Cytokine gene polymorphism in inflammatory bowel disease: study of IL-1alpha and IL-1RA genes, Suppl.2.A22
Cytokine gene polymorphisms in patients with an ileal pouch anal anastomosis for ulcerative colitis, Suppl.2.A15
Cytokines
Cytokine profiles of blood and mucosal T-lymphocytes in children with and without gastrointestinal disease, Suppl.2.A16
Effect of *H. pylori* constituents and inflammatory cytokines on gastrin release from cultured canine G cells, Suppl.1.A84
Evidence for the involvement of inflammatory cytokines and *Helicobacter pylori* products in producing hypergastrinaemia: effects in a cell culture model, Suppl.2.A40
Modulation of the expression of B7, ICAM-1 and LFA3 on the surface of gastric epithelial cells following exposure to *H. pylori* and cytokines, Suppl.1.A31
Th2 cytokines, interleukin-4 and interleukin-10 in the small intestine of patients with coeliac disease, Suppl.2.A42
The balance of immunoregulatory and pro-inflammatory cytokines in active ulcerative colitis: untreated and in treatment failure, Suppl.2.A22
Cytology
A prospective evaluation of cytology from biliary strictures, Suppl.2.A2
Laparoscopic peritoneal cytology in the staging of pancreatic cancer, Suppl.2.A3
***Cytosensor* microphysiometer**, Monitoring of metabolic activity of *H. pylori* using a *Cytosensor* microphysiometer: drastic changes in cellular activity induced by acidic pH and urea, Suppl.1.A17
Cytotoxicity
Cytotoxicity of *Helicobacter pylori* on human gastric epithelial cells, Suppl.1.A82
Helicobacter pylori strain variability in adhesion, cytotoxicity and IL-8 release, Suppl.1.A3
Cytotoxin
Antimicrobial activity of lansoprazole against *Helicobacter pylori* in vitro and relation with cytotoxin production of strains, Suppl.1.A46
Cytotoxic *H. pylori* strains and urease activity in a population at high gastric cancer risk, Suppl.1.A37
Cytotoxin production and neutrophil activation by *Helicobacter pylori* in patients with peptic ulceration and chronic gastritis, Suppl.1.A3
Detection of *Helicobacter pylori* cytotoxin-associated protein by small format polyacrylamide gel electrophoresis and application to identifying potentially ulcerogenic strains, Suppl.1.A64
Helicobacter pylori cytotoxin: structure and function, Suppl.1.A94
Helicobacter pylori gastritis with cytotoxin associated protein antibodies (CagA) in a population at high risk for gastric cancer: a semiquantitative and computer aided morphological study, Suppl.1.A37
Cytotoxin associated gene product, Infection with CagA *H. pylori* positive strains is associated with reduced gastric juice vitamin C concentrations, Suppl.2.A16

D cell counts, *H. pylori* positive patients with duodenal ulcer have increased D cell counts in the duodenal bulb, Suppl.2.A44
D cells, Tumour necrosis factor-alpha decreases somatostatin release and the somatostatin content of cultured canine D cells, Suppl.1.A84
Danish children, Possible spontaneous eradication or suppression of *H. pylori* in Danish children compared to children of foreign origin, Suppl.1.A14
Dehydroquinase, Cloning, sequencing, overexpression and purification of a type II dehydroquinase from *Helicobacter pylori*, Suppl.1.A16
Dent sleeve, Monitoring the lower oesophageal sphincter – sphincterometer or sleeve?, Suppl.2.A45
Dental plaque, Polymerase chain reaction for detection of *Helicobacter pylori* DNA in patients with *H. pylori* induced gastritis suggests that dental plaque is not a reservoir, Suppl.2.A31
Depression, Anxiety, depression and intestinal transit, Suppl.2.A47
Dialysate, Rectal dialysate bioactivity in the absence of faeces, Suppl.2.A15
Diarrhoea, A randomized controlled trial of albendazole for treatment of diarrhoea in Africans with AIDS, Suppl.2.A41
Diathermy, Port site skin burns and diathermy in surgical laparoscopy, Suppl.2.A2
Disk diffusion, Discrepancies between the results of antimicrobial susceptibility testing of *Helicobacter pylori* using E-test compared to broth microdilution or disk diffusion, Suppl.1.A67
DNA
cDNA deletion associated with abnormal DNA mismatch repair in HNPCC?, Suppl.2.A19
Inhibition of DNA synthesis in mitogen stimulated rate hepatocytes by the peptide acetyl-SER-ASP-LYS-PRO, Suppl.2.A20
DNA sequence, DNA sequence of *cagII*, a new multigene locus implicated in *H. pylori* virulence, Suppl.1.A61
Drinking water, Detection of *Helicobacter pylori* in drinking water using polymerase chain reaction, Suppl.1.A27
Dual therapy, Dual therapy versus triple therapy: high dose of lansoprazole plus amoxicillin in combination or not with clarithromycin for *Helicobacter pylori* infection, Suppl.1.A92
Duodenal bulb
Effect of *H. pylori* eradication of D and G cell populations in the duodenal bulb, Suppl.1.A74
H. pylori positive patients with duodenal ulcer have increased D cell counts in the duodenal bulb, Suppl.2.A44
Parietal cells in the duodenal bulb are more common in *H. pylori* negative patients with duodenal ulcer, Suppl.1.A73

Prevalence and extent of gastric metaplasia in the duodenal bulb are not related to *H. pylori*, Suppl.2.A39
Prevalence and extent of gastric metaplasia in the duodenal bulb is not changed six months after *H. pylori* eradication, Suppl.1.A74

Duodenal ulcer
Alternative triple therapy for *Helicobacter pylori* related duodenal ulcers, Suppl.1.A86
Basal and stimulated gastrin levels and gastric acid output five months after therapy for *H. pylori* eradication in duodenal ulcer patients, Suppl.1.A30
Clarithromycin and omeprazole in the prevention of duodenal ulcer recurrence and eradication of *H. pylori*, Suppl.1.A85
Clarithromycin in the treatment and eradication of *Helicobacter pylori* in duodenal ulcer patients, Suppl.1.A97
Clarithromyhcin in combination with omeprazole for healing duodenal ulcers, prevention of DU recurrence, and eradication of *H. pylori* in two European studies, Suppl.1.A4
Do most subjects with *H. pylori* associated dyspepsia have duodenal ulcer disease? Suppl.2.A6
Duodenal ulcer healing and *Helicobacter pylori* eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole, Suppl.1.A41
Effect of smoking on *H. pylori* eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole, Suppl.1.A85
Factors affecting the eradication success in gastric and duodenal ulcer patients, Suppl.1.A44
Frequency of antral intestinal metaplasia after *H. pylori* eradication in duodenal ulcer patients, Suppl.1.A36
Gastric acid output, bacterial load and gastritis in *Helicobacter pylori* positive patients with duodenal ulcer, Suppl.1.A73
H. pylori positive patients with duodenal ulcer have increased D cell counts in the duodenal bulb, Suppl.2.A44
Hypergastrinemia is associated with *Helicobacter pylori* infective load in duodenal ulcer patients, Suppl.1.A29
Is gastric *H. pylori* colonisation density in duodenal ulcer patients dependent on Lewis/ABO-blood groups?, Suppl.1.A28
Long term *H. pylori* eradication after antibiotic therapy in duodenal ulcer patients in Chile, Suppl.1.A41
Omeprazole plus clarithromycin: efficacy of two treatment regimens on *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A41
Ranitidine vs omeprazole: short-term triple therapy in patients with *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A42
Safety of dual therapy with clarithromycin and omeprazole in the treatment of patients with duodenal ulcer, Suppl.1.A43
Specific *Helicobacter pylori vacA* genotypes are asspciated with presence of duodenal and gastric ulceration, and degree of gastric inflammation, Suppl.1.A3
Spectrum of *H. pylori* in duodenal ulcer patients from different countries, Suppl.1.A4
Systemic IgG antibodies to *Helicobacter pylori* CagA protein in blood donors with asymptomatic duodenal ulcers, Suppl.1.A31
Time-course of histological changes in *Helicobacter pylori* associated gastritis during the early phase of cure therapy with omeprazole and amoxycillin in duodenal ulcer patients, Suppl.1.A34
Treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and amoxycillin, Suppl.1.A42

Dyspepsia
2579 Italian dyspeptics referred to first upper GI endoscopy, Suppl.1.A53
Does a previous history of dyspepsia delay referral and diagnosis for gastric cancer?, Suppl.2.A38
Effect of eradication of *Helicobacter pylori* on symptoms of non-ulcer dyspepsia, Suppl.1.A56
Effect of *H. pylori* eradication on the severity of dyspeptic symptoms in DU patients – a one year follow up study, Suppl.1.A86
H. pylori colonization of the gastric mucosa is likely to be found in dyspeptic patients without antral phase 3 of migrating motor complex, Suppl.1.A82
H. pylori infection and dyspepsia within the general population, Suppl.1.A11
Helicobacter pylori, dyspepsia and peptic ulcer: perspectives and practice from primary care, Suppl.1.A88
Helicobacter pylori infection in young dyspeptic patients referred for upper gastrointestinal endoscopy, Suppl.1.A25
High efficacy of a clarithromycin-amoxycillin-omeprazole association for *H. pylori* eradication and treatment of ulcer-like or reflux-like dyspeptic symptoms, Suppl.1.A87
Impact of *H. pylori* infection on symptoms and effect of ranitidine in patients with functional dyspepsia, Suppl.1.A45
Management guidelines for dyspepsia. Do they reduce open access gastroscopy workload?, Suppl.2.A10
Salivary specific IgG in the diagnosis of *Helicobacter pylori* infection in dyspeptic patients, Suppl.1.A52
Treatment of patients with new dyspeptic symptoms and duodenal ulcers: guidelines for the general practitioner, Suppl.1.A87

Dysphagia, malignant, A prospective study of quality of life after endoscopic intubation with metal or plastic stents for malignant dysphagia, Suppl.2.A5

E-test, Discrepancies between the results of antimicrobial susceptibility testing of *Helicobacter pylori* using E-test compared to broth microdilution or disk diffusion, Suppl.1.A67
Eastern Europe, Seroprevalence of *Helicobacter pylori* infection in six countries of eastern Europe using a common methodology, Suppl.1.A71
Elderly patients, A serological and histological study on *Helicobacter pylori* infection in the elderly patients, Suppl.1.A82
Electron microscopic techniques, Ultrastructural characterization of the interaction between phospholipid liposomes and *Helicobacter pylori* by electron microscopic techniques, Suppl.1.A20
ELISPOT method, Detection of locally produced IgA- and IgG-antibodies against *Helicobacter pylori* in human gastric mucosa by ELISPOT method, Suppl.1.A81
ENA78, mRNA transcript for inflammatory mediators in *H. pylori*-associated gastritis, Suppl.1.A81
Endoloops, Experimental and clinical studies of endoloops: a new method of mechanical haemostasis for oesophageal varices, Suppl.2.A1

Endoluminal suturing
Anti reflux surgery using endoluminal suturing at gastroscopy – and alternative treatment for GORD, Suppl.2.A3
Reflux control at flexible endoscopy using endoluminal suturing in an in-vivo model, Suppl.2.A52

Endonuclease, A new typing method for *Helicobacter pylori*: end labelling of endonuclease digested DNA fragments, Suppl.1.A68

Endoscopic biopsies
A comparison of biopsy specimens from the antrum and corpus for culture of *H. pylori*, Suppl.1.A14
Frozen section of endoscopic gastric biopsies: a rapid and reliable method for diagnosis of *H. pylori* infection and chronic gastritis, Suppl.1.A13

Endoscopic gastroplasty, Reflux control at flexible endoscopy using endoluminal suturing in an in-vivo model, Suppl.2.A52
Endoscopic ultrasound, Evaluation of large gastric folds in patients with *Helicobacter pylori* infection by endoscopic ultrasound before and after antimicrobial therapy, Suppl.1.A38

Endoscopy, Suppl.2.A9-12
2579 Italian dyspeptics referred to first upper GI endoscopy, Suppl.1.A53
Association of *Helicobacter pylori* and anti-CagA serum IgG with gastroduodenal endoscopic lesions in the population of San Marino, Suppl.1.A71
Open access endoscopy facilitates early diagnosis of malignant and pre-malignant lesions of the stomach and oesophagus, Suppl.2.A35
Quantitative noninvasive testing for *H. pylori* does not predict gastroduodenal ulcer disease, Suppl.1.A13

Endothelin-1, Levels of endothelin-1 in the gastric tissue in gastric ulcer patients infection by *H. pylori*, Suppl.1.A28
Endotoxin sensitivity, Are autoimmunity and endotoxin sensitivity part of the spectrum of *Helicobacter*-induced disease?, Suppl.1.A51
Enteral nutrition, Supplemental enteral nutrition in patients undergoing major resectional surgery, Suppl.2.A43
Enzyme linked oligonucleotide chemiluminescence assay, Induction of gastric epithelial interleukin 8 expression with natural *H. pylori* infection, detected by a new enzyme linked oligonucleotide chemiluminescence assay, Suppl.1.A79

Epidemiology
Epidemiology of *Helicobacter pylori* infection among 4,742 randomly selected subjects from Northern Ireland, Suppl.1.A70
H. pylori infection in infancy, Suppl.1.A24
Helicobacter pylori – epidemiologic and microbiological aspects in a Norwegian population, Suppl.1.A16
The epidemiology of *Helicobacter pylori* antimicrobial resistance – preliminary findings of a national survey, Suppl.2.A6

Epidermal growth factor
Mechanism of gastro protection by epidermal growth factor in the rat: influence of capsaicin desensitisation and close arterial infusion of a calcitonin gene-related peptide antagonist on gastric mucosal blood flow, Suppl.2.A53
The effect of *H. felis* infection on proliferation and growth factor expression, Suppl.1.A77

Epithelial cells
Cytotoxicity of *Helicobacter pylori* on human gastric epithelial cells, Suppl.1.A82
Helicobacter pylori gastritis is associated with expression of variant forms of CD44 on gastric epithelial cells: implications for gastric cancer, Suppl.1.A7

Identification of a *Helicobacter pylori*-specific protein involved in adherence to gastric epithelial cells, Suppl.1.A1
Influence of *H. pylori* on interleukin 8 secretion by human gastric epithelial cells in culture, Suppl.1.A32

Epithelium
Evaluations of inflammatory, metaplastic, preneoplastic and neoplastic changes in the gastric surface epithelium by the AgNOR method, Suppl.1.A34
How does gastric metaplasia in the duodenum differ from gastric epithelium?, Suppl.1.A29
Increased gastric epithelial cell proliferation in *H. pylori* associated follicular gastritis, Suppl.1.A76
Modulation of the expression of B7, ICAM-1 and LFA3 on the surface of gastric epithelial cells following exposure to *H. pylori* and cytokines, Suppl.1.A31
Preferential induction of interleukin-8 from gastric epithelial cell lines by *Helicobacter pylori* lipopolysaccharide, Suppl.1.A31

Eradication
Helicobacter pylori and non-*Helicobacter pylori* bacterial flora before and after eradication therapy for *Helicobacter pylori*, Suppl.1.A14
Possible spontaneous eradication or suppression of *H. pylori* in Danish children compared to children of foreign origin, Suppl.1.A14
Serological evaluation of *Helicobacter pylori* eradication using recombinant CagA protein, Suppl.1.A14

ERCP
ERCP as a daycase procedure – safe and well tolerated, Suppl.2.A11
Value of ERCP in patients with suspected bile duct injury following laparoscopic cholecystectomy, Suppl.2.A1

Essential fatty acids deficiency, Malnutrition, essential fatty acids deficiency and intake threshold in biliary atresia, Suppl.2.A30

Estonia
A cohort study of *Helicobacter pylori* colonisation in children, Suppl.1.A72
The comparison of occurrence of IgG antibodies to high molecular weight proteins of *Helicobacter pylori* antigen in gastric cancer patients and controls in Estonia, Suppl.1.A96

Ethnic groups, Different seroprevalences of *Helicobacter pylori* between ethnic groups of New Zealand, Suppl.1.A26

Faecal occult blood tests, Current practice – use and abuse of chemical faecal occult blood tests, Suppl.2.A49
Faecal pH, The influence of intestinal transit time on faecal pH, Suppl.2.A51
Faecal samples, Immunomagnetic separation and PCR for the detection of *Helicobacter pylori* in water and fecal samples, Suppl.1.A24
Farm animals, *Helicobacter pylori* infection in asymptomatic Sardinian shepherds, Suppl.1.A68
Farmworkers, Incidence of *Helicobacter pylori* in farmworkers and the role of zoonotic spread, Suppl.1.A24
Fat induced CCK release, Fat induced CCK release and effects on antral and gallbladder motility are dependent on meal composition, Suppl.2.A51
Ferrets, Inability of a urease-negative isogenic mutant of *Helicobacter mustelae* to colonize the ferret stomach, Suppl.1.A48
Fibrinogen, Influence of *Helicobacter pylori* status on plasma fibrinogen, Suppl.1.A25
Finland, Prevalence of *Helicobacter* antibodies in 1973 and 1994 in the adult population of Vammala, Finland, Suppl.1.A26
***Fla A* genes**, Phylogenic analysis of *ure B* and *fla A* genes among isolates of *Helicobacter pylori* in relation to restriction length polymorphism, Suppl.1.A19
Flagellar biosynthesis, The *H. pylori* flagellar biosynthesis regulatory protein FlbA affects the expression of flagellar components on the transcriptional level and is probably a membrane protein, Suppl.1.A62
Flagellar sheath protein, Gene cloning of a flagellar sheath protein of *Helicobacter pylori*, Suppl.1.A63
Flagellins, Reporter gene analyses show that expression of both *H. pylori* flagellins is dependent on the growth phase, Suppl.1.A62
FlbA protein, The *H. pylori* flagellar biosynthesis regulatory protein FlbA affects the expression of flagellar components on the transcriptional level and is probably a membrane protein, Suppl.1.A62
***FlexSure*™*HP* whole blood test**, *FlexSure*™*HP* whole blood test – a rapid method to detect antibodies against *Helicobacter pylori*, Suppl.1.A60
Follicular gastritis, Increased gastric epithelial cell proliferation in *H. pylori* associated follicular gastritis, Suppl.1.A76
Food intake, Acute and chronic effect of lansoprazole and omeprazole in relation to food intake, Suppl.2.A32
France, Seroprevalence of *Helicobacter pylori* infection among gastroenterologists in France, Suppl.1.A78

Fulminant hepatic failure
Serum from patients in fulminant hepatic failure enhances hepatocyte function in culture, Suppl.2.A25
The improved results of emergency orthotopic liver transplantation for fulminant and subacute hepatic failure, Suppl.2.A34
Fumarate reductase, A potential therapeutic target in *Helicobacter pylori*, Suppl.1.A88

G cell binding, *Helicobacter pylori* and G cell binding, Suppl.1.A81
G cells, Effect of *H. pylori* constituents and inflammatory cytokines on gastrin release from cultured canine G cells, Suppl.1.A84
Gabexate mesilate, Gabexate mesilate (FOY) in the prevention of pancreatic damage secondary to endoscopic manoeuvres on Vater's papilla, Suppl.2.A29

Gallbladder motility
Nitric oxide may influence gallbladder motility, Suppl.2.A51
The differential effect of PACAP on *in vitro* gallbladder motility is modulated via prostaglandins, Suppl.2.A52

Gallstones, The benefits of laparoscopic surgery in the management of gallstones, Suppl.2.A2

Gastric acid
Basal and stimulated gastrin levels and gastric acid output five months after therapy for *H. pylori* eradication in duodenal ulcer patients, Suppl.1.A30
Chemotactic response to mucus and acid by *Helicobacter pylori*, Suppl.1.A64
Gastric acid output, bacterial load and gastritis in *Helicobacter pylori* positive patients with duodenal ulcer, Suppl.1.A73
Pentagastrin stimulated gastric acid secretion and postprandial gastrin profile in *Helicobacter pylori* positive and negative healthy volunteers, Suppl.1.A9
Recurrence of duodenal ulcer after *Helicobacter pylori* eradication is related to high gastric acid output, Suppl.1.A8
Regression of columnar-lined oesophagus following laser ablation and acid suppression, Suppl.2.A4

Gastric acid secretion
Divergent effects of *H. pylori* on acid secretion, Suppl.1.A82, Suppl.2.A6
H. pylori eradication and gastric acid secretion: a 12 month follow-up study in DU subjects, Suppl.2.A39
H. pylori-induced disturbance of gastric acid secretion is unrelated to bacterial CagA status, Suppl.1.A83
Helicobacter pylori infection influences on the gastric acid secretions, Suppl.1.A37

Gastric atrophy
Antibodies to Cag A protein in patients with *H. pylori* infection and atrophic gastritis, Suppl.1.A37
Antigastric autoantibodies in *Helicobacter pylori* gastritis. Prevalence, in situ binding sites and positive correlation with gastric atrophy and hypergastrinemia, Suppl.1.A33
Circulating IgA antibodies to the 60 kDa heat shock protein family are raised in patients with *Helicobacter pylori*-related gastric atrophy, Suppl.1.A80
Circulating IgA antibodies to 60kDa but not 32kDa heat shock proteins are raised in patients with *Helicobacter pylori*-related gastric atrophy, Suppl.2.A44

Gastric biopsy
Nested-polymerase chain reaction for the detection of *Helicobacter pylori* in gastric biopsy samples, Suppl.2.A40
Reducing the gastric biopsy histopathology workload through audit, Suppl.2.A8

Gastric cancer (carcinoma)
Association between gastric cancer and *H. pylori* with reference to age, Suppl.1.A8
Basement membrane degradation by gastric and oesophageal cancer cells: the effect of plasminogen, Suppl.2.A21
Comparison of occurrence of IgG antibodies to high molecular weight proteins of *Helicobacter pylori* antigen in gastric cancer patients and controls in Estonia, Suppl.1.A96
Cytotoxic *H. pylori* strains and urease activity in a population at high gastric cancer risk, Suppl.1.A37
Different expression of *Helicobacter pylori* gastritis in gastric cancer patients, Suppl.1.A39
Does open access gastroscopy increase the detection rate of early gastric cancer? Results of a 5 year study, Suppl.2.A35
Does a previous history of dyspepsia delay referral and diagnosis for gastric cancer? Suppl.2.A38
Glutathione-S-transferase (GST theta 1) genotypes and susceptibility to gastric and colorectal carcinoma, Suppl.2.A36
Helicobacter pylori and gastric cancer: an endoscopic survey of healthy children in high and low risk areas for gastric cancer in China, Suppl.1.A38
Helicobacter pylori gastritis is associated with expression of variant forms of CD44 on gastric epithelial cells: implications for gastric cancer, Suppl.1.A7

Helicobacter pylori infection is significantly more common in association with tumours of the gastric antrum than tumours of cardia, Suppl.2.A7
Host's genetic analysis in patients with atrophic gastritis or gastric carcinoma harboring *Helicobacter pylori*, Suppl.1.A7
Open access endoscopy facilitates early diagnosis of malignant and pre-malignant lesions of the stomach and oesophagus, Suppl.2.A35
Prevalence of gastric atrophy, the precursor lesion of gastric carcinoma, is independent of the prevalence of Hp infection: evidence that while *Hp* infection may be the major determining factor for gastric cancer it is not for gastric atrophy, Suppl.1.A7
Prospective investigation of the association between *H. pylori* infection and gastric cancer in China, Suppl.1.A77
Seroprevalence of *Helicobacter pylori* infection in gastric and non-gastric carcinoma, Suppl.1.A40
Total N-nitroso compound concentration correlates with increasing risk of gastric cancer, Suppl.2.A35

Gastric endothelial (HuGE) cells, Isolation and culture of human gastric endothelial (HuGE) cells, Suppl.2.A18

Gastric histology, *Helicobacter pylori*, gastric histology and gastro-oesophageal reflux disease, Suppl.1.A36

Gastric inflammation, Specific *Helicobacter pylori vacA* genotypes are asspciated with presence of duodenal and gastric ulceration, and degree of gastric inflammation, Suppl.1.A3

Gastric juice
Detection of *Helicobacter pylori* DNA in gastric juice by PCR: comparison with *H. pylori* DNA in biopsy specimens, Suppl.1.A54
Gastric juice polymerase chain reaction for *Helicobacter pylori* diagnosis: an alternative to histology?, Suppl.1.A15

Gastric juice aspirates, Comparison of *H. pylori ure-B* gene between gastric mucosae and gastric juice aspirates using restriction pattern analysis, Suppl.1.A95

Gastric juice β-carotene, *H. pylori* infection is associated with decreased gastric juice β-carotene concentration, Suppl.2.A44

Gastric luminal antioxidant, A study of the relationship between alcohol intake and gastric luminal antioxidant concentrations, Suppl.2.A40

Gastric metaplasia
How does gastric metaplasia in the duodenum differ from gastric epithelium?, Suppl.1.A29
The prevalence and extent of gastric metaplasia in the duodenal bulb are not related to *H. pylori*, Suppl.2.A39

Gastric mucosal atrophy, Long-term infection of *Helicobacter pylori* promotes gastric mucosal atrophy in Cynomolgus monkey, Suppl.1.A49

Gastric ulcer
Diagnosis of *H. pylori* infection in peptic gastric ulcer. How to do it properly?, Suppl.1.A58
Double-blind trial of 80 mg omeprazole and 2250 mg amoxicillin for cure of *Helicobacter pylori* infection in gastric ulcer patients, Suppl.1.A44
Effect of exogenous co-factors on ulcerogenesis by *H. heilmannii*-like bacteria in mice, Suppl.1.A48
Factors affecting the eradication success in gastric and duodenal ulcer patients, Suppl.1.A44
Gastric ulcer recurrence following treatment for eradication of *Helicobacter pylori*, Suppl.1.A54
Inoculation of *Helicobacter pylori* delays the healing of gastric ulcer in the rat, Suppl.1.A29
Levels of endothelin-1 in the gastric tissue in gastric ulcer patients infection by *H. pylori*, Suppl.1.A28
Specific *Helicobacter pylori vacA* genotypes are asspciated with presence of duodenal and gastric ulceration, and degree of gastric inflammation, Suppl.1.A3
UGI bleeding and gastric ulcer location are independent clues to NSAID use in patients with peptic ulcer regardless of *H. pylori* status, Suppl.1.A89

Gastrimmune, Gastrimmune reduces lung metastases in a human colorectal model, Suppl.2.A37

Gastrin
Basal and stimulated gastrin levels and gastric acid output five months after therapy for *H. pylori* eradication in duodenal ulcer patients, Suppl.1.A30
Determination of *Helicobacter pylori* exposure, serum gastrin and gastrin releasing peptide in patients with colorectal carcinoma, Suppl.1.A68
Direct enhancement of gastrin release by *H. pylori* water soluble proteins, Suppl.1.A9
H. pylori alters the changes in somatostatin and gastrin mRNAs induced by infusion of gastrin releasing peptide, Suppl.1.A9
Parietal cell sensitivity to gastrin distinguishes *H. pylori* infected DU patients from infected healthy volunteers, Suppl.2.A39

Gastrin releasing peptide, Determination of *Helicobacter pylori* exposure, serum gastrin and gastrin releasing peptide in patients with colorectal carcinoma, Suppl.1.A68

Gastritis
Cigarette smoking and gastritis activity are predicting factors of *Helicobacter pylori* eradication rate, Suppl.1.A47
Frozen section of endoscopic gastric biopsies: a rapid and reliable method for diagnosis of *H. pylori* infection and chronic gastritis, Suppl.1.A13
Gastric acid output, bacterial load and gastritis in *Helicobacter pylori* positive patients with duodenal ulcer, Suppl.1.A73
H. pylori, gastritis and serum pepsinogen A in a male non-patient population, Suppl.1.A4
Host's genetic analysis in patients with atrophic gastritis or gastric carcinoma harboring *Helicobacter pylori*, Suppl.1.A7
Peptic ulcer and gastritis in uraemia, Suppl.2.A32
Spectrum of gastritis in Zambian patients with AIDS, Suppl.1.A36
Spectrum of *Helicobacter pylori* gastritis in duodenal ulcer patients from different countries, Suppl.1.A4

Gastro-oesophageal reflux
Characteristics of reflux in relation with symptom event in patients with gastro-oesophageal reflux resistant to omeprazole therapy, Suppl.2.A46
Oesophageal motor responses to gastro-oesophageal reflux in healthy controls and reflux patients, Suppl.2.A46

Gastro-oesophageal reflux disease
Anti reflux surgery using endoluminal suturing at gastroscopy – and alternative treatment for GORD, Suppl.2.A3
Comparison of omeprazole 10mg and 20mg om with ranitidine 150mg bd for the treatment of GORD in primary care, Suppl.2.A45
Helicobacter pylori, gastric histology and gastro-oesophageal reflux disease, Suppl.1.A36

Gastro protection, Mechanism of gastro protection by epidermal growth factor in the rat: influence of capsaicin desensitisation and close arterial infusion of a calcitonin gene-related peptide antagonist on gastric mucosal blood flow, Suppl.2.A53

Gastroduodenal, Suppl.2.A37-40

Gastroduodenal disease, *H. pylori*-associated gastroduodenal disease: survey of British physicians' views, Suppl.1.A87

Gastroenterologists
Do senior gastroenterologists experience more 'burnout' and psychiatric disorder than other hospital consultants, Suppl.2.A9
Seroprevalence of *Helicobacter pylori* infection among gastroenterologists in France, Suppl.1.A78

Gastrointestinal cancer, Suppl.2.A35-37

Gastrointestinal haemorrhage, A safe and cost effective transfusion policy in gastrointestinal haemorrhage, Suppl.2.A8

Gastroscopy
Anti reflux surgery using endoluminal suturing at gastroscopy – and alternative treatment for GORD, Suppl.2.A3
Does open access gastroscopy increase the detection rate of early gastric cancer? Results of a 5 year study, Suppl.2.A35
Management guidelines for dyspepsia. Do they reduce open access gastroscopy workload?, Suppl.2.A10
Open access gastroscopy: second BSG survey, Suppl.2.A10
Open access gastroscopy – effects of pretreatment – closing the audit cycle, Suppl.2.A7

Gastrospirillum suis
Establishment of an animal model of ulcerogenesis induced by *Helicobacter* using swine, Suppl.1.A92
Gastric and intestinal motility in rats experimentally infected with *Gastrospirillum suis*, Suppl.1.A35

***Gastrospirrillum* infection**, Reservoir hosts for human *Gastrospirrillum* infection, Suppl.1.A26

Gene characterization, Identification and characterisation of the *Helicobacter pylori* gene encoding a homologue of the ClpB heat shock protein of *Escherichia coli*, Suppl.1.A23

Gene cloning
Gene cloning of a flagellar sheath protein of *Helicobacter pylori*, Suppl.1.A63
Monoclonal antibody recognition and gene cloning of a 22 kDa surface-associated protein of *Helicobacter pylori*, Suppl.1.A63

Gene expression, Regulation of gene expression by pH and urea in *Helicobacter pylori*, Suppl.1.A2

Gene inactivation, A random insertion mutagenesis system for the inactivation of *Helicobacter pylori* gene using a construction derived from the gram positive conjugative transposon Tn*1545*, Suppl.1.A65

General practitioner, Treatment of patients with new dyspeptic symptoms and duodenal ulcers: guidelines for the general practitioner, Suppl.1.A87

Genes
Complexity of P type ATPase genes in the genome of *Helicobacter pylori*, Suppl.1.A21
Identification of genes encoding exported protein sequences in *Helicobacter pylori* using alkaline phosphatase vectors, Suppl.1.A22

Genetic anticipation, Clinical patterns of familial inflammatory

bowel disease: evidence for genetic anticipation? Suppl.2.A50
Genetic characterization
Genetic characterization of an unprocessed 30 kDa *Helicobacter pylori*-specific surface protein, Suppl.1.A22
Genetic characterization of the *Helicobacter pylori recA* gene, Suppl.1.A21
Genetic nomenclature, Proposal for development of a uniform genetic nomenclature for *Helicobacter pylori*, Suppl.1.A23
Geographical distribution, Spectrum of *Helicobacter pylori* gastritis in duodenal ulcer patients from different countries, Suppl.1.A4
Glandular proliferation and homeostasis, Glandular proliferation and homeostasis of specific cells are differentially affected in gastric corpus and antrum in *Helicobacter pylori* induced gastritis, Suppl.1.A38
Glucose hydrogen breath tests, Positive glucose hydrogen breath tests for small bowel bacterial overgrowth in residents of elderly peoples homes, Suppl.2.A13
Glutamine, Effect of oral glutamine on intestinal permeability and nutritional status in Crohn's disease, Suppl.2.A13
Glutathione-S-transferase, Glutathione-S-transferase (GST theta 1) genotypes and susceptibility to gastric and colorectal carcinoma, Suppl.2.A36
Gluten peptide, Characterisation of gluten peptide HLA DQ2 binding in coeliac disease, Suppl.2.A41
Glyceryl trinitrate, The use of glyceryl trinitrate in the treatment of anal fissure, Suppl.2.A5
Glycoprotein synthesis, Glycoprotein synthesis in *H. pylori* gastritis, Suppl.1.A35
GR122311X
GR122311X can significantly reduce the emergence of *H. pylori* strains resistant to antibiotics, Suppl.1.A62
GR122311X (ranitidine bismuth citrate) with amoxycillin for the eradication of *Helicobacter pylori*, Suppl.1.A42
GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of *Helicobacter pylori*, Suppl.1.A42
The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and amoxycillin, Suppl.1.A42
The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin, Suppl.1.A5
Growth hormone, Metabolic manipulation of hypercatabolic chronically septic patients using recombinant human growth hormone, Suppl.2.A43
Growth phase, Growth phase and pH-related regulation of *cag*A, *cag*C and *ure*A expression in *H. pylori*, Suppl.1.A1

Haemophilia, *H. pylori* detection and eradication in haemophilic patients, Suppl.1.A45
Heat shock protein
Circulating IgA antibodies to the 60 kDa heat shock protein family are raised in patients with *Helicobacter pylori*-related gastric atrophy, Suppl.1.A80
Circulating IgA antibodies to 60kDa but not 32kDa heat shock proteins are raised in patients with *Helicobacter pylori*-related gastric atrophy, Suppl.2.A44
Identification and characterisation of the *Helicobacter pylori* gene encoding a homologue of the ClpB heat shock protein of *Escherichia coli*, Suppl.1.A23
Heat-shock protein A, Immunisation with *H. pylori* heat-shock protein A and urease subunit B affords total protection against *H. felis* infection in mice, Suppl.1.A51
Helico Blot 2.0
Evaluation of Helico Blot 2.0 – a new commercial western blot test – for the serological diagnosis of *Helicobacter pylori* infection, Suppl.1.A59
Serum reactivity to *Helicobacter pylori* antigens assessed by Helico Blot 2.0 in *H. pylori*-positive children from different ethnic groups, Suppl.1.A79
Helicobacter felis
Are autoimmunity and endotoxin sensitivity part of the spectrum of *Helicobacter*-induced disease?, Suppl.1.A51
Evidence of the viability of non culturable coccoidal forms of *Helicobacter felis*, Suppl.1.A94
H. felis isolates of differing virulence: bacterial virulence factors and host response as mediators of the infection process, Suppl.1.A65
Helicobacter felis surface antigen recognition by three strains of immune mice, Suppl.1.A95
Helicobacter felis surface antigens serve as protective targets in orally immunised mice, Suppl.1.A93
Identification of a novel protective antigen in *Helicobacter felis*, Suppl.1.A31
Immunisation with *H. pylori* heat-shock protein A and urease subunit B affords total protection against *H. felis* infection in mice, Suppl.1.A51
Induction of gastric dysplasia by *H. felis* in p53-deficient mice, Suppl.1.A40
Protective immunisation against *Helicobacter* spp stimulates long term immunity, Suppl.1.A48
Specific immune colostrum in the prevention of *Helicobacter felis* infection in mice, Suppl.1.A92
Helicobacter heilmannii
Culture and characteristics of a 'new' *Helicobacter* sp resembling *H. heilmannii* isolated from gastric biopsies of dogs, Suppl.1.A49
The effect of exogenous co-factors on ulcerogenesis by *H. heilmannii*-like bacteria in mice, Suppl.1.A48
Helicobacter mustelae, Inability of a urease-negative isogenic mutant of *Helicobacter mustelae* to colonize the ferret stomach, Suppl.1.A48
Helicobacter pylori, Suppl.1.A1-A96, Suppl.2.A6-7, A44
Audit of a specialised *Helicobacter pylori* treatment clinic, Suppl.2.A31
Clarithromycin or amoxicillin dual and triple therapies in *H. pylori* eradication: a meta-analysis, Suppl.2.A31
Comparison of five commercial serological tests for *Helicobacter pylori* detection, Suppl.2.A31
Comparison of serum, salivary and rapid whole-blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy-based tests, Suppl.2.A39
Evidence for the involvement of inflammatory cytokines and *Helicobacter pylori* products in producing hypergastrinaemia: effects in a cell culture model, Suppl.2.A40
H. pylori eradication and gastric acid secretion: a 12 month follow-up study in DU subjects, Suppl.2.A39
Helicobacter pylori eradication in the long term management of peptic ulcer disease in general practice, Suppl.2.A38
Is it necessary to test for *Helicobacter pylori* eradication after treatment?, Suppl.2.A38
Molecular characterisation of immunoglobulins in gastric aspirates of *Helicobacter pylori* infected patients, Suppl.2.A16
Nested-polymerase chain reaction for the detection of *Helicobacter pylori* in gastric biopsy samples, Suppl.2.A40
Outcome of *Helicobacter pylori* eradication in omeprazole, clarithromycin and tinidazole treatment failures, Suppl.2.A32
Parietal cell sensitivity to gastrin distinguishes *H. pylori* infected DU patients from infected healthy volunteers, Suppl.2.A39
Polymerase chain reaction for detection of *Helicobacter pylori* DNA in patients with *H. pylori* induced gastritis suggests that dental plaque is not a reservoir, Suppl.2.A31
The prevalence and extent of gastric metaplasia in the duodenal bulb are not related to *H. pylori*, Suppl.2.A39
Urea solution for direct *H.pylori* testing, Suppl.2.A30
VIIIth International Workshop on Gastro-duodenal Pathology and *Helicobacter pylori*, July 1995, Edinburgh, abstracts, Suppl.1.A1-97
Helisal Rapid Whole Blood Test, Validation of the Helisal Rapid Whole Blood Test for the detection of IgG antibodies to *H. pylori*, Suppl.1.A56
HELISAL tests, Validation of HELISAL whole blood, serum and saliva tests for the non-invasive diagnosis of *H. pylori* infection, Suppl.1.A13
Helper T cells, The regulation of activated helper T cells in the gastric mucosa during infection with *H. pylori*, Suppl.1.A50
Heparin
Helicobacter pylori interacts with heparin and heparin-dependent growth factors, Suppl.1.A74
Treatment of corticosteroid resistant ulcerative colitis with heparin, Suppl.2.A49
Heparin-coated magnetic beads, The use of heparin-coated magnetic beads to monitor a *Helicobacter pylori* colonisation in Balb-C mice, Suppl.1.A93
Heparin-dependent growth factors, *Helicobacter pylori* interacts with heparin and heparin-dependent growth factors, Suppl.1.A74
Hepatic 31 phosphorus magnetic resonance spectroscopy, *In vivo* hepatic ^{31}P magnetic resonance spectroscopy: a prognostic marker in patients with primary biliary cirrhosis?, Suppl.2.A28
Hepatic arterial lipiodol, Pre-operative hepatic arterial lipiodol for the detection of hepatocellular cancers in cirrhotic explant livers, Suppl.2.A36
Hepatic injury, Haemodynamic changes in toxic hepatic injury, Suppl.2.A48
Hepatic stellate cells, Hepatic stellate cells produce membrane-type matrix metalloproteinase, Suppl.2.A26
Hepatitis, Autoimmune hepatitis: application of International Group criteria and clinical experience in a single centre, **Suppl.2.A34**
Hepatitis B virus, Liver transplantation for hepatitis B virus infection – past, present and future, Suppl.2.A26
Hepatitis C
Association between chronic hepatitis C virus infection and hepatocellular carcinoma in a Scottish population, Suppl.2.A27
Disease severity in chronic hepatitis C virus infection is related to mode of transmission, Suppl.2.A28

Interferon vs interferon+tauro-ursodeoxycholic acid for treatment of chronic active hepatitis C, Suppl.2.A27
Multiple chemokine genes are expressed in liver tissue from patients with chronic hepatitis C infection, Suppl.2.A33
Hepatocellular cancers, Pre-operative hepatic arterial lipiodol for the detection of hepatocellular cancers in cirrhotic explant livers, Suppl.2.A36
Hepatocyte function, Serum from patients in fulminant hepatic failure enhances hepatocyte function in culture, Suppl.2.A25
Hepatocyte protein synthesis, Liver failure plasma contains inhibitors of hepatocyte protein synthesis – relevance to extracorporeal liver support, Suppl.2.A26
Hepatocytes, Inhibition of DNA synthesis in mitogen stimulated rate hepatocytes by the peptide acetyl-SER-ASP-LYS-PRO, Suppl.2.A20
Hereditary non polyposis colon cancer, cDNA deletion associated with abnormal DNA mismatch repair in HNPCC? Suppl.2.A19
High molecular weight proteins, The comparison of occurrence of IgG antibodies to high molecular weight proteins of *Helicobacter pylori* antigen in gastric cancer patients and controls in Estonia, Suppl.1.A96
Histamine antagonists, The clinical consequences of *Helicobacter pylori* eradication in patients previously taking long-term histamine antagonists. A general practice study, Suppl.1.A45
Histology
A serological and histological study on *Helicobacter pylori* infection in the elderly patients, Suppl.1.A82
Comparison of immunohistochemistry and histology for the diagnosis of *Helicobacter pylori* infection after treatment, Suppl.1.A35
Time-course of histological changes in *Helicobacter pylori* associated gastritis during the early phase of cure therapy with omeprazole and amoxycillin in duodenal ulcer patients, Suppl.1.A34
HIV, Jejunal water and electrolyte transport in intestinal microsporidiosis in HIV positive patients, Suppl.2.A12
HIV infection, Serodiagnosis of *Helicobacter pylori* infection in patients with human immunodeficiency virus infection, Suppl.1.A95
HLA class II genes, HLA class II genes are important determinants of disease susceptibility in ulcerative colitis but not in Crohn's disease, Suppl.2.A21
HLA DQ2
A three dimensional model of the HLA DQ2 peptide binding motif in coeliac disease, Suppl.2.A19
Characterisation of gluten peptide HLA DQ2 binding in coeliac disease, Suppl.2.A41
HLA-DR tissue expression, Aberrant HLA-DR tissue expression and activated lymphocyte response in different types of chronic pancreatitis, Suppl.2.A29
Household living conditions, Household living conditions and *Helicobacter pylori* infection in children undergoing elective day surgery, Suppl.1.A70
HP54K, Surface localization of *H. pylori* urease and HP54K requires bacterial lysis, Suppl.1.A19
HspA, Relationship between the immune response to HspA and clinical features in *Helicobacter pylori*-infected patients, Suppl.1.A79
HspA antigen, The HspA antigen is highly conserved among *Helicobacter pylori* clinical isolates and its use in serological and protection studies is warranted, Suppl.1.A65
Hydrogenase, Sequencing and inactivation of a *Helicobacter pylori* hydrogenase, Suppl.1.A18
Hyergastrinemia, Antigastric autoantibodies in *Helicobacter pylori* gastritis. Prevalence, in situ binding sites and positive correlation with gastric atrophy and hypergastrinemia, Suppl.1.A33
Hypercoagulability, Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography, Suppl.2.A34
Hypergastrinaemia
Evidence for the involvement of inflammatory cytokines and *Helicobacter pylori* products in producing hypergastrinaemia: effects in a cell culture model, Suppl.2.A40
Helicobacter pylori infection causes increased hypergastrinaemia during omeprazole therapy, Suppl.1.A59
Hypergastrinemia is associated with *Helicobacter pylori* infective load in duodenal ulcer patients, Suppl.1.A29
Hypnosis, Visceral sensation and emotion: a study using hypnosis, Suppl.2.A51
Hypothermic reperfusion, 31P-ATP regeneration following storage and reperfusion of the donor pig liver, Suppl.2.A34
Hypoxaemia, Hypoxaemia during diagnostic laparoscopy, Suppl.2.A2

ICAM-1, Modulation of the expression of B7, ICAM-1 and LFA3 on the surface of gastric epithelial cells following exposure to *H. pylori* and cytokines, Suppl.1.A31
Ileal bile acid binding proteins, Human ileal bile acid binding proteins: partial sequence and tissue expression, Suppl.2.A17
Immune response, Relationship between the immune response to HspA and clinical features in *Helicobacter pylori*-infected patients, Suppl.1.A79
Immunisation
Immunisation with *H. pylori* heat-shock protein A and urease subunit B affords total protection against *H. felis* infection in mice, Suppl.1.A51
Infection by *Helicobacter pylori* in a mouse model that mimics human disease: protection by oral vaccination, Suppl.1.A51
Oral immunization with recombinant *Helicobacter pylori* urease apoenzyme in the treatment of *Helicobacter* infection, Suppl.1.A94
Protective immunisation against *Helicobacter* spp stimulates long term immunity, Suppl.1.A48
Therapeutic immunisation – the future for *Helicobacter* treatment?, Suppl.1.A93
Immunoglobulin A antibodies
Circulating IgA antibodies to 60kDa but not 32kDa heat shock proteins are raised in patients with *Helicobacter pylori*-related gastric atrophy, Suppl.2.A44
Factors associated with seropositivity of IgG, IgM, and IgA antibodies to *Helicobacter pylori*, Suppl.1.A27
Immunoglobulin A autoantibodies, Gastric juice IL-8 and IL-8 IgA autoantibodies: relationship to gastric pH, Suppl.1.A33
Immunoglobulin G 50, Identification of a novel protective antigen in *Helicobacter felis*, Suppl.1.A31
Immunoglobulin G antibodies
Factors associated with seropositivity of IgG, IgM, and IgA antibodies to *Helicobacter pylori*, Suppl.1.A27
IgG-antibodies against *H. pylori* and prognosis of effective eradication, Suppl.1.A60
The comparison of occurrence of IgG antibodies to high molecular weight proteins of *Helicobacter pylori* antigen in gastric cancer patients and controls in Estonia, Suppl.1.A96
Immunoglobulin G serology, *H. pylori* IgG serology following successful eradication: four year follow-up, Suppl.1.A12
Immunoglobulin M antibodies, Factors associated with seropositivity of IgG, IgM, and IgA antibodies to *Helicobacter pylori*, Suppl.1.A27
Immunoglobulins
Detection of locally produced IgA- and IgG-antibodies against *Helicobacter pylori* in human gastric mucosa by ELISPOT method, Suppl.1.A81
Identification and characterization of a metalloprotease activity from *Helicobacter pylori* which is capable of degrading immunoglobulins, Suppl.1.A50
Molecular characterisation of immunoglobulins in gastric aspirates of *Helicobacter pylori* infected patients, Suppl.1.A80, Suppl.2.A16
Immunohistochemical analysis, Immunohistochemical analysis of p53 and bcl-2 in primary gastric non-Hodgkin's lymphomas, Suppl.1.A40
Immunohistochemistry, Comparison of immunohistochemistry and histology for the diagnosis of *Helicobacter pylori* infection after treatment, Suppl.1.A35
Immunological adhesion molecules, Immunological adhesion molecules on gastric mucosa. Does *H. pylori*, and specifically Cag A+ strains influence its expression, Suppl.1.A34
Immunomagnetic separation, Immunomagnetic separation and PCR for the detection of *Helicobacter pylori* in water and fecal samples, Suppl.1.A24
In situ hybridization, Detection of *Helicobacter pylori* in gastric biopsies by in situ hybridization, Suppl.1.A59
Indocyanine green clearance, Indocyanine green clearance reflects the degree of reperfusion injury and accurately predicts graft function following orthotopic liver transplantation, Suppl.2.A48
Infancy, *H. pylori* infection in infancy, Suppl.1.A24
Infants, Evaluation of the role of branched chain amino acids in the treatment of protein malnutrition in infants with liver disease, Suppl.2.A30
Infection risk
Incidence of *Helicobacter pylori* in farmworkers and the role of zoonotic spread, Suppl.1.A24
Prevalence of *H. pylori* infection and related gastroduodenal lesions in spouses of *H. pylori*-positive duodenal ulcer patients, Suppl.1.A23
Inflammatory bowel disease, Suppl.2.A21-23, A40-41
Anti-TNFα antibody reduces the systemic inflammatory response in experimental colitis, Suppl.2.A16
Antineutrophil cytoplasmic antibodies in inflammatory bowel disease distinguish between ulcerative colitis and Crohn's disease, Suppl.2.A14
Clinical patterns of familial inflammatory bowel disease: evidence for genetic anticipation?, Suppl.2.A50
Inter-observer variation in describing endoscopic findings in

inflammatory bowel disease using tapes of video colonoscopy, Suppl.2.A11
Mononuclear cells from inflammatory bowel disease, but not normal, colonic mucosa are capable of processing pro-interleukin-1beta to the mature peptide, Suppl.2.A18
The significance of cryptolytic lesions in inflammatory bowel disease, Suppl.2.A21
Inflammatory cell infiltration, Quantitative computer-aided evaluation of *Helicobacter pylori* gastritis: effect of anti-*HP* therapy on inflammatory cell infiltration and acquired MALT, Suppl.1.A96
Interferon, Interferon vs interferon+tauro-ursodeoxycholic acid for treatment of chronic active hepatitis C, Suppl.2.A27
Interferon gamma, Correlation between inflammation of *Hp*-infected gastric mucosa and interleukin-10, gamma interferon and interleukin-12, Suppl.1.A80
Interleukin-1 alpha
Cytokine gene polymorphism in inflammatory bowel disease: study of IL-1α and IL-1RA genes, Suppl.2.A22
Upregulation of IL-1α after partial hepatectomy: implications for the control of liver regeneration, Suppl.2.A20
Interleukin-1 beta, New genetic association of an interleukin-1β gene variation with primary biliary cirrhosis, Suppl.2.A17
Interleukin-1RA, Cytokine gene polymorphism in inflammatory bowel disease: study of IL-1α and IL-1RA genes, Suppl.2.A22
Interleukin-4, Th2 cytokines, interleukin-4 and interleukin-10 in the small intestine of patients with coeliac disease, Suppl.2.A42
Interleukin-8
Gastric juice IL-8 and IL-8 IgA autoantibodies: relationship to gastric pH, Suppl.1.A33
Helicobacter pylori strain variability in adhesion, cytotoxicity and IL-8 release, Suppl.1.A3
Induction of gastric epithelial interleukin 8 expression with natural *H. pylori* infection, detected by a new enzyme linked oligonucleotide chemiluminescence assay, Suppl.1.A79
Influence of *H. pylori* on interleukin 8 secretion by human gastric epithelial cells in culture, Suppl.1.A32
mRNA transcript for inflammatory mediators in *H. pylori*-associated gastritis, Suppl.1.A81
Preferential induction of interleukin-8 from gastric epithelial cell lines by *Helicobacter pylori* lipopolysaccharide, Suppl.1.A31
Steroid resistant increases in interleukin 8 and inducible nitric oxide synthase in patients requiring surgery for ulcerative colitis, Suppl.2.A15
Interleukin-10
Correlation between inflammation of *Hp*-infected gastric mucosa and interleukin-10, gamma interferon and interleukin-12, Suppl.1.A80
Th2 cytokines, interleukin-4 and interleukin-10 in the small intestine of patients with coeliac disease, Suppl.2.A42
Interleukin-12, Correlation between inflammation of *Hp*-infected gastric mucosa and interleukin-10, gamma interferon and interleukin-12, Suppl.1.A80
Interpersonal transmission, Evidence of interpersonal transmission of *H. pylori* between adults, Suppl.1.A10
Intestinal transit, Anxiety, depression and intestinal transit, Suppl.2.A47
Intestinal transit time, The influence of intestinal transit time on faecal pH, Suppl.2.A51
Intralesional chemotherapy, Intralesional chemotherapy in the treatment of gastric Kaposi's sarcoma in AIDS, Suppl.2.A41
Intubation
Costs, morbidity and mortality following intubation for carcinoma of the oesophagus, Suppl.2.A4
Intubation under vision is an essential part of upper gastrointestinal endoscopy and facilitates diagnosis of pharyngeal pathology, Suppl.2.A10
Prospective study of quality of life after endoscopic intubation with metal or plastic stents for malignant dysphagia, Suppl.2.A5
Iron-regulated outer membrane proteins, Identification of iron-regulated outer membrane proteins of *Helicobacter pylori*, Suppl.1.A23
Irritable bowel syndrome, Enhanced sensitivity of the whole gut in patients with irritable bowel syndrome, Suppl.2.A46
Ischaemic heart disease, *Helicobacter pylori* infection: relation with cardiovascular risk factors, ischaemic heart disease and social class, Suppl.1.A11

JO 1784, Effect of the sigma ligand JO 1784 on cholera toxin induced jejunal secretion, Suppl.2.A12

Kaposi's sarcoma, Intralesional chemotherapy in the treatment of gastric Kaposi's sarcoma in AIDS, Suppl.2.A41
Katalase, Interactions of a katalase- and a urease-negative mutant of *Helicobacter pylori* with polymorphonuclear granulocytes, Suppl.1.A21
30 kDa protein, Genetic characterization of an unprocessed 30 kDa *Helicobacter pylori*-specific surface protein, Suppl.1.A22
22 kDa surface-associated protein, Monoclonal antibody recognition and gene cloning of a 22 kDa surface-associated protein of *Helicobacter pylori*, Suppl.1.A63
128 kDa virulence associated protein, A monoclonal antibody to the *Helicobacter pylori* 128 kDa virulence associated protein, Suppl.1.A60
Kupffer cells, Selective depletion of Kupffer cells in resting rat liver initiates DNA synthesis in hepatocytes, Suppl.2.A33

Laboratory techniques, Suppl.2.A17-21
Lactulose, Measurement of lactulose and mannitol in serum and the development of a serum test for assessing small intestinal permeability: preliminary results in untreated coeliac disease, Suppl.2.A13
Lansoprazole
A 2-hour topical therapy for the treatment of *Helicobacter pylori* infection, Suppl.1.A44
Acute and chronic effect of lansoprazole and omeprazole in relation to food intake, Suppl.2.A32
Antimicrobial activity of lansoprazole against *Helicobacter pylori* in vitro and relation with cytotoxin production of strains, Suppl.1.A46
Comparison of one and two weeks of lansoprazole, amoxycillin and clarithromycin in eradicating *Helicobacter pylori*, Suppl.2.A7
Dual therapy versus triple therapy: high dose of lansoprazole plus amoxicillin in combination or not with clarithromycin for *Helicobacter pylori* infection, Suppl.1.A92
Efficacy of amoxycillin compared with classical triple therapy in the eradication of *H. pylori* after pre-treatment with lansoprazole, Suppl.1.A41
Factors affecting the eradication success in gastric and duodenal ulcer patients, Suppl.1.A44
The in-vitro activity of proton pump inhibitors against *H. pylori* is atmosphere dependant, Suppl.1.A88
Laparoscopic cholecystectomy, Value of ERCP in patients with suspected bile duct injury following laparoscopic cholecystectomy, Suppl.2.A1
Laparoscopic fundoplication, 24 hour pH study of laparoscopic versus open fundoplication, Suppl.2.A1
Laparoscopic gastrojejunostomy, Laparoscopic gastrojejunostomy, Suppl.2.A1
Laparoscopic peritoneal cytology, Laparoscopic peritoneal cytology in the staging of pancreatic cancer, Suppl.2.A3
Laparoscopic surgery, The benefits of laparoscopic surgery in the management of gallstones, Suppl.2.A2
Laparoscopy
Hypoxaemia during diagnostic laparoscopy, Suppl.2.A2
Port site skin burns and diathermy in surgical laparoscopy, Suppl.2.A2
Laser ablation
Laser ablation of ampullary carcinoma. The effects and outcome of endoscopic treatment, Suppl.2.A3
Nd-YAG laser: ineffective therapy for Barrett's oesophagus, Suppl.2.A4
Prospective triple-randomised trial of laser vs expandable metal (covered and uncovered) stents in the management of inoperable oesophageal carcinoma, preliminary results, Suppl.2.A4
Regression of columnar-lined oesophagus following laser ablation and acid suppression, Suppl.2.A4
Launch Premier kit, A comparison of five commercial serological tests for *Helicobacter pylori* detection, Suppl.1.A15
Lectin-like laminin-binding protein, Identification of the lectin-like laminin-binding protein of *Helicobacter pylori*, Suppl.1.A2
Leukocytes, Blood leukocytes in *H. pylori* infection, Suppl.1.A36
Lewis/ABO-blood groups, Is gastric *H. pylori* colonisation density in duodenal ulcer patients dependent on Lewis/ABO-blood groups? Suppl.1.A28
LFA 3, Modulation of the expression of B7, ICAM-1 and LFA3 on the surface of gastric epithelial cells following exposure to *H. pylori* and cytokines, Suppl.1.A31
Lipid, A comparison of gastric mucosal lipid composition in *Helicobacter pylori* infected and non-infected subjects, Suppl.1.A84
Lipopolysaccharide
Chemical structures of lipopolysaccharides. A window on strain to strain variations in *Helicobacter pylori*, Suppl.1.A17
Preferential induction of interleukin-8 from gastric epithelial cell lines by *Helicobacter pylori* lipopolysaccharide, Suppl.1.A31
Preliminary structural analysis of *Helicobacter pylori* lipid A, Suppl.1.A16
Liver, Suppl.2.A25-28, A33-35

Liver biopsies, Risk management: an audit of ultrasourd guided liver biopsies, Suppl.2.A9
Liver disease, Evaluation of the role of branched chain amino acids in the treatment of protein malnutrition in infants with liver disease, Suppl.2.A30
Liver failure plasma, Liver failure plasma contains inhibitors of hepatocyte protein synthesis – relevance to extracorporeal liver support, Suppl.2.A26
Liver metastases, Tumour response to regional chemotherapy depends upon tumour vascularity in colorectal liver metastases, Suppl.2.A36
Liver perfusion, Suppl.2.A48
Liver regeneration, Upregulation of IL-1α after partial hepatectomy: implications for the control of liver regeneration, Suppl.2.A20
Liver transplantation
Biliary microflora and its relation to biliary sepsis after liver transplantation, Suppl.2.A33
Indocyanine green clearance reflects the degree of reperfusion injury and accurately predicts graft function following orthotopic liver transplantation, Suppl.2.A48
Liver transplantation for hepatitis B virus infection – past, present and future, Suppl.2.A26
Nutritional status after orthotopic liver transplantation, Suppl.2.A14
Role of cGMP on haemodynamic changes during liver transplantation, Suppl.2.A48
The improved results of emergency orthotopic liver transplantation for fulminant and subacute hepatic failure, Suppl.2.A34
Lower oesophageal sphincter, Monitoring the lower oesophageal sphincter – sphinctometer or sleeve? Suppl.2.A45
Lung metastases, Gastrimmune reduces lung metastases in a human colorectal model, Suppl.2.A37
Lymphocyte homing molecules, Lymphocyte homing molecules in the normal and inflamed gut, Suppl.2.A22
Lymphocytes, Adoptive transfer of *Helicobacter*-specific lymphocytes enhances inflammation in mice, Suppl.1.A33
Lymphocytic gastritis
Helicobacter pylori infection and lymphocytic gastritis in gastric lymphoma, Suppl.1.A77
Lymphocytic gastritis in a 10-year follow-up, Suppl.1.A35
Lymphoid cell infiltration, PCR improves the differential diagnosis between *Helicobacter pylori* infection induced lymphoid cell infiltration and gastric MALT lymphoma, Suppl.1.A39
Lymphoid follicles, Lymphoid follicles in gastric mucosa of *Helicobacter pylori* infected patients: regression 6-12 months after eradication, Suppl.1.A76
Lymphoma
Helicobacter heilmanii infection and primary gastric low-grade MALT lymphoma, Suppl.1.A38
Helicobacter pylori infection and lymphocytic gastritis in gastric lymphoma, Suppl.1.A77
The prevalence of *Helicobacter pylori* in gastric lymphomas, Suppl.1.A40

MAC*H* 1 Study, The MAC*H* 1 Study: optimal one-week treatment for *H. pylori* defined? Suppl.1.A4
Macrolides, Macrolides and *Helicobacter pylori*. Determination of MICs and effect of pH, Suppl.1.A91
Macrophages, The role of *H. pylori* surface structures in bacterial interaction with macrophages, Suppl.1.A32
Magenstrasse and Mill operation, Magenstrasse and Mill operation – results of a new procedure for morbid obesity, Suppl.2.A14
Major resectional surgery, Supplemental enteral nutrition in patients undergoing major resectional surgery, Suppl.2.A43
MALT, Quantitative computer-aided evaluation of *Helicobacter pylori* gastritis: effect of anti-*HP* therapy on inflammatory cell infiltration and acquired MALT, Suppl.1.A96
MALT lymphoma
Gastric B-cell lymphomas induced in a single mouse strain by various isolates of *Helicobacter heilmannii*: similarities and differences, Suppl.1.A7
Helicobacter heilmanii infection and primary gastric low-grade MALT lymphoma, Suppl.1.A38
Long-term effect of anti-*Helicobacter pylori* therapy on gastric MALT lymphoma. Histological and molecular evaluation of 15 cases, Suppl.1.A6
PCR improves the differential diagnosis between *Helicobacter pylori* infection induced lymphoid cell infiltration and gastric MALT lymphoma, Suppl.1.A39
MALT-type lymphomas, Evidence for the role of *Helicobacter pylori* in the pathogenesis of MALT-type lymphomas of the stomach through an autoimmune mechanism, Suppl.1.A76
Mannitol, Measurement of lactulose and mannitol in serum and the development of a serum test for assessing small intestinal permeability: preliminary results in untreated coeliac disease, Suppl.2.A13
Manometry, Computerised recording and display of oesophageal manometry with video barium swallow, Suppl.2.A50
Maternal *Helicobacter pylori* positivity, Mother's *Helicobacter pylori* positivity as a risk factor of infant infection, Suppl.1.A27
Matrix metalloproteinase, Hepatic stellate cells produce membrane-type matrix metalloproteinase, Suppl.2.A26
MBCs, Determination of MIC and MBC of 14 agents against 85 clinical isolates of *Helicobacter pylori*, Suppl.1.A63
Media for growth, Evaluation of media for growth and antigen expression by *Helicobacter pylori*, Suppl.1.A17
Metabolic-enzyme profiles, Diversity in metabolic-enzyme profiles of *Helicobacter pylori*, Suppl.1.A66
Metabolic pathways, Metabolic pathways in metronidazole sensitive and resistant strains of *Helicobacter pylori*, Suppl.1.A66
Metalloprotease, Identification and characterization of a metalloprotease activity from *Helicobacter pylori* which is capable of degrading immunoglobulins, Suppl.1.A50
Metaplasia
Evaluations of inflammatory, metaplastic, preneoplastic and neoplastic changes in the gastric surface epithelium by the AgNOR method, Suppl.1.A34
The prevalence and extent of gastric metaplasia in the duodenal bulb is not changed six months after *H. pylori* eradication, Suppl.1.A74
Metronidazole
Clinical and endoscopic characteristics of metronidazole resistant *Helicobacter pylori*, Suppl.1.A72
Comparison of two low dose one-week triple therapy regimens with and without metronidazole for cure of *H. pylori* infection, Suppl.1.A43
Cost-effective, European approach to *H. pylori* eradication, Suppl.1.A91
Duodenal ulcer healing and *Helicobacter pylori* eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole, Suppl.1.A41
Evolution of the resistance to several antibiotics in *H. pylori* over a 4 year period, Suppl.1.A97
Helicobacter pylori infection and metronidazole resistance, Suppl.1.A86
Helicobacter pylori infection and metronidazole resistance in Gloucester, Suppl.1.A46
Metabolic pathways in metronidazole sensitive and resistant strains of *Helicobacter pylori*, Suppl.1.A66
Metronidazole resistant mutant isolated from *H. pylori* infected euthymic mice model, Suppl.1.A49
Pharmacokinetic modelling of the effects of omeprazole on secretion of intravenous metronidazole into gastric fluid, Suppl.1.A45
Preliminary report on the impact of the Suffolk GP-based *Helicobacter pylori* eradication programme on the prescribing of ulcer healing drugs in general practice, Suppl.2.A6
Prevalence and clinical implication of metronidazole resistant *Helicobacter pylori* in Taiwan, Suppl.1.A70
Randomised comparison of 3 omeprazole-based eradication regimens in an inner-city area, Suppl.1.A90
Microbiology
Helicobacter pylori – epidemiologic and microbiological aspects in a Norwegian population, Suppl.1.A16
Serological and microbiological results of a 48-months follow-up: recurrence of *H. pylori* infection after eradication, Suppl.1.A95
Micronodular pattern, Antral and bulbar micronodular pattern in young children infected with *Helicobacter pylori*, Suppl.1.A57
Micronutrient anitoxidant status, Investigation of micronutrient antioxidant status as a potential determinant of susceptibility to chronic pancreatitis among alcoholics at Soweto, Suppl.2.A29
Microsporidiosis, Jejunal water and electrolyte transport in intestinal microsporidiosis in HIV positive patients, Suppl.2.A12
Microsurgery, Transanal endoscopic microsurgery – initial experience from three centres in the United Kingdom, Suppl.2.A5
MICs
Determination of MIC and MBC of 14 agents against 85 clinical isolates of *Helicobacter pylori*, Suppl.1.A63
Macrolides and *Helicobacter pylori*. Determination of MICs and effect of pH, Suppl.1.A91
Mitogen, The inhibition of antigen- or mitogen-induced response to T cells by *H. pylori* bacteria and their products, Suppl.1.A32
Molecular mechanisms, *Helicobacter pylori* and molecular mechanisms of gastric mucosa proliferation, Suppl.1.A78
Monoclonal antibody
A monoclonal antibody to the *Helicobacter pylori* 128 kDa virulence associated protein, Suppl.1.A60
Monoclonal antibody recognition and gene cloning of a 22 kDa surface-associated protein of *Helicobacter pylori*, Suppl.1.A63
Mononuclear cells, Mononuclear cells from inflammatory bowel

disease, but not normal, colonic mucosa are capable of processing pro-interleukin-1beta to the mature peptide, Suppl.2.A18
Morantel, A potential therapeutic target in *Helicobacter pylori*, Suppl.1.A88
Morocco
Frequency of *cagA* in *Helicobacter pylori* strains isolated from Belgian and Moroccan patients, Suppl.1.A69
Serum reactivity to *Helicobacter pylori* antigens assessed by Helico Blot 2.0 in *H. pylori*-positive children from different ethnic groups, Suppl.1.A79
Motility, Suppl.2. A45-47, A50-52
Gastric and intestinal motility in rats experimentally infected with *Gastrospirillum suis*, Suppl.1.A35
Mouse
Helicobacter felis surface antigen recognition by three strains of immune mice, Suppl.1.A95
Helicobacter felis surface antigens serve as protective targets in orally immunised mice, Suppl.1.A93
Immunisation with *H. pylori* heat-shock protein A and urease subunit B affords total protection against *H. felis* infection in mice, Suppl.1.A51
Immunization with *H. pylori* urease do not induce serum auto-antibodies against the gastric mucosa in mice, Suppl.1.A93
Specific immune colostrum in the prevention of *Helicobacter felis* infection in mice, Suppl.1.A92
Mouse model
Development of a mouse model of gastric colonisation with *Helicobacter pylori*, Suppl.1.A50
Eradication of *H. pylori* without antibiotics, Suppl.1.A63
In-vivo selection of a highly adapted *H. pylori* isolate and the development of an *H. pylori* mouse model for studying vaccine efficacy and attenuating lesions, Suppl.1.A94
Infection by *Helicobacter pylori* in a mouse model that mimics human disease: protection by oral vaccination, Suppl.1.A51
Metronidazole resistant mutant isolated from *H. pylori* infected euthymic mice model, Suppl.1.A49
Protective immunisation against *Helicobacter* spp stimulates long term immunity, Suppl.1.A48
Screening of anti-*Helicobacter* therapies in mice colonised with *H. pylori*, Suppl.1.A92
The effect of exogenous co-factors on ulcerogenesis by *H. heilmannii*-like bacteria in mice, Suppl.1.A48
mRNA, Effect of *H. pylori* on expression of somatostatin mRNA in the gastric antrum and corpus, Suppl.1.A83
mRNA transcript, mRNA transcript for inflammatory mediators in *H. pylori*-associated gastritis, Suppl.1.A81
Mucins, Soluble mucins in the gastric juice of *H. pylori*-infected patients, Suppl.1.A75
Mucosa
Comparison of gastric mucosal lipid composition in *Helicobacter pylori* infected and non-infected subjects, Suppl.1.A84
Comparison of *H. pylori ure-B* gene between gastric mucosae and gastric juice aspirates using restriction pattern analysis, Suppl.1.A95
Correlation between inflammation of *Hp*-infected gastric mucosa and interleukin-10, gamma interferon and interleukin-12, Suppl.1.A80
Detection of locally produced IgA- and IgG-antibodies against *Helicobacter pylori* in human gastric mucosa by ELISPOT method, Suppl.1.A81
Effect of *H. felis* infection on proliferation and growth factor expression, Suppl.1.A77
H. pylori colonization of the gastric mucosa is likely to be found in dyspeptic patients without antral phase 3 of migrating motor complex, Suppl.1.A82
Helicobacter pylori and molecular mechanisms of gastric mucosa proliferation, Suppl.1.A78
Immunization with *H. pylori* urease do not induce serum auto-antibodies against the gastric mucosa in mice, Suppl.1.A93
Immunological adhesion molecules on gastric mucosa. Does *H. pylori*, and specifically Cag A+ strains influence its expression, Suppl.1.A34
Isolation of *Helicobacter* species from mouse caecal mucosa, Suppl.1.A20
Isotypic pattern of *Helicobacter pylori* antibody response in gastric mucosa, saliva and serum. Relation to ulcer, gastritis and intragastric extent of *H. pylori*, Suppl.1.A78
Lymphoid follicles in gastric mucosa of *Helicobacter pylori* infected patients: regression 6-12 months after eradication, Suppl.1.A76
Profound increase of *Helicobacter pylori* urease activity in gastric antral mucosa at low pH, Suppl.1.A83
Regulation of activated helper T cells in the gastric mucosa during infection with *H. pylori*, Suppl.1.A50
Mucosal surface, Urease influences *Helicobacter pylori* motility at the gastric mucosal surface, Suppl.1.A19
Mucus
Chemotactic response to mucus and acid by *Helicobacter pylori*, Suppl.1.A64
The effect of omeprazole on gastric mucus viscosity, Suppl.1.A96
Mutagenesis system, A random insertion mutagenesis system for the inactivation of *Helicobacter pylori* gene using a construction derived from the gram positive conjugative transposon Tn*545*, Suppl.1.A65

Na^+/bile acid cotransporter, The small intestinal Na^+/bile acid cotransporter is encoded by mRNA of two different sizes, Suppl.2.A17
Nasogastric nutritional supplements, A comparison between oral and nasogastric nutritional supplements in malnourished patients, Suppl.2.A43
Natural history, The natural history of *Helicobacter pylori* gastritis: a 30-year histologic follow-up study, Suppl.1.A69
Nd-YAG laser
Nd-YAG laser: ineffective therapy for Barrett's oesophagus, Suppl.2.A4
Prospective triple-randomised trial of laser vs expandable metal (covered and uncovered) stents in the management of inoperable oesophageal carcinoma, preliminary results, Suppl.2.A4
Neutrophil activation
Cytotoxin production and neutrophil activation by *Helicobacter pylori* in patients with peptic ulceration and chronic gastritis, Suppl.1.A3
Expression of *cag*A gene and nonopsonic neutrophil activation by *Helicobacter pylori*, Suppl.1.A3
Neutrophil toxic oxygen radical release, The role of *Helicobacter pylori* in neutrophil toxic oxygen radical release, Suppl.1.A2
New Zealand, Different seroprevalences of *Helicobacter pylori* between ethnic groups of New Zealand, Suppl.1.A26
Nickel transport systems, Screening for *H. pylori* genes that encode alternate nickel transport systems necessary for synthesis of catalytically active urease, Suppl.1.A65
Nicotine, Transdermal nicotine compared with oral prednisolone for active ulcerative colitis, Suppl.2.A40
Nitrate, Gastric juice nitrate and *Helicobacter pylori* infection, Suppl.1.A33
Nitric oxide
Nitric oxide may influence gallbladder motility, Suppl.2.A51
Nitric oxide in the small intestinal mucosa of patients with coeliac disease, Suppl.2.A42
Nitric oxide synthase
Expression of inducible nitric oxide synthase as a local defence mechanism in *H. pylori*-associated gastritis, Suppl.1.A81
Induction of nitric oxide synthase by an extract of *Helicobacter pylori* in rat duodenum, Suppl.1.A30
Steroid resistant increases in interleukin 8 and inducible nitric oxide synthase in patients requiring surgery for ulcerative colitis, Suppl.2.A15
NixA
Allelic exchange mutagenesis of NixA in *Helicobacter pylori* results in reduced nickel transport and reduced urease activity, Suppl.1.A66
Screening for *H. pylori* genes that encode alternate nickel transport systems necessary for synthesis of catalytically active urease, Suppl.1.A65
Non-gastric carcinoma, Seroprevalence of *Helicobacter pylori* infection in gastric and non-gastric carcinoma, Suppl.1.A40
Non-Hodgkin's lymphoma, Immunohistochemical analysis of p53 and bcl-2 in primary gastric non-Hodgkin's lymphomas, Suppl.1.A40
Non-steroidal anti-inflammatory drugs, UGI bleeding and gastric ulcer location are independent clues to NSAID use in patients with peptic ulcer regardless of *H. pylori* status, Suppl.1.A89
Non-ulcer dyspepsia, The effect of eradication of *Helicobacter pylori* on symptoms of non-ulcer dyspepsia, Suppl.1.A56
Northern Ireland, Epidemiology of *Helicobacter pylori* infection among 4,742 randomly selected subjects from Northern Ireland, Suppl.1.A70
Norwegian population, *Helicobacter pylori* – epidemiologic and microbiological aspects in a Norwegian population, Suppl.1.A16

Obesity, Magenstrasse and Mill operation – results of a new procedure for morbid obesity, Suppl.2.A14
Oesophageal cancer (carcinoma)
Basement membrane degradation by gastric and oesophageal cancer cells: the effect of plasminogen, Suppl.2.A21
Costs, morbidity and mortality following intubation for carcinoma of the oesophagus, Suppl.2.A4
Open access endoscopy facilitates early diagnosis of malignant and

pre-malignant lesions of the stomach and oesophagus, Suppl.2.A35
Prospective study of quality of life after endoscopic intubation with metal or plastic stents for malignant dysphagia, Suppl.2.A5
Prospective triple-randomised trial of laser vs expandable metal (covered and uncovered) stents in the management of inoperable oesophageal carcinoma, preliminary results, Suppl.2.A4
Oesophageal manometry, Computerised recording and display of oesophageal manometry with video barium swallow, Suppl.2.A50
Oesophageal protection, Are salivary antiproteases important in oesophageal protection?, Suppl.2.A53
Oesophageal varices, Experimental and clinical studies of endoloops: a new method of mechanical haemostasis for oesophageal varices, Suppl.2.A1
Oesophagitis
Patients with oesophagitis have low levels of TGFα in fasting gastric juice, Suppl.2.A52
Symptom relief with omeprazole in patients without unequivocal oesophagitis, Suppl.2.A45
Oesophagus, Suppl.2. A45-47, A52-53
Omeprazole
Acute and chronic effect of lansoprazole and omeprazole in relation to food intake, Suppl.2.A32
Amoxicillin plus omeprazole versus triple therapy for the eradication of *H. pylori* and healing of duodenal ulcers, Suppl.1.A6
An increasing dose of omeprazole combined with amoxicillin improves the cure of *Helicobacter pylori* infection, Suppl.1.A89
Characteristics of reflux in relation with symptom event in patients with gastro-oesophageal reflux resistant to omeprazole therapy, Suppl.2.A46
Clarithromycin in combination with omeprazole for healing duodenal ulcers, prevention of DU recurrence, and eradication of *H. pylori* in two European studies, Suppl.1.A4
Clarithromycin and omeprazole in the prevention of duodenal ulcer recurrence and eradication of *H. pylori*, Suppl.1.A85
Comparison of omeprazole 10mg and 20mg OM with ranitidine 150mg bd for the treatment of GORD in primary care, Suppl.2.A45
Comparison of omeprazole+amoxicillin *versus* OM+clarithromycin in the eradication of *Helicobacter pylori* – results from a randomized study involving 120 patients, Suppl.1.A55
Continuous treatment of patients with Barrett's oesophagus with omeprazole 20 mg daily over 3 years, Suppl.2.A32
Cost-effective, European approach to *H. pylori* eradication, Suppl.1.A91
Decision analysis of healthcare costs following eradication of *H. pylori* with omeprazole in combination with either amoxycillin or clarithromycin, Suppl.1.A47
Double-blind trial of 80 mg omeprazole and 2250 mg amoxicillin for cure of *Helicobacter pylori* infection in gastric ulcer patients, Suppl.1.A44
Dual therapy of clarithromycin and omeprazole for treatment of patients with duodenal ulcers associated with *H. pylori* infection, Suppl.1.A5
Duodenal ulcer healing and *Helicobacter pylori* eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole, Suppl.1.A41
Effect of omeprazole and clarithromycin plus tinidazole on the eradication of *Helicobacter pylori* and the recurrence of duodenal ulcer, Suppl.1.A5
Effect of omeprazole on gastric mucus viscosity, Suppl.1.A96
Effect of omeprazole on quality of life in patients with the 'sensitive oesophagus', Suppl.2.A45
Effect of smoking on *H. pylori* eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole, Suppl.1.A85
Efficacy of ten days of clarithromycin, amoxycillin and omeprazole in eradicating *Helicobacter pylori* infection, Suppl.1.A44
Eradication of *Helicobacter pylori* infection: is a double therapy still suitable? Suppl.1.A85
Eradication of *Helicobacter pylori* using clarithromycin, omeprazole and amoxycillin for one week, Suppl.1.A88
H. pylori urease activity is inhibited by high dose omeprazole in vivo, Suppl.1.A60
Helicobacter pylori augments the pH-raising effect of omeprazole in duodenal ulcer patients, Suppl.1.A8
Helicobacter pylori infection causes increased hypergastrinaemia during omeprazole therapy, Suppl.1.A59
High efficacy of a clarithromycin-amoxycillin-omeprazole association for *H. pylori* eradication and treatment of ulcer-like or reflux-like dyspeptic symptoms, Suppl.1.A87
In-vitro activity of proton pump inhibitors against *H. pylori* is atmosphere dependant, Suppl.1.A88
Omeprazole+amoxicillin+clarithromycin therapy for *H. pylori* infection, Suppl.1.A89
Omeprazole based therapies for eradication of *Helicobacter pylori*, Suppl.1.A90
Omeprazole and clarithromycin vs. omeprazole and amoxicillin: a comparison of one-week and two-week treatments, Suppl.1.A91
Omeprazole has no effect on the gastric mucosal bioavailability of amoxycillin, Suppl.1.A90
Omeprazole plus clarithromycin: efficacy of two treatment regimens on *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A41
Omeprazole pre-treatment does not affect the eradication rate of *H. pylori* infection, Suppl.2.A7
One-week treatment with omeprazole, amoxycillin and clarithromycin or metronidazole for cure of *Helicobacter pylori* infection, Suppl.1.A43
Patient factors that predict failure of omeprazole, clarithromycin and tinidazole to eradicate *Helicobacter pylori*, Suppl.1.A46
Pharmacokinetic modelling of the effects of omeprazole on secretion of intravenous metronidazole into gastric fluid, Suppl.1.A45
Preliminary report on the impact of the Suffolk GP-based *Helicobacter pylori* eradication programme on the prescribing of ulcer healing drugs in general practice, Suppl.2.A6
Randomised comparison of 3 omeprazole-based eradication regimens in an inner-city area, Suppl.1.A90
Ranitidine and omeprazole and their combination with antibiotics in the eradication of *Helicobacter pylori*, Suppl.1.A55
Ranitidine vs omeprazole: short-term triple therapy in patients with *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A42
Safety of dual therapy with clarithromycin and omeprazole in the treatment of patients with duodenal ulcer, Suppl.1.A43
Symptom relief with omeprazole in patients without unequivocal oesophagitis, Suppl.2.A45
Time-course of histological changes in *Helicobacter pylori* associated gastritis during the early phase of cure therapy with omeprazole and amoxycillin in duodenal ulcer patients, Suppl.1.A34
Twice a day triple therapy with omeprazole for cure of *Helicobacter pylori* infection, Suppl.1.A86
Open access endoscopy, Open access endoscopy facilitates early diagnosis of malignant and pre-malignant lesions of the stomach and oesophagus, Suppl.2.A35
Open access flexible sigmoidoscopy, Open access flexible sigmoidoscopy, Suppl.2.A9
Open access gastroscopy
Does open access gastroscopy increase the detection rate of early gastric cancer? Results of a 5 year study, Suppl.2.A35
Management guidelines for dyspepsia. Do they reduce open access gastroscopy workload?, Suppl.2.A10
Open access gastroscopy: second BSG survey, Suppl.2.A10
Open access gastroscopy – effects of pretreatment – closing the audit cycle, Suppl.2.A7
Open fundoplication, 24 hour pH study of laparoscopic versus open fundoplication, Suppl.2.A1
Oral immunization, Oral immunization with recombinant *Helicobacter pylori* urease apoenzyme in the treatment of *Helicobacter* infection, Suppl.1.A94
Oral nutritional supplements
A comparison between oral and nasogastric nutritional supplements in malnourished patients, Suppl.2.A43
Two-phase randomised controlled clinical trial of oral dietary supplements in surgical patients, Suppl.2.A43
Oral vaccination, Infection by *Helicobacter pylori* in a mouse model that mimics human disease: protection by oral vaccination, Suppl.1.A51
Outer membrane vesicles, *Helicobacter felis* surface antigens serve as protective targets in orally immunised mice, Suppl.1.A93
Oxantel, A potential therapeutic target in *Helicobacter pylori*, Suppl.1.A88
Oxygen supply, Changes in substrate levels during culture of *H. pylori* and the effect of oxygen supply, Suppl.1.A17

p53
Co-operativity between APC and p53 in murine pancreatic cancer, Suppl.2.A18
Immunohistochemical analysis of p53 and bcl-2 in primary gastric non-Hodgkin's lymphomas, Suppl.1.A40
Induction of gastric dysplasia by *H. felis* in p53-deficient mice, Suppl.1.A40
P type ATPase genes, Complexity of P type ATPase genes in the genome of *Helicobacter pylori*, Suppl.1.A21
Pancreas, Suppl.2.A28-30
Pancreas divisum, Pancreas divisum in acute pancreatitis: curious coincidence or covert culprit? Suppl.2.A30
Pancreatic cancer
Co-operativity between APC and p53 in murine pancreatic cancer, Suppl.2.A18
Laparoscopic peritoneal cytology in the staging of pancreatic cancer, Suppl.2.A3

Pancreatitis
Amylase and lipase levels in the diagnosis of acute pancreatitis, Suppl.2.A29
Investigation of micronutrient antioxidant status as a potential determinant of susceptibility to chronic pancreatitis among alcoholics at Soweto, Suppl.2.A29
Pancreas divisum in acute pancreatitis: curious coincidence or covert culprit?, Suppl.2.A30
Parietal cells
Parietal cell sensitivity to gastrin distinguishes *H. pylori* infected DU patients from infected healthy volunteers, Suppl.1.A8, Suppl.2.A39
Parietal cells in the duodenal bulb are more common in *H. pylori* negative patients with duodenal ulcer, Suppl.1.A73
Partial hepatectomy, Upregulation of IL-1α after partial hepatectomy: implications for the control of liver regeneration, Suppl.2.A20
PEG tubes, Use of PEG tubes: a hospital and community based audit, Suppl.2.A8
Pentagastrin, Pentagastrin stimulated gastric acid secretion and postprandial gastrin profile in *Helicobacter pylori* positive and negative healthy volunteers, Suppl.1.A9
Pepsinogen, *H. pylori*, gastritis and serum pepsinogen A in a male non-patient population, Suppl.1.A4
Pepsinogen A and C, One year monitoring of *Helicobacter pylori* eradication by serum pepsinogen A and C, Suppl.1.A57
Peptic ulcer
A controlled study of adrenaline injection in peptic ulcer bleeding within a specialised unit, Suppl.2.A37
Adherence-induced expression of a novel *Helicobacter pylori* gene and correlation with peptic ulceration, Suppl.1.A75
Diagnosis of *H. pylori* infection in peptic gastric ulcer. How to do it properly? Suppl.1.A58
Early feeding in patients with bleeding peptic ulcer and a visible vessel, Suppl.2.A37
Eradication of *Helicobacter pylori* in practice: an audit of three years clinical experience with peptic ulcer patients, Suppl.1.A86
Healing of peptic ulcers by curing *Helicobacter pylori* infection, Suppl.1.A43
Helicobacter pylori, dyspepsia and peptic ulcer: perspectives and practice from primary care, Suppl.1.A88
Helicobacter pylori eradication in the long term management of peptic ulcer disease in general practice, Suppl.2.A38
Helicobacter pylori eradication as a surrogate for reduced peptic ulcer recurrence, Suppl.1.A46
Peptic ulcer and gastritis in uraemia, Suppl.2.A32
Peptic ulcer is rare in asymptomatic adults with *Helicobacter pylori* infection, Suppl.1.A10
Reduced long term survival following major peptic ulcer haemorrhage, Suppl.2.A38
Peripheral parenteral nutrition, PPN: rotate the vein, Suppl.2.A14
Peruvian water sources, Detection of *Helicobacter pylori* in Peruvian water sources by two PCR assays based on independent genes, Suppl.1.A10
pH
Gastric juice IL-8 and IL-8 IgA autoantibodies: relationship to gastric pH, Suppl.1.A33
Helicobacter pylori augments the pH-raising effect of omeprazole in duodenal ulcer patients, Suppl.1.A8
High pH is unfavourable for growth of *H. felis* in the rat gastric antrum, Suppl.1.A49
Macrolides and *Helicobacter pylori*. Determination of MICs and effect of pH, Suppl.1.A91
Profound increase of *Helicobacter pylori* urease activity in gastric antral mucosa at low pH, Suppl.1.A83
Regulation of gene expression by pH and urea in *Helicobacter pylori*, Suppl.1.A2
pH monitoring, Does intolerance of pH monitoring cause false negative results?, Suppl.2.A46
pH-related regulation, Growth phase and pH-related regulation of *cag*A, *cag*C and *ure*A expression in *H. pylori*, Suppl.1.A1
Pharyngeal pathology, Intubation under vision is an essential part of upper gastrointestinal endoscopy and facilitates diagnosis of pharyngeal pathology, Suppl.2.A10
Phospholipid liposomes, Ultrastructural characterization of the interaction between phospholipid liposomes and *Helicobacter pylori* by electron microscopic techniques, Suppl.1.A20
Phospholipid methyltransferase activity, Demonstration and partial characterisation of phospholipid methyltransferase activity in bile canalicular membrane from hamster liver, Suppl.2.A19
Phylogenic analysis, Phylogenic analysis of *ure B* and *fla A* genes among isolates of *Helicobacter pylori* in relation to restriction length polymorphism, Suppl.1.A19
Pigs, Establishment of an animal model of ulcerogenesis induced by *Helicobacter* using swine, Suppl.1.A92
Pituitary adenylate cyclase activating polypeptide, The differential effect of PACAP on *in vitro* gallbladder motility is modulated via prostaglandins, Suppl.2.A52
Plasma factors, The role of plasma factors in the abnormal calcium signalling of platelets from patients with cirrhosis, Suppl.2.A33
Plasmid, *Helicobacter felis* plasmid: a good candidate for a shuttle vector?, Suppl.1.A2
Plasminogen
Activation of *Helicobacter pylori* bound plasminogen by tissue-type plasminogen activator, Suppl.1.A61
Basement membrane degradation by gastric and oesophageal cancer cells: the effect of plasminogen, Suppl.2.A21
Platelet aggregate formation, Platelet aggregate formation in the mesenteric microcirculation in Crohn's disease: further evidence for their role in pathogenesis, Suppl.2.A21
Polymerase chain reaction
AP-PCR as typing method in clinical isolates of *Helicobacter pylori*, Suppl.1.A72
Comparison of PCR to other routine invasive methods in the diagnosis of *Helicobacter pylori* infection, Suppl.1.A57
Detection of *Helicobacter pylori* DNA in gastric juice by PCR: comparison with *H. pylori* DNA in biopsy specimens, Suppl.1.A54
Detection of *Helicobacter pylori* in drinking water using polymerase chain reaction, Suppl.1.A27
Gastric juice polymerase chain reaction for *Helicobacter pylori* diagnosis: an alternative to histology?, Suppl.1.A15
Immunomagnetic separation and PCR for the detection of *Helicobacter pylori* in water and fecal samples, Suppl.1.A24
Nested-polymerase chain reaction for the detection of *Helicobacter pylori* in gastric biopsy samples, Suppl.2.A40
PCR improves the differential diagnosis between *Helicobacter pylori* infection induced lymphoid cell infiltration and gastric MALT lymphoma, Suppl.1.A39
Polymerase chain reaction for detection of *Helicobacter pylori* DNA in patients with *H. pylori* induced gastritis suggests that dental plaque is not a reservoir, Suppl.2.A31
Polymorphonuclear granulocytes, Interactions of a katalase- and a urease-negative mutant of *Helicobacter pylori* with polymorphonuclear granulocytes, Suppl.1.A21
Polymorphonuclear leukocyte elastase, Plasma level of polymorphonuclear leukocyte elastase is related to the degree of *Helicobacter pylori*-associated gastritis, Suppl.1.A34
Polyphosphate, Characteristics of polyphosphate granules of *Helicobacter pylori*, Suppl.1.A72
Port site skin burns, Port site skin burns and diathermy in surgical laparoscopy, Suppl.2.A2
Portal hypertension, Clinical vs haemodynamic response to drugs in portal hypertension, Suppl.2.A48
Portal venous system thrombosis, Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis, Suppl.2.A28
Pouch, Do ambulatory pouch and anal motility patterns in colon pouches explain poor functional results?, Suppl.2.A47
Pouchitis, Bismuth carbomer enemas in treatment of chronic unremitting pouchitis, Suppl.2.A49
Prednisolone, Transdermal nicotine compared with oral prednisolone for active ulcerative colitis, Suppl.2.A40
Prednisolone enemas, Butyrate enemas are less effective than prednisolone enemas in treating distal or left sided ulcerative colitis, Suppl.2.A41
Prescribing, Prescribing of community-dispensed ulcer-healing drugs – implications for *Helicobacter pylori* eradication, Suppl.1.A90
Prevalence
A cohort study of *Helicobacter pylori* colonisation in children, Suppl.1.A72
Different seroprevalences of *Helicobacter pylori* between ethnic groups of New Zealand, Suppl.1.A26
Prevalence of *H. pylori* antibodies in children and young adults living in the southeast of Turkey, Suppl.1.A26
Prevalence of *Helicobacter* antibodies in 1973 and 1994 in the adult population of Vammala, Finland, Suppl.1.A26
Seroprevalence of *Helicobacter pylori* infection among gastroenterologists in France, Suppl.1.A78
Seroprevalence of *Helicobacter pylori* infection in six countries of eastern Europe using a common methodology, Suppl.1.A71
Primary biliary cirrhosis
Combination ursodeoxycholic acid and immunosuppressive therapy for the treatment of primary biliary cirrhosis, Suppl.2.A27
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography, Suppl.2.A34
Vitamin D and markers of bone formation in primary biliary cirrhosis, Suppl.2.A26

Primary sclerosing cholangitis
A district general hospital's experience of primary sclerosing cholangitis, Suppl.2.A35
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography, Suppl.2.A34
Primary sclerosing cholangitis: standard liver function tests during long term treatment with ursodeoxycholic acid and value of serial quantitative liver function tests, Suppl.2.A25
Primary slcerosing cholangitis, Detection of antineutrophil cytoplasmic antibody in primary sclerosing cholangitis: comparison of the alkaline phosphatase and immunofluorescent techniques, Suppl.2.A25
Pro-interleukin-1beta, Mononuclear cells from inflammatory bowel disease, but not normal, colonic mucosa are capable of processing pro-interleukin-1beta to the mature peptide, Suppl.2.A18
Proctocolitis, Twenty years experience of non-specific proctocolitis in north-east Scotland, Suppl.2.A50
Proliferation
Helicobacter pylori and molecular mechanisms of gastric mucosa proliferation, Suppl.1.A78
The effect of *H. felis* infection on proliferation and growth factor expression, Suppl.1.A77
Pronase, A 2-hour topical therapy for the treatment of *Helicobacter pylori* infection, Suppl.1.A44
Prostaglandins, The differential effect of PACAP on *in vitro* gallbladder motility is modulated via prostaglandins, Suppl.2.A52
Protective antigen, Identification of a novel protective antigen in *Helicobacter felis*, Suppl.1.A31
Protein
Genetic characterization of an unprocessed 30 kDa *Helicobacter pylori*-specific surface protein, Suppl.1.A22
Identification of a *Helicobacter pylori*-specific protein involved in adherence to gastric epithelial cells, Suppl.1.A1
Identification of the lectin-like laminin-binding protein of *Helicobacter pylori*, Suppl.1.A2
Protein kinase C, Tumour necrosis factor alpha acutely stimulates release of somatostatin from cultured D-cells via a protein kinase C dependent pathway, Suppl.2.A18
Protein malnutrition, Evaluation of the role of branched chain amino acids in the treatment of protein malnutrition in infants with liver disease, Suppl.2.A30
Proton pump inhibitor
Efficacy of amoxycillin compared with classical triple therapy in the eradication of *H. pylori* after pre-treatment with lansoprazole, Suppl.1.A41
Open access gastroscopy – effects of pretreatment – closing the audit cycle, Suppl.2.A7
Proton pump inhibitor pretreatment affects *Helicobacter pylori* sensitivity to antibiotics, Suppl.1.A18
The in-vitro activity of proton pump inhibitors against *H. pylori* is atmosphere dependant, Suppl.1.A88
Triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for *Helicobacter pylori* eradication, Suppl.1.A91
Psychiatric disorder, Do senior gastroenterologists experience more 'burnout' and psychiatric disorder than other hospital consultants, Suppl.2.A9
Public health, Public health implication of *H. pylori* in cats: presence of *H. pylori* in cat saliva, gastric juice, and feces, Suppl.1.A10
Putative virulence factors, Kinetics of putative virulence factors in *Hl pylori*, Suppl.1.A22
Pyloriset, A comparison of five commercial serological tests for *Helicobacter pylori* detection, Suppl.1.A15
Pyloriset EIA-G, False negative serological EIA results in *Helicobacter pylori* infected children, Suppl.1.A15
Pyloriset™ tests, Evaluation of three new Pyloriset™ tests, RIA-G, EIA-A and dry latex, for serological diagnosis of *Helicobacter pylori* infection, Suppl.1.A12
Pyruvate:flavodoxin oxidoreductase, Characterisation of *Helicobacter pylori* pyruvate:flavodoxin oxidoreductase, Suppl.1.A18

QuickVue One-Step H. Pylori test, Evaluation of a physician's office rapid serology test which detects *Helicobacter pylori* IgG antibodies with whole blood samples, Suppl.1.A15

Radical release, The role of *Helicobacter pylori* in neutrophil toxic oxygen radical release, Suppl.1.A2
Random genome sequencing, Elucidation of *Helicobacter pylori* metabolism by random genome sequencing, Suppl.1.A67
Ranitidine
Comparison of omeprazole 10mg and 20mg OM with ranitidine 150mg bd for the treatment of GORD in primary care, Suppl.2.A45
Impact of *H. pylori* infection on symptoms and effect of ranitidine in patients with functional dyspepsia, Suppl.1.A45
Ranitidine and omeprazole and their combination with antibiotics in the eradication of *Helicobacter pylori*, Suppl.1.A55
Ranitidine vs omeprazole: short-term triple therapy in patients with *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A42
Ranitidine bismuth citrate
GR122311X can significantly reduce the emergence of *H. pylori* strains resistant to antibiotics, Suppl.1.A62
GR122311X (ranitidine bismuth citrate) with amoxycillin for the eradication of *Helicobacter pylori*, Suppl.1.A42
GR122311X (ranitidine bismuth citrate) with clarithromycin for the eradication of *Helicobacter pylori*, Suppl.1.A42
Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of *Helicobacter pylori* and prevention of duodenal ulcer relapse, Suppl.1.A5
The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and amoxycillin, Suppl.1.A42
The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin, Suppl.1.A5
Rapid blood tests, Validation of two new rapid blood tests for *H. pylori*, Suppl.1.A58
Rapid western blotting assay, Rapid western blotting assay: role in determining which *H. pylori* patients have duodenal ulceration, Suppl.1.A16
Rapid whole blood test
FlexSure™HP whole blood test – a rapid method to detect antibodies against *Helicobacter pylori*, Suppl.1.A60
Validation of the Helisal Rapid Whole Blood Test for the detection of IgG antibodies to *H. pylori*, Suppl.1.A56
Validation of a rapid whole blood test for the diagnosis of *Helicobacter pylori* infection, Suppl.1.A53
Rat, High pH is unfavourable for growth of *H. felis* in the rat gastric antrum, Suppl.1.A49
Reactive oxygen species, Reactive oxygen species activity and damage in *Helicobacter pylori* associated gastritis – effect of eradication therapy, Suppl.1.A39
Rectal bleeding, Assessment of the incidence and present management of rectal bleeding based on patient questionnaires, Suppl.2.A23
Rectal cancer
Self expanding metallic prosthesis in the palliative treatment of rectal cancer, Suppl.2.A5
Transanal endoscopic microsurgery – initial experience from three centres in the United Kingdom, Suppl.2.A5
Recurrence
Clarithromycin and omeprazole in the prevention of duodenal ulcer recurrence and eradication of *H. pylori*, Suppl.1.A85
Effect of smoking on *H. pylori* eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole, Suppl.1.A85
Factors involved in reinfection by *H. pylori* in Brazil, Suppl.1.A71
Gastric ulcer recurrence following treatment for eradication of *Helicobacter pylori*, Suppl.1.A54
Helicobacter pylori eradication as a surrogate for reduced peptic ulcer recurrence, Suppl.1.A46
Helicobacter pylori reinfection in duodenal and gastric ulcer patients after antibacterial treatment, Suppl.1.A54
Serological and microbiological results of a 48-months follow-up: recurrence of *H. pylori* infection after eradication, Suppl.1.A95
Severity of gastritis predicts duodenal ulcer relapse, Suppl.1.A89
Reflux control, Reflux control at flexible endoscopy using endoluminal suturing in an in-vivo model, Suppl.2.A52
Reflux esophagitis, Long-term clinical course of ulcer disease and incidence of reflux esophagitis in a large cohort of duodenal ulcer patients followed after eradication of *Helicobacter pylori*, Suppl.1.A6
Reporter gene analyses, Reporter gene analyses show that expression of both *H. pylori* flagellins is dependent on the growth phase, Suppl.1.A62
Resin, radiolabelled, Colonic distribution of daily dosed, radiolabelled resin: right-sided reservoir and left-sided conduit?, Suppl.2.A47
Resistance
A randomised comparison of 3 omeprazole-based eradication regimens in an inner-city area, Suppl.1.A90
Effects of antibiotic-resistance on clarithromycin-combined triple therapy for *Helicobacter pylori*, Suppl.1.A55
Helicobacter pylori infection and metronidazole resistance, Suppl.1.A86
The prevalence and clinical implication of metronidazole resistant *Helicobacter pylori* in Taiwan, Suppl.1.A70
Restorative proctocolectomy, Restorative proctocolectomy in children and young adults, Suppl.2.A24
Restriction pattern analysis, Comparison of *H. pylori ure-B* gene between gastric mucosae and gastric juice aspirates using restriction pattern analysis, Suppl.1.A95

Rhesus monkey, Experimental infection of rhesus monkeys with *H. pylori*, Suppl.1.A50
23S Ribosomal RNA, Mutations in 23S ribosomal RNA confer clarithromycin resistance in *Helicobacter pylori*, Suppl.1.A67
Risk management, Risk management: an audit of ultrasound guided liver biopsies, Suppl.2.A9
Russia, Contribution of socioeconomic factors to *Helicobacter pylori* acquisition in Russia, Suppl.1.A71

Salicylates, Salicylates inhibit bacterial sulphide production within the colonic lumen in ulcerative colitis, Suppl.2.A15
Saliva, Isotypic pattern of *Helicobacter pylori* antibody response in gastric mucosa, saliva and serum. Relation to ulcer, gastritis and intragastric extent of *H. pylori*, Suppl.1.A78
Salivary antiproteases, Are salivary antiproteases important in oesophageal protection?, Suppl.2.A53
Salivary assay, Comparison of serum, salivary and rapid whole-blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy-based tests, Suppl.2.A39
Salivary secretion, Oesophageal acidification does not affect salivary secretion, but stimulated salivary flow decreases acid clearance time, Suppl.2.A52
Salivary specific IgG, Salivary specific IgG in the diagnosis of *Helicobacter pylori* infection in dyspeptic patients, Suppl.1.A52
San Marino, Association of *Helicobacter pylori* and anti-CagA serum IgG with gastroduodenal endoscopic lesions in the population of San Marino, Suppl.1.A71
Sardinian shepherds, *Helicobacter pylori* infection in asymptomatic Sardinian shepherds, Suppl.1.A68
School children, Prevalence of *Helicobacter pylori* infection in school children related to socio-economic status, Suppl.1.A11
Screening
Family based colorectal cancer screening in a district hospital, Suppl.2.A23
Screenaing for colorectal cancer by flexible sigmoidoscopy, Suppl.2.A24
Screening of anti-*Helicobacter* therapies in mice colonised with *H. pylori*, Suppl.1.A92
'Sensitive oesophagus', The effect of omeprazole on quality of life in patients with the 'sensitive oesophagus', Suppl.2.A45
Sensitivity of the whole gut, Enhanced sensitivity of the whole gut in patients with irritable bowel syndrome, Suppl.2.A46
Septic patients, Metabolic manipulation of hypercatabolic chronically septic patients using recombinant human growth hormone, Suppl.2.A43
Seroconversion, High seroconversion for *Helicobacter pylori* in children, Suppl.1.A27
Serological diagnosis, Evaluation of Helico Blot 2.0 – a new commercial western blot test – for the serological diagnosis of *Helicobacter pylori* infection, Suppl.1.A59
Serological tests, Serological tests for diagnosing *Helicobacter pylori* eradication, Suppl.1.A57
Serology
A serological and histological study on *Helicobacter pylori* infection in the elderly patients, Suppl.1.A82
Serodiagnosis of *Helicobacter pylori* infection in patients with human immunodeficiency virus infection, Suppl.1.A95
Serological and microbiological results of a 48-months follow-up: recurrence of *H. pylori* infection after eradication, Suppl.1.A95
Seropositivity, Factors associated with seropositivity of IgG, IgM, and IgA antibodies to *Helicobacter pylori*, Suppl.1.A27
Seroprevalence
Different seroprevalences of *Helicobacter pylori* between ethnic groups of New Zealand, Suppl.1.A26
Seroprevalence of *Helicobacter pylori* infection among gastro-enterologists in France, Suppl.1.A78
Seroprevalence of *Helicobacter pylori* infection in six countries of eastern Europe using a common methodology, Suppl.1.A71
Serum, Isotypic pattern of *Helicobacter pylori* antibody response in gastric mucosa, saliva and serum. Relation to ulcer, gastritis and intragastric extent of *H. pylori*, Suppl.1.A78
Severity of gastritis, Severity of gastritis predicts duodenal ulcer relapse, Suppl.1.A89
Sex differences, In vivo studies: sex differences in the growth of gastrointestinal tumours, Suppl.2.A37
Sigma ligand, Effect of the sigma ligand JO 1784 on cholera toxin induced jejunal secretion, Suppl.2.A12
Sigmoidoscopy
Open access flexible sigmoidoscopy, Suppl.2.A9
Screening for colorectal cancer by flexible sigmoidoscopy, Suppl.2.A24
Small bowel, Suppl.2.A12-14, A41-43
The small intestinal Na^+/bile acid cotransporter is encoded by mRNA of two different sizes, Suppl.2.A17
Smoking
Cigarette smoking and gastritis activity are predicting factors of *Helicobacter pylori* eradication rate, Suppl.1.A47
Effect of smoking on *H. pylori* eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole, Suppl.1.A85
Social class, *Helicobacter pylori* infection: relation with cardiovascular risk factors, ischaemic heart disease and social class, Suppl.1.A11
Socio-economic status, Prevalence of *Helicobacter pylori* infection in school children related to socio-economic status, Suppl.1.A11
Socioeconomic factors, Contribution of socioeconomic factors to *Helicobacter pylori* acquisition in Russia, Suppl.1.A71
Somatostatin
Antral somatostatin cell density and *Helicobacter pylori* in man, Suppl.1.A9
Effect of *H. pylori* on expression of somatostatin mRNA in the gastric antrum and corpus, Suppl.1.A83
H. pylori alters the changes in somatostatin and gastrin mRNAs induced by infusion of gastrin releasing peptide, Suppl.1.A9
Somatostatin release from cultured canine D-cells is inhibited by prolonged exposure to tumour necrosis factor alpha, Suppl.2.A17
Tumour necrosis factor alpha acutely stimulates release of somatostatin from cultured D-cells via a protein kinase C dependent pathway, Suppl.2.A18
Tumour necrosis factor-alpha decreases somatostatin release and the somatostatin content of cultured canine D cells, Suppl.1.A84
Somatostatin receptor 1, Somatostatin receptor 1 mRNA is reduced in *Helicobacter pylori* infection, Suppl.2.A44
Somatostatin receptor subtypes, The distribution of somatostatin receptor subtypes in normal and malignant colonic epithelium, Suppl.2.A36
Soweto, Investigation of micronutrient antioxidant status as a potential determinant of susceptibility to chronic pancreatitis among alcoholics at Soweto, Suppl.2.A29
Sphincterotome, A modified sphincterotome designed for safety, Suppl.2.A12
Sphincterotomy, Long term sequelae after sphincterotomy for anal fissure, Suppl.2.A49
Sphinctometer, Monitoring the lower oesophageal sphincter – sphinctometer or sleeve?, Suppl.2.A45
Sphingomyelinase activity, The sphingomyelinase activity of *Helicobacter pylori*, Suppl.1.A29
Spouses, Prevalence of *H. pylori* infection and related gastroduodenal lesions in spouses of *H. pylori*-positive duodenal ulcer patients, Suppl.1.A23
Stents
A prospective study of quality of life after endoscopic intubation with metal or plastic stents for malignant dysphagia, Suppl.2.A5
Prospective triple-randomised trial of laser vs expandable metal (covered and uncovered) stents in the management of inoperable oesophageal carcinoma, preliminary results, Suppl.2.A4
Self expanding metallic prosthesis in the palliative treatment of rectal cancer, Suppl.2.A5
Strain diversity and selection, Strain diversity and selection in patients treated for *Helicobacter pylori* infection, Suppl.1.A20
Structural analysis, Preliminary structural analysis of *Helicobacter pylori* lipid A, Suppl.1.A16
Subacute hepatic failure, The improved results of emergency orthotopic liver transplantation for fulminant and subacute hepatic failure, Suppl.2.A34
Sulphide production, Salicylates inhibit bacterial sulphide production within the colonic lumen in ulcerative colitis, Suppl.2.A15
Sulphur metabolism, Is there a defect in sulphur metabolism in ulcerative colitis?, Suppl.2.A22
Systemic inflammatory effects, Systemic inflammatory effects of *Helicobacter pylori* infection, Suppl.1.A69

T cells
Cytokine profiles of blood and mucosal T-lymphocytes in children with and without gastrointestinal disease, Suppl.2.A16
Distribution of dividing T cells throughout the bowel wall in inflammtory bowel disease, Suppl.2.A23
The inhibition of antigen- or mitogen-induced response to T cells by *H. pylori* bacteria and their products, Suppl.1.A32
Tauro-ursodeoxycholic acid, Interferon vs interferon+tauro-ursodeoxycholic acid for treatment of chronic active hepatitis C, Suppl.2.A27
Test meals, Analysis of the accuracy of the 13c-urea breath test for the detection of *H. pylori* infection by using different test meals, Suppl.1.A58
Thiabendazole, A potential therapeutic target in *Helicobacter pylori*, Suppl.1.A88
Thromboelastography, Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography, Suppl.2.A34

Tight junctions, Ultrastructural evidence for the destruction of gastric epithelial tight junctions by *Helicobacter pylori*, Suppl.1.A73

Tinidazole
- Effect of omeprazole and clarithromycin plus tinidazole on the eradication of *Helicobacter pylori* and the recurrence of duodenal ulcer, Suppl.1.A5
- Patient factors that predict failure of omeprazole, clarithromycin and tinidazole to eradicate *Helicobacter pylori*, Suppl.1.A46

TIPSS, Management of refractory ascites with TIPSS, Suppl.2.A3

Topical therapy, A 2-hour topical therapy for the treatment of *Helicobacter pylori* infection, Suppl.1.A44

Total N-nitroso compound, Total N-nitroso compound concentration correlates with increasing risk of gastric cancer, Suppl.2.A35

Transanal endoscopic microsurgery, Transanal endoscopic microsurgery – initial experience from three centres in the United Kingdom, Suppl.2.A5

Transforming growth factor alpha, Patients with oesophagitis have low levels of TGFα in fasting gastric juice, Suppl.2.A52

Transmission, Evidence of interpersonal transmission of *H. pylori* between adults, Suppl.1.A10

Transposon Tn*l545*, A random insertion mutagenesis system for the inactivation of *Helicobacter pylori* gene using a construction derived from the gram positive conjugative transposon Tn*l545*, Suppl.1.A65

Triglyceride lipase, *H. pylori* triglyceride lipase has no pathogenic role *in vivo*, Suppl.1.A75

Triple therapy
- Alternative triple therapy for *Helicobacter pylori* related duodenal ulcers, Suppl.1.A86
- Amoxicillin plus omeprazole versus triple therapy for the eradication of *H. pylori* and healing of duodenal ulcers, Suppl.1.A6
- Comparison of two low dose one-week triple therapy regimens with and without metronidazole for cure of *H. pylori* infection, Suppl.1.A43
- Dual therapy versus triple therapy: high dose of lansoprazole plus amoxicillin in combination or not with clarithromycin for *Helicobacter pylori* infection, Suppl.1.A92
- Duodenal ulcer healing and *Helicobacter pylori* eradication by one-week low-dose triple therapy with omeprazole, clarithromycin and metronidazole, Suppl.1.A41
- Effects of antibiotic-resistance on clarithromycin-combined triple therapy for *Helicobacter pylori*, Suppl.1.A55
- Efficacy of amoxycillin compared with classical triple therapy in the eradication of *H. pylori* after pre-treatment with lansoprazole, Suppl.1.A41
- Efficacy of ten days of clarithromycin, amoxycillin and omeprazole in eradicating *Helicobacter pylori* infection, Suppl.1.A44
- Eradication of *Helicobacter pylori* in practice: an audit of three years clinical experience with peptic ulcer patients, Suppl.1.A87
- Eradication of *Helicobacter pylori* using clarithromycin, omeprazole and amoxycillin for one week, Suppl.1.A88
- High efficacy of a clarithromycin-amoxycillin-omeprazole association for *H. pylori* eradication and treatment of ulcer-like or reflux-like dyspeptic symptoms, Suppl.1.A87
- Omeprazole+amoxicillin+clarithromycin therapy for *H. pylori* infection, Suppl.1.A89
- Omeprazole based therapies for eradication of *Helicobacter pylori*, Suppl.1.A90
- One-week treatment with omeprazole, amoxycillin and clarithromycin or metronidazole for cure of *Helicobacter pylori* infection, Suppl.1.A43
- Ranitidine and omeprazole and their combination with antibiotics in the eradication of *Helicobacter pylori*, Suppl.1.A55
- Ranitidine vs omeprazole: short-term triple therapy in patients with *Helicobacter pylori* positive duodenal ulcer, Suppl.1.A42
- Triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for *Helicobacter pylori* eradication, Suppl.1.A91
- Twice a day triple therapy with omeprazole for cure of *Helicobacter pylori* infection, Suppl.1.A86

Tumour necrosis factor alpha
- Anti-TNFα antibody reduces the systemic inflammatory response in experimental colitis, Suppl.2.A16
- Somatostatin release from cultured canine D-cells is inhibited by prolonged exposure to tumour necrosis factor α, Suppl.2.A17
- Tumour necrosis factor α acutely stimulates release of somatostatin from cultured D-cells via a protein kinase C dependent pathway, Suppl.2.A18
- Tumour necrosis factor-α decreases somatostatin release and the somatostatin content of cultured canine D cells, Suppl.1.A84

Turkey, Prevalence of *H. pylori* antibodies in children and young adults living in the southeast of Turkey, Suppl.1.A26

Tyrosine phosphorylation, Attachment of *H. pylori* to gastric cells occurs by an EPEC-like mechanism and induces tyrosine phosphorylation of host cell proteins, Suppl.1.A1

Ulcer healing drugs, Preliminary report on the impact of the Suffolk GP-based *Helicobacter pylori* eradication programme on the prescribing of ulcer healing drugs in general practice, Suppl.2.A6

Ulcerative colitis
- Butyrate enemas are less effective than prednisolone enemas in treating distal or left sided ulcerative colitis, Suppl.2.A41
- Cytokine gene polymorphisms in patients with an ileal pouch anal anastomosis for ulcerative colitis, Suppl.2.A15
- HLA class II genes are important determinants of disease susceptibility in ulcerative colitis but not in Crohn's disease, Suppl.2.A21
- Is there a defect in sulphur metabolism in ulcerative colitis?, Suppl.2.A22
- Salicylates inhibit bacterial sulphide production within the colonic lumen in ulcerative colitis, Suppl.2.A15
- Steroid resistant increases in interleukin 8 and inducible nitric oxide synthase in patients requiring surgery for ulcerative colitis, Suppl.2.A15
- The balance of immunoregulatory and pro-inflammatory cytokines in active ulcerative colitis: untreated and in treatment failure, Suppl.2.A22
- Transdermal nicotine compared with oral prednisolone for active ulcerative colitis, Suppl.2.A40
- Treatment of corticosteroid resistant ulcerative colitis with heparin, Suppl.2.A49

Ultrasound, Risk management: an audit of ultrasound guided liver biopsies, Suppl.2.A9

Upper gastrointestinal bleeding
- Causative role of *Helicobacter pylori* in upper gastrointestinal bleeding, Suppl.1.A28
- Selection of patients for early discharge following acute upper gastrointestinal bleeding, Suppl.2.A11
- UGI bleeding and gastric ulcer location are independent clues to NSAID use in patients with peptic ulcer regardless of *H. pylori* status, Suppl.1.A89

Uraemia, Peptic ulcer and gastritis in uraemia, Suppl.2.A32

Ure A, Growth phase and pH-related regulation of *cag*A, *cag*C and *ure*A expression in *H. pylori*, Suppl.1.A1

***Ure B* genes**, Phylogenic analysis of *ure B* and *fla A* genes among isolates of *Helicobacter pylori* in relation to restriction length polymorphism, Suppl.1.A19

Urea
- Eradication of *H. pylori* without antibiotics, Suppl.1.A63
- *H. pylori* uses urea for amino acid synthesis at neutral pH, Suppl.1.A62
- Regulation of gene expression by pH and urea in *Helicobacter pylori*, Suppl.1.A2

Urea solution, Urea solution for direct *H.pylori* testing, Suppl.2.A30

Urease
- Allelic exchange mutagenesis of NixA in *Helicobacter pylori* results in reduced nickel transport and reduced urease activity, Suppl.1.A66
- Development of recombinant *Helicobacter pylori* urease as an oral vaccine: current status, Suppl.1.A52
- *H. pylori* urease activity is inhibited by high dose omeprazole in vivo, Suppl.1.A60
- Immunization with *H. pylori* urease do not induce serum auto-antibodies against the gastric mucosa in mice, Suppl.1.A93
- Interactions of a katalase- and a urease-negative mutant of *Helicobacter pylori* with polymorphonuclear granulocytes, Suppl.1.A21
- Oral immunization with recombinant *Helicobacter pylori* urease apoenzyme in the treatment of *Helicobacter* infection, Suppl.1.A94
- Profound increase of *Helicobacter pylori* urease activity in gastric antral mucosa at low pH, Suppl.1.A83
- Screening for *H. pylori* genes that encode alternate nickel transport systems necessary for synthesis of catalytically active urease, Suppl.1.A65
- Surface localization of *H. pylori* urease and HP54K requires bacterial lysis, Suppl.1.A19
- Urease influences *Helicobacter pylori* motility at the gastric mucosal surface, Suppl.1.A19

Urease-B, Comparison of *H. pylori ure-B* gene between gastric mucosae and gastric juice aspirates using restriction pattern analysis, Suppl.1.A95

Urease subunit B, Immunisation with *H. pylori* heat-shock protein A and urease subunit B affords total protection against *H. felis* infection in mice, Suppl.1.A51

Urease test
- Commercially available rapid urease tests vary in efficacy for detecting *Helicobacter pylori* infection, Suppl.1.A13
- Comparison of brushing cytology with urease test histology, and urea breath test in the detection of *Helicobacter pylori* infection, Suppl.1.A12
- Confirmation of successful therapy of *H. pylori* infection: number and site of biopsies vs. a rapid urease test, Suppl.1.A59

Validity of a new biopsy urease test and a simplified 13C-urea breath test for diagnosis of *Helicobacter pylori* infection and estimation of severity of gastritis, Suppl.1.A54

Ursodeoxycholic acid

Combination ursodeoxycholic acid and immunosuppressive therapy for the treatment of primary biliary cirrhosis, Suppl.2.A27

Primary sclerosing cholangitis: standard liver function tests during long term treatment with ursodeoxycholic acid and value of serial quantitative liver function tests, Suppl.2.A25

***vacA* phenotype**, Detection of *vacA* by PCR and correlation with *cagA* in *Helicobacter pylori* strains isolated from patients with different diseases, Suppl.1.A67

***vacA* protein**, Genotypic analysis of *vacA* and *cagA* in *Helicobacter pylori* isolates from the U.S., Thailand, Peru and China, Suppl.1.A69

Vaccine efficacy, *In-vivo* selection of a highly adapted *H. pylori* isolate and the development of an *H. pylori* mouse model for studying vaccine efficacy and attenuating lesions, Suppl.1.A94

Variceal haemorrhage, Variceal haemorrhage: changing pattern of management and its effect on outcome, Suppl.2.A8

Vater's papilla, Gabexate mesilate (FOY) in the prevention of pancreatic damage secondary to endoscopic manoeuvres on Vater's papilla, Suppl.2.A29

Video barium swallow, Computerised recording and display of oesophageal manometry with video barium swallow, Suppl.2.A50

Viral markers, Viral markers for mode of transmission in *Helicobacter pylori* infected adolescents, Suppl.1.A70

Visceral sensation and emotion, Visceral sensation and emotion: a study using hypnosis, Suppl.2.A51

Vitamin C concentrations, Infection with CagA *H. pylori* positive strains is associated with reduced gastric juice vitamin C concentrations, Suppl.2.A16

Vitamin D, Vitamin D and markers of bone formation in primary biliary cirrhosis, Suppl.2.A26

Vitamin D_3, The steroid vitamin D_3 reduces cell proliferation in human duodenal epithelium, Suppl.2.A12

Water samples, Immunomagnetic separation and PCR for the detection of *Helicobacter pylori* in water and fecal samples, Suppl.1.A24

Water soluble proteins, Direct enhancement of gastrin release by *H. pylori* water soluble proteins, Suppl.1.A9

Water source, Detection of *Helicobacter pylori* in Peruvian water sources by two PCR assays based on independent genes, Suppl.1.A10

Whole-blood test, Comparison of serum, salivary and rapid whole-blood diagnostic tests for *Helicobacter pylori* and their validation against endoscopy-based tests, Suppl.2.A39

Wilson's disease, Screening for Wilson's disease mutations, Suppl.2.A20

Zambia, The spectrum of gastritis in Zambian patients with AIDS, **Suppl.1.A36**

Zoonotic spread, Incidence of *Helicobacter pylori* in farmworkers and the role of zoonotic spread, Suppl.1.A24